Společnost Howard Hughes oznámila změnu ve vedení Vantage Group Holdings: Marc Grandisson se stal výkonným předsedou a David Gansberg se stane CEO po skončení jeho konkurenčních doložek, nejpozději v červnu 2027.
July 16, 2026 08:30 ET | Source: Howard Hughes Holdings Inc.
Marc Grandisson Appointed Executive Chairman of Vantage
David Gansberg Named CEO-Designate
THE WOODLANDS, Texas, July 16, 2026 (GLOBE NEWSWIRE) -- Howard Hughes Holdings Inc. (NYSE: HHH) (“the Company” or “Howard Hughes”) today announced a leadership transition at Vantage Group Holdings Ltd. (“Vantage”) with Marc Grandisson to become Executive Chairman, effective immediately, and David Gansberg to become CEO once his non-competition obligations are no longer in effect by June 2027.
Marc and David bring decades of specialty insurance leadership to Vantage, having spent much of their careers together at Arch Capital Group (NASDAQ: ACGL), which they helped build into one of the world's most respected and profitable specialty insurers and reinsurers.
Mr. Grandisson began his career working with insurance executives including Ajit Jain from Berkshire Hathaway and Paul Ingrey at F&G Re before joining Arch's founding team in 2001. He served as CEO of Arch from 2018 until his retirement in 2024, during which Arch generated a total shareholder return of 298%, or 23.2% per annum, driven by disciplined underwriting and skilled cycle management.
Mr. Gansberg, who also joined Arch in 2001, led the company's Global Mortgage Group as CEO from 2019 to 2024 and built it into a market leader, before being named President of Arch Capital Group with accountability for its Global Insurance Group.
Greg Hendrick, who has served as CEO of Vantage since co-founding the company in 2020, will continue to lead Vantage as CEO until Mr. Gansberg assumes the role, ensuring a seamless transition. Mr. Grandisson will work alongside Mr. Hendrick and the Vantage leadership team during this period.
“In Marc and David, we have two of the most accomplished leaders in the industry to guide Vantage into its next chapter,” said Bill Ackman, Executive Chairman of Howard Hughes. “Greg has built the foundations for an exceptional specialty insurance and reinsurance operation, and we are grateful for his leadership. As we look to the future, Marc’s deep underwriting and operating expertise and David’s proven track record of building profitable, durable insurance businesses position Vantage to scale into a large, highly profitable insurance company and an enduring source of long-term value creation for Howard Hughes and its shareholders for decades to come.”
"When I joined the Howard Hughes board, I saw a company at an exciting inflection point, and my conviction in the opportunity at Vantage has only grown since," said Marc Grandisson. "Vantage is an exceptional diversified insurance platform which offers tremendous opportunity, and I am honored to join the company as Executive Chairman.”
"Building Vantage these past six years has been the privilege of my career," said Greg Hendrick, CEO of Vantage. “We set out to build a specialty reinsurer that sees risk differently — one defined by talent, technology, and a genuine curiosity about the world. I am proud of every person who made it possible. With our recent sale to Howard Hughes, we are now closing our founding chapter and opening an extremely promising long-term future for the company. I am committed to a transition that sets up Marc, David and the Vantage team for even greater success in the future.”
About Marc Grandisson
Marc Grandisson is the former CEO of Arch Capital Group Ltd. (NASDAQ: ACGL), which he joined in 2001 and became CEO in March 2018. Born and raised in Quebec, Canada, he earned an undergraduate degree in Actuarial Science from Université Laval in 1990 and an MBA from the Wharton School of the University of Pennsylvania in 2000. He is a Fellow of the Casualty Actuarial Society and a member of the American Academy of Actuaries and served as Chairman of ABIR (the Association of Bermuda Insurers and Reinsurers) from 2021-22. Prior to ACGL, he worked for Berkshire Hathaway, F&G Re, and Towers Watson. Mr. Grandisson is a minority investor in the NHL’s Carolina Hurricanes and the NBA’s Portland Trail Blazers.
About David Gansberg
David Gansberg was President, Arch Capital Group Ltd., beginning Nov. 7, 2024 until his recent departure from the company. As President Mr. Gansberg had primary accountability for Arch’s Global Insurance Group, which includes Arch’s North American and International Insurance Operations. From February 2013 through February 2019, he was the President and CEO of Arch Mortgage Insurance Company. From July 2007 to February 2013, Mr. Gansberg was Executive Vice President and a director at Arch Reinsurance Company (“Arch Re (U.S.)”). Prior to that, he held various underwriting, operational and strategic roles at Arch Re Bermuda and Arch Capital Services LLC, which he joined in December 2001. Mr. Gansberg currently serves on the board of directors of Coface SA. He holds a bachelor’s degree in actuarial mathematics from the University of Michigan and an MBA from Duke University.
About Vantage
Vantage Group Holdings Ltd. (Vantage) was established in late 2020 as a re/insurance partner designed for the future. Driven by relentless curiosity, the Vantage team of trusted experts provides a fresh perspective on clients' risks and adds creativity to tech-enabled efficiency and robust analytics to address risks others avoid. Vantage is a subsidiary of Howard Hughes Holdings Inc. Additional information about Vantage can be found at www.vantagerisk.com.
About Howard Hughes Holdings Inc.
Howard Hughes Holdings Inc. (NYSE: HHH) is a diversified holding company focused on growing long-term shareholder value. Its principal subsidiaries are Vantage Group Holdings, a leading specialty insurance, reinsurance, and partnership capital platform, and Howard Hughes Communities™, one of the nation’s leading real estate platforms. HHH brings together long-duration capital, high-quality operating businesses, and disciplined capital allocation to build long-term value. For additional information, visit howardhughes.com.
Forward-Looking Statements
Statements made in this press release that are not historical facts, including statements accompanied by words such as “anticipate,” “will,” “believe,” “expect,” “position,” “assume,” and other words of similar expression, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s expectations, estimates, assumptions, and projections as of the date of this release and are not guarantees of future performance. Actual results may differ materially from those expressed or implied in these statements. Factors that could cause actual results to differ materially are set forth as risk factors in Howard Hughes Holdings Inc.’s filings with the Securities and Exchange Commission, including its Quarterly and Annual Reports. Howard Hughes Holdings Inc. cautions you not to place undue reliance on the forward-looking statements contained in this release. Howard Hughes Holdings Inc. does not undertake any obligation to publicly update or revise any forward-looking statements to reflect future events, information or circumstances that arise after the date of this release.
Eaton, Vertiv a Caterpillar těží z výstavby datových center s umělou inteligencí: všechny tři ve 1. čtvrtletí překonaly odhady a zvýšily celoroční výhled. Největší tah trh vidí u energetiky a chlazení.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
AI data center construction is a power problem before it is a compute problem, and the equipment that moves, conditions, cools and backs up electricity inside those buildings is where the earnings leverage is showing up first.
Three U.S.-listed industrials have become the cleanest ways to own that buildout: Eaton (NYSE:ETN | ETN Price Prediction) for switchgear and thermal management, Vertiv (NYSE:VRT) for critical power and cooling infrastructure and Caterpillar (NYSE:CAT) for on-site backup generation. Each posted a first-quarter beat, each raised guidance, and each is trading with a forward multiple that reflects real order acceleration rather than a story. Here is how they stack up going into the July earnings cycle.
The macro backdrop is unusually supportive. The Department of Energy projects data centers will account for up to 12% of U.S. electrical demand by 2028, and PJM Interconnection’s independent market monitor concluded that “data center load growth is the primary reason for recent and expected capacity market conditions” in the country’s largest grid region. That is the tailwind these three names are monetizing.
Eaton (ETN): The Compounding Acquirer Eaton makes the electrical guts of a data center: switchgear, busway, power distribution and now liquid cooling after closing Boyd Thermal. Shares traded around $413.98 on July 15, up 26.48% year to date, with a market cap near $158 billion. Forward earnings sits at 30x and the analyst consensus target at $455.79, with 22 Buy or Strong Buy ratings against four Hold ratings.
Q1 delivered adjusted EPS of $2.81 versus a $2.73 consensus on revenue of $7.45 billion, up 16.8% year over year. The number to anchor on is Electrical Americas: revenue rose 20% while the twelve-month rolling order book grew 42% organically, driven by data center demand. Total Electrical backlog is up 48%. Management closed $11 billion in acquisitions in the quarter, headlined by Boyd Thermal at $9.55 billion, and raised full-year adjusted EPS guidance to $13.05 to $13.50. CEO Paulo Ruiz called out “significant capacity expansion investments to meet demand” in Electrical Americas.
Risk: integration. Net interest expense jumped to $106 million from $33 million year over year, and GAAP EPS fell to $2.22 from $2.45 on acquisition charges. A stumble on Boyd or the planned Q1 2027 Mobility spin-off would compress the multiple quickly.
Vertiv (VRT): The High-Growth Pure Play Vertiv is the closest thing to a listed data-center-infrastructure pure play. On July 15, shares changed hands around $300.86, up more than 71% year to date and more than 136% over the past year. Forward earnings sits at 52x, with a consensus target of $377.40 and 22 Buy or Strong Buy ratings calls versus three Hold ratings.
SoFi Active Invest is offering a limited-time promotion. Open an account, fund it with $50 or more, and you could receive up to $1,000 in complimentary stock for Active Invest accounts. See for yourself by clicking here now.
The re-rating has fundamentals behind it. Q1 revenue grew 30.1% to $2.65 billion, adjusted EPS of $1.17 beat by 15.68%, and Americas organic sales expanded 44%. Adjusted operating margin expanded 430 basis points to 20.8%. The leading indicator is Q4 2025 orders, which grew 252% year over year, pushing backlog to $15 billion at a book-to-bill near 2.9x. Vertiv joined the S&P 500 in March 2026 after picking up investment-grade ratings in February. Full-year adjusted EPS guidance was raised to $6.30 to $6.40, implying 50% to 52% growth at the midpoint.
Risk: valuation and geography. EMEA revenue declined 20.3%, and at 52x forward earnings with a beta of 2.03, any hiccup in the AI CapEx cycle would land squarely on this multiple. Shares already slipped 3.96% in the past week.
Caterpillar (CAT): The Scale Play With a Backup Power Kicker Caterpillar is the biggest of the three, at $438 billion in market cap, and its data center exposure runs through large reciprocating engines and turbines used for prime and backup power. Shares traded around $917.58 on July 15, up 53.34% year to date and 126.76% over the past 12 months. Forward earnings comes in at 39x, with an analyst target of $962.49 and a more mixed rating split: 15 Buy or Strong Buy ratings, 11 Hold ratings and two Sell ratings.
Q1 EPS of $5.54 topped the $4.64 consensus by 19.3% on revenue of $17.415 billion, up 22.2%. Power Generation, the product line closest to AI infrastructure, grew 41% to $2.817 billion. Momentum has been building for four straight quarters: +28% in Q2 2025, +31% in Q3, +44% in Q4, and +41% in Q1 2026. CEO Joe Creed pointed to “a record backlog” as the foundation for continued momentum. Capital returns underline the scale: $5.0 billion in buybacks and roughly $0.7 billion in dividends in the quarter, with a yield near 0.64%.
Risk: tariffs and cyclicality. Resource Industries segment profit fell 39% on tariff-driven manufacturing costs, and Caterpillar’s construction and mining exposure remains cyclical if dealer inventory builds outrun end-user demand.
Investors get three distinct expressions of the same trade here: Eaton for compounding execution and M&A optionality, Vertiv for the highest earnings growth rate at the highest multiple, and Caterpillar for scale, capital returns, and a Power Generation line that keeps re-accelerating. Second-quarter reports across the group will be the near-term catalyst worth watching.
Want Up To $1,000? SoFi Is Giving New Active Invest Users Free StockLooking to grow your money but unsure where to begin? SoFi Active Invest is offering a limited-time promotion—open an account, fund it with $50 or more, and you could receive up to $1,000 in complimentary stock for Active Invest accounts.
From $0 commission trading to fractional shares and automated investing, this app is designed to simplify investing for everyone, whether you’re just starting or already experienced. Its easy to sign up and secure your bonus.
Kennedy Wilson zahájila soukromou nabídku dodatečných seniorních dluhopisů za 200 milionů USD se splatností v letech 2031 a 2033. Výnosy použije na splacení části dluhu z revolvingového úvěru.
BEVERLY HILLS, Calif.--(BUSINESS WIRE)--Kennedy-Wilson, Inc. (the “Issuer”), a wholly-owned subsidiary of global real estate investment company Kennedy-Wilson Holdings, Inc. (the “Company” or “Kennedy Wilson”), today announced that it has commenced a private offering (the “Offering”) of $200 million aggregate principal amount of additional 7.250% senior notes due 2033 and/or additional 7.000% senior notes due 2031 (as applicable, the “Additional Notes”) pursuant to Rule 144A and Regulation S under the Securities Act of 1933, as amended (the “Securities Act”).
On May 29, 2026, the Issuer issued an aggregate principal amount of $700 million of 7.250% senior notes due 2033 and $1.1 billion of 7.000% senior notes due 2031 (as applicable, the “Existing Notes”). The Additional Notes and the Existing Notes will be treated as the same series for all purposes under the indenture that governs the Existing Notes, and that will govern the Additional Notes. The Additional Notes will have the same terms, other than issue date and initial price, as the Existing Notes.
The Existing Notes are, and on the issue date of the Additional Notes, the Additional Notes will be, fully and unconditionally guaranteed on an unsecured basis by the Company and certain subsidiaries of the Issuer. The guarantees will rank equally in right of payment with all existing and future senior indebtedness of the guarantors and senior in right of payment to all existing and future subordinated indebtedness of the guarantors. There can be no assurance that the Offering will be completed.
The Issuer intends to use the net proceeds from the sale of the Additional Notes to repay a portion of the indebtedness outstanding under the unsecured revolving credit facility.
This press release is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities. The Additional Notes and the guarantees will be offered only to persons reasonably believed to be “qualified institutional buyers” (as defined in Rule 144A under the Securities Act) and to certain persons outside the United States pursuant to Regulation S under the Securities Act. The Additional Notes have not been and will not be registered under the Securities Act or under any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act, and, accordingly, are subject to significant restrictions on transfer and resale.
About Kennedy Wilson
Kennedy Wilson is a leading real estate investment company with $36 billion of assets under management in high growth markets across the United States, the UK and Ireland. Drawing on decades of experience, its relationship-oriented team excels at identifying opportunities and building value through market cycles, closing more than $60 billion in total transactions across the property spectrum since 2009. Kennedy Wilson owns, operates, and builds real estate within its high-quality, core real estate portfolio and through its investment management platform, where the company targets opportunistic equity and debt investments alongside partners.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the Issuer’s financing plans, including statements related to the Offering of the Additional Notes and the intended use of net proceeds of the Offering. These forward-looking statements are necessarily estimates reflecting the judgment of the Company’s senior management based on the Company’s current estimates, expectations, forecasts and projections and include comments that express the Company’s current opinions about trends and factors that may impact future results. Disclosures that use words such as “believe,” “may,” “anticipate,” “estimate,” “intend,” “could,” “plan,” “expect,” “project” or the negative of these, as well as similar expressions, are intended to identify forward-looking statements. Forward-looking statements involve significant known and unknown risks and uncertainties that may cause the Company’s actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. The inclusion of such statements should not be regarded as a representation that such plans, estimates or expectations will be achieved. There can be no assurance that the Offering of the Additional Notes will be completed, and there are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements made herein as a result of various factors, including, without limitation, risks related to whether the Issuer will consummate the offering of the Additional Notes on the expected terms, or at all, market and other general economic conditions, whether the Issuer and the guarantors will be able to satisfy the conditions required to close any sale of the Additional Notes, the ability of the Issuer to use the proceeds from any sale of the Additional Notes as currently intended and other risks that could affect the Company’s business, financial condition or results of operations. Forward-looking statements are not guarantees of future performance, rely on a number of assumptions concerning future events, many of which are outside of the Company’s control, and involve known and unknown risks and uncertainties that could cause the Company’s actual results, performance or achievement, or industry results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties may include the risks and uncertainties described elsewhere in this press release, in other filings with the Securities and Exchange Commission (the “SEC”) and in the offering memorandum for the Additional Notes. Any such forward-looking statements, whether made in this press release or elsewhere, should be considered in the context of the various disclosures made by the Company about its business including, without limitation, the risk factors discussed in the Company’s filings with the SEC. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. Except as required by applicable law, neither the Issuer nor the Company undertakes any obligation to update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
The EUR/TRY pair is testing a major 54.00 resistance level, a psychological barrier that previously triggered a significant technical rejection of the euro Persistent double-digit inflation and high energy import costs continue to structurally weaken the Turkish lira against the euro’s ongoing upward momentum Traders are awaiting the July 23 central bank policy meeting, where any unexpected hawkish signals could spark a sharp rally in the lira The euro has regained some ground against the Turkish lira after a period of decline in late June. The pair is currently trading near the 54.00 level, which has previously acted as a resistance point. This technical level raises questions about the potential for further advances and the continuation of the broader upward trend.
Why the Lira Keeps Losing Ground Several factors are contributing to the lira’s continued depreciation. Turkey is experiencing persistent high inflation, with the annual rate at 32.11% in June, a slight decrease from 32.61% in May. This figure remains significantly above the central bank’s medium-term objectives.
The Central Bank of the Republic of Turkey (CBRT) has maintained its policy rate at 37% for three consecutive meetings. This pause followed an aggressive easing cycle, which was complicated by rising energy prices due to Middle East conflict, impacting the path to lower inflation.
Turkey relies heavily on imported energy, so when Brent crude oil prices jump, it puts a strain on the country’s trade balance. This forces local businesses to keep selling lira to buy foreign currency to pay for fuel.
Governor Fatih Karahan has clearly stated that the bank needs to see more solid proof of inflation slowing down and better clarity on the geopolitical situation before they start cutting rates again. The next policy meeting is on July 23. Until then, the central bank’s message is basically wait and see.
Can the EUR/TRY Pair Break 54.00? Regarding the potential for the EUR/TRY pair to break above 54.00, the underlying macroeconomic conditions have not substantially changed, suggesting a continued test of recent highs. Analysts describe the lira’s depreciation as a managed, gradual movement rather than a sharp devaluation.
The CBRT has intervened periodically to moderate volatility without reversing the overall trend. This approach typically results in incremental movements toward resistance levels, which is consistent with the pair’s two previous attempts at the 54.00 mark.
For a decisive break, we’d probably need one of a fresh worsening of Turkish inflation expectations, a hawkish surprise from the ECB, or renewed geopolitical escalation pushing energy prices even higher. Without one of those catalysts, the pair might just keep consolidating right below that barrier.
If the EUR/TRY fails to break past this barrier over the next few sessions, a technical double-top pattern could emerge. This would likely trigger quick profit-taking by short-term momentum traders, potentially sending the pair sliding back down to test support at 53.50 and 53.12.
The Euro is also fighting its own battle. Softening economic growth indicators in the Eurozone or a shift by the ECB towards a more aggressive rate-cutting cycle could diminish the euro’s inherent buying support, thereby capping upside potential for the EUR/TRY.
Why is EUR/TRY struggling near 54.00?
This level marked a prior rejection point, and with no fresh catalyst yet, the pair is consolidating there rather than breaking through decisively.
Where does the Central Bank of the Republic of Turkey’s primary benchmark one-week repo rate currently sit?
The Monetary Policy Committee of the Central Bank of the Republic of Turkey has held its key one-week repo interest rate at 37%.
Why does a rise in global oil prices structurally weaken the Turkish lira against major foreign currencies?
Turkey imports nearly all its energy. Therefore, surging oil costs widen its trade deficit by forcing domestic firms to sell lira for foreign currencies.
Apollo Global Management bylo vyřazeno z Russell 1000 Growth a přesunuto do Russell 1000 Value, což po rebalancování stlačilo akcie asi o 15 % v posledních týdnech. Firma zároveň uvedla, že po podání u SEC z 22. června omezila odkupy na 5 %.
Apollo Global Management's (APO +1.58%) stock price is down about 15% in recent weeks. The decline is mainly tied to the annual reconstitution of the Russell indexes. Apollo, an alternative asset manager, was removed from the Russell 1000 Growth Index following the latest reconstitution, which took effect on June 26.
In the algorithms that Russell uses to reconstitute its various indexes, Apollo no longer exhibited the traits of a growth stock. Instead, it was deemed a value stock and was moved into the Russell 1000 Value Index.
Right after the rebalancing took effect, Apolloʻs stock price dropped sharply and is now trading at roughly $120 per share, off 18% year to date. But is this an opportunity to buy low on this growth-turned-value stock?
Image source: Getty Images.
Growth to value A big reason Apollo stock dropped is that it got kicked out of two massive growth exchange-traded funds (ETFs) -- the $127 billion iShares Russell 1000 Growth ETF (IWF +0.28%) and the $44 billion Vanguard Russell 1000 Growth ETF (VONG +0.26%). Losing invested capital from these sizeable funds, literally overnight, can leave a big dent in the stock price.
It did get added to two value ETFs -- the $81 billion iShares Russell 1000 Value ETF (IWD +0.37%) and the $20 billion Vanguard Russell 1000 Value ETF (VONV +0.47%). But combined, these two ETFs have almost $75 billion less in assets to invest than the two growth ETFs.
That aside, Apollo Global still has strong fundamentals, and this rebalancing could present an excellent buying opportunity.
Showtime for Apollo? Apollo stock looks like a good buy right now, with some momentum following a strong first quarter. As an alternative asset manager, it invests in private equity, private debt, and other alternative investments. These assets tend to have a low correlation to stocks, often performing well when stocks don't -- like they did in the first quarter.
Today's Change
(
1.58
%) $
1.90
Current Price
$
121.83
In Q1, Apollo had record fee-related income of $728 million, up 30% year over year, while adjusted net income rose 8% to $1.2 billion. Wall Street analysts project 21% revenue growth in 2026 and 14% growth in 2027. Earnings are expected to rise 6% this year and another 20% in 2027.
One concern that contributed to the sell-off was a June 22 Securities and Exchange Commission (SEC) filing that said Apollo was capping redemptions at 5%. This was most likely due to high redemption requests to its flagship fund, Apollo Debt Solutions, totalling 16.8% of the fund. This was sparked by heightened concerns among investors about problems in the private credit market. It's the second quarter in a row that they've put redemption caps in place. While private credit has been resilient, it is something to watch.
Apollo is a good value on a forward earnings basis Apollo's price-to-earnings (P/E) ratio is high, but that's because it took GAAP (generally accepted accounting principles) losses last quarter due to a high one-time offshore tax-related expense. But on a forward earnings basis, it is relatively cheap, trading at 13 times forward earnings.
Some 73% of Wall Street analysts rate it as a buy, with a median price target of $150 per share. That would suggest 25% upside.
I think reconstitution will benefit investors, as they can now get this value stock at a discount.
Bath & Body Works vstoupila do Brazílie otevřením první prodejny v Morumbi Shopping v São Paulu a spuštěním lokálního e-shopu. Firma tím rozšiřuje mezinárodní působení, které už zahrnuje více než 550 mezinárodních lokalit ve více než 45 zemích.
COLUMBUS, Ohio, July 16, 2026 (GLOBE NEWSWIRE) -- Bath & Body Works, a global leader in personal care and home fragrance, today announced its entry into Brazil with the debut of its first store and digital destination, bathandbodyworks.com.br. This entry strengthens Bath & Body Works' global footprint as the brand expands its reach into prime international markets where consumer demand for fragrance and self-care is strong and growing.
Now open at Morumbi Shopping—one of São Paulo’s premier retail destinations—Bath & Body Works’ first store in Brazil brings the brand’s market-leading fragrance expertise to new consumers with an assortment of iconic and beloved scents across body care and home.
Brazil is recognized as one of the world’s largest beauty markets where demand for accessible, high-quality fragrance is growing. Brazilian consumers see fragrance as an essential part of their daily self-care routine, often layering multiple scents to create a more personalized experience. As a global fragrance leader with a wide portfolio of accessible, high-quality scents, Bath & Body Works is well positioned to meet this consumer demand.
"The best opportunities are where consumers already love the category,” said Daniel Heaf, Bath & Body Works chief executive officer. “Brazil is one of the largest and most passionate fragrance markets in the world, making it a natural place for Bath & Body Works. We're excited to bring our fragrances to more consumers and become part of how they express themselves every day.”
Brazilian consumers can shop a wide assortment of Bath & Body Works’ perfumer-crafted, fan-favorite collections. These include Champagne Toast, A Thousand Wishes, In the Stars, Into the Night, Gingham and Warm Vanilla Sugar across body care and home fragrance, including fine fragrance mist, body cream, lotion, eau de parfum, body wash, hand soap, 3-wick candles and more.
In addition to best-sellers and brand icons, Bath & Body Works localizes its assortments through a strong franchise partner model. By tapping into partners’ deep regional consumer expertise, the brand can refine its approach and curate product offerings that resonate with fragrance preferences across global markets.
In Brazil where demand for fruity and tropical scents is strong, the product assortment was tailored to meet these specific preferences. Consumers can explore fragrances like Waikiki Beach Coconut, Pink Pineapple Sunrise, Mango Papaya Paradise, Rainforest Falls and Sea Salt Coast.
The Viva collection, which first debuted in U.S. stores, is also represented in this assortment. It was developed alongside world-class perfumers and features fragrances inspired by Brazil’s vibrant culture, energetic spirit and breathtaking scenery.
This collection includes:
Viva Brazil, a bright, juicy blend of fresh guava, maracuja zest and coconut water. Available in body care, 3-wick and single wick candles, diffusers and hand soap. Dreaming of Rio, an evocative escape featuring golden banana, gardenia petals and sunlit cedarwood. Available in body care.Warm Summer Evening, warm florals, calming amber and velvety sandalwood. Available in 3-wick and single wick candles and hand soap.Banana Cream Latte, a playful gourmand scent with whipped banana, smooth espresso and sweet cream. Available in a 3-wick candle. International growth remains a key pillar of the brand’s strategy to place Bath & Body Works in new environments that strengthen discovery, drive awareness and attract new consumers, creating new pathways into the brand.
Today, Bath & Body Works has more than 550 international locations spanning six continents and over 45 countries.
Driven by strong global demand, Bath & Body Works continues to accelerate international growth, expanding its store footprint and reach to consumers worldwide.
ABOUT BATH & BODY WORKS
Bath & Body Works is a global leader in personal care and home fragrance, driven by the belief that everybody deserves to feel good.
The brand’s beloved and iconic scents are expertly crafted for exceptional performance and a luxury fragrance experience. Formulated with thoughtfully chosen ingredients, Bath & Body Works’ body care products are available in multiple forms including fine fragrance mist, body cream, lotion, eau de parfum, body wash, hand soap, sanitizer and more. The brand’s famous 3-wick candles are made with rich, high-quality fragrance oils layered throughout a premium soy wax base, for up to 45 hours of room-filling fragrance.
Consumers can shop Bath & Body Works anytime and anywhere they choose, from welcoming, in-store experiences at more than 1,900 stores in the U.S. and Canada, 550-plus international locations and select Ulta Beauty stores. Online, consumers can visit bathandbodyworks.com, Amazon and Ulta.com.
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Marex Group Limited (NASDAQ: MRX), the diversified financial services platform, today announced that clients will be able to utilize USDC, a regulated1, fully reserved dollar-denominated stablecoin issued by Circle, serving as the digital collateral asset in this workflow, as initial margin (IM) collateral. This initiative is enabled in collaboration with Coinbase, and will assist clients in deploying their digital asset portfolios more effectively while tapping into the benefits of blockchain-native transfer rails. Coinbase provides the underlying infrastructure supporting custody, on/off-ramps, and reporting required for this capability.
“The future of finance is unfolding before our eyes,” said Stephen Hood, Head of Clearing, Americas at Marex. “With regulatory clarity helping to shape the future of USDC and other stablecoins, the speed and accessibility of blockchain technology is transforming clearing globally. For clients actively trading digital assets, the ability to use USDC as good segregated collateral will enhance capital efficiencies and set the stage for a new wave of innovation.”
The launch of this service follows the issuance of a no-action letter from the Commodities Futures Trading Commission (CFTC) in December 2025, on the use of digital assets as collateral. The letter effectively permits Futures Commission Merchants (FCMs) to accept non-securities digital assets, including USDC, Bitcoin and Ethereum, as customer margin collateral for CFTC-regulated derivatives and to treat them in certain risk calculations, subject to strict conditions. Coinbase supports Marex’s implementation through NYDFS-qualified custody, 1:1 instant fiat-to-USDC conversion, and bespoke reporting infrastructure aligned with CME requirements.
The integration of USDC marks a significant step toward modernizing global derivatives market infrastructure. In today’s markets, risk moves in response to global events as they unfold, yet collateral relies on traditional banking rails constrained by operating hours and multi-day settlement. The ability to post USDC as initial margin empowers Marex clients to manage risk in near real time, moving collateral 24/7 at internet-speed to keep pace with always-on markets. Over time, as the use of tokenized collateral becomes more prevalent, its real-time mobility and transparency can help drive down risks across the system.
“USDC, when integrated into institutional trading and clearing workflows, enables initial margin to move at internet speed, unlocking new levels of efficiency and programmability in collateral management all while meeting the rigorous standards institutional markets demand,” said Claire Ching, VP of Global Capital Markets at Circle. “By supporting USDC as IM collateral, Marex is equipping institutional trading clients to operate seamlessly in a 24/7 global market environment.”
“Stablecoin collateral is moving from concept to production. Coinbase is providing the institutional infrastructure underneath: NYDFS-qualified custody, instant fiat-to-USDC conversion, and reporting built to meet clearing-grade requirements. The same infrastructure that safeguards assets for the majority of US spot crypto ETFs is now powering collateral workflows in regulated derivatives clearing. We expect this model to extend across more clearinghouses and margin workflows as the market moves toward always-on collateral,” said Liz Martin, Coinbase VP of Markets and Head of Derivatives.
Joe Balcarcel, Chief Administrative Officer, said: “Prime Trading, LLC is excited to partner with Marex on this innovative initiative and support the continued evolution of digital asset infrastructure within traditional derivatives markets. We believe this represents an important step forward for the trading industry, as blockchain-based collateral solutions have the potential to enhance capital efficiency, improve the speed and flexibility of collateral management, and provide the ability to respond to significant market events and trading opportunities beyond traditional banking hours.”
Ram Vittal, Chief Executive Officer, Marex Americas, said: “We’re proud to be at the forefront of the convergence of digital assets and traditional finance to enhance market access and responsibly reshape the financial ecosystem for clients and future generations.”
For its first transaction, Marex accepted USDC as IM collateral from Prime Trading, with Coinbase’s supporting custody, settlement, and reporting infrastructure, and delivered cash to fund positions.
Marex is a leader in digital assets innovation and regulated crypto markets. In addition to being a large clearer of crypto derivatives on CME, Cboe, SGX, Coinbase Derivatives Exchange, and Bitnomial, Recently, Marex was a day one clearer for the launch of SGX Crypto Perpetual Futures, cleared the first-ever Bitcoin Friday Futures block trade and the first-ever Bitcoin Friday Futures options trade on CME.
About Marex:
Marex Group Limited (NASDAQ: MRX) provides market access, infrastructure services and essential liquidity to clients across global commodity and financial markets. The Group provides comprehensive breadth and depth of coverage across four services: Clearing, Agency and Execution, Market Making and Hedging and Investment Solutions. It has a leading franchise in many major metals, energy and agricultural products, with access to more than 60 exchanges. Marex has over 3,400 active clients, including some of the largest commodity producers, consumers and traders, banks, hedge funds and asset managers. With more than 50 offices worldwide, the Group has over 3000 employees across Europe, Asia and the Americas. For more information visit www.marex.com.
About Circle Internet Group, Inc.
Circle (NYSE: CRCL) is one of the world’s leading internet financial platform companies, building the foundation of a more open, global economy through programmable blockchain infrastructure, digital assets, and payment applications. Circle’s platform includes the world’s largest stablecoin network anchored by USDC, Circle Payments Network for global money movement, and Arc, an enterprise-grade blockchain designed to become the Economic OS for the internet. Enterprises, financial institutions, and developers use Circle to power trusted, internet-scale financial innovation.
About Coinbase
Crypto creates economic freedom by ensuring that people can participate fairly in the economy, and Coinbase (NASDAQ: COIN) is on a mission to increase economic freedom for more than 1 billion people. We’re updating the century-old financial system by providing a trusted platform that makes it easy for people and institutions to engage with crypto assets, including trading, staking, safekeeping, spending, and fast, free global transfers. We also provide critical infrastructure for onchain activity and support builders who share our vision that onchain is the new online. And together with the crypto community, we advocate for responsible rules to make the benefits of crypto available around the world.
About Prime Trading LLC
Prime Trading LLC is a Chicago-based proprietary trading firm specializing in futures, options, equities, and digital assets across global markets. The firm combines experienced discretionary traders with systematic and quantitative trading strategies, supported by dedicated teams in operations, technology, and risk management. Prime maintains memberships and market access across major global derivatives exchanges through longstanding clearing and execution relationships, enabling it to trade a diverse range of asset classes worldwide. Through continued investment in technology and its traders, the firm remains focused on innovation, disciplined risk management, and long-term growth.
Garmin představil G2000 PRIME, prémiový integrovaný letový systém pro vysoce výkonná pístová a elektrická letadla. Nabízí dotykové displeje, pokročilou konektivitu a bezpečnostní funkce včetně Autoland.
G2000 PRIME brings turbine-class avionics technology to high-performance piston and electric aircraft
, /PRNewswire/ -- Garmin (NYSE: GRMN) today introduced G2000® PRIME, its new premium integrated flight deck for high-performance Class I/II piston and electric aircraft. Leveraging innovations debuted in the G3000 PRIME flight deck, G2000 PRIME refines the flight deck experience for another class of aircraft with sleek, intuitive, all-touchscreen displays. State-of-the-art user interface design and advanced connectivity enable G2000 PRIME to leverage cutting-edge technologies that can enhance safety potential and efficiency while minimizing pilot workload in every phase of flight.
Garmin unveils G2000 PRIME Integrated Flight Deck "The response to our PRIME flight decks has been incredibly enthusiastic, and we're excited to bring this next-generation technology to high-performance light general aviation aircraft with G2000 PRIME. As pilots and aircraft manufacturers continue to seek more intuitive, capable and connected avionics, G2000 PRIME delivers on that demand with a premium flight deck experience designed to help simplify operations, enhance situational awareness and support advanced safety-enhancing technologies. It represents an important step forward in bringing Garmin's most advanced integrated flight deck innovations to more aircraft and more pilots."
–Phil Straub, Garmin Executive Vice President and Managing Director, Aviation
Stunning edge-to-edge glass flight displays
G2000 PRIME features expansive 14-inch touchscreen primary display units (PDU) with edge-to-edge, sunlight-readable, fingerprint-resistant glass, redefining expectations in cockpit aesthetics and functionality. The vibrant displays include multiple performance enhancements such as quadruple the memory and gigabit system connectivity that is up to 100 times faster than earlier systems. New, faster multi-core processors more than double the processing power – leveraging Garmin's experience certifying multi-core technology for civil and military aviation markets as early as 2017. Additionally, higher display refresh rates provide crisp, smooth animations and an impressively responsive and fluid experience.
The secondary display units (SDU) provide data entry and system control, with the added capability to display multi-function applications. The high-resolution, 7-inch SDUs boast a 40% increase in screen area over prior Garmin touch controllers. Additionally, in certain aircraft applications, the SDUs can double as an integrated standby flight instrument display, removing the need for a dedicated standby flight instrument in the panel.
G2000 PRIME's new advanced multi-touch touchscreen interface, capable of recognizing up to 10 touchscreen inputs at once, allows both pilot and copilot to interact with the same display simultaneously. The enhanced multi-touch technology also enables on-screen hand stabilization, allowing pilots to give precise touchscreen inputs while simultaneously resting their fingers on the display.
Modern & intuitive new user interface
G2000 PRIME boasts a modern, yet familiar user interface, blending Garmin's rich experience in avionics design with a sleek, contemporary look and feel. Enhanced fonts and iconography ensure clarity and familiarity, while smartly organized and shallow application menus provide quick access to critical functions.
Primary Flight Windows (PFW) and Multi-Function Windows (MFW) maximize situational awareness with full-screen or split-screen options. New quick access bars allow pilots to open common apps such as maps, traffic, weather and charts with one touch. While viewing maps, pilots can touch anywhere to open a radial menu with options for accessing additional airport, weather, or airspace information, or quickly adjusting a flight plan via graphical editing. Interactive engine and electrical indications allow pilots to quickly open systems controls and information such as cabin environmental controls, synoptics and more.
To further ease information management, the Window Manager feature allows pilots to configure app display, window sizing, and more across the entire flight deck from one SDU. The Window Manager also provides multiple preset options that can configure all displays with one command, eliminating the need for operators to manually configure each window for various phases of flight.
Advanced flight tools
G2000 PRIME provides enhanced flight management system (FMS) tools like the Modified Flight Plan, which allows pilots to use both the PDU and SDUs to provide a side-by-side graphical preview of flight plan changes, including performance calculation comparisons or what-if scenarios. During initialization, pilots can also elect to set up an Emergency Return function, which simplifies pilot responses to in-flight emergencies shortly after takeoff. Recently introduced to Garmin integrated flight decks,
Taxiway Routing has been further improved to provide automated route guidance on the 2D navigational maps and 3D Synthetic Vision Technology (SVT™) depictions.
G2000 PRIME provides advanced automation with smart checklists that are linked to crew alerting system (CAS) messages. When pilots receive a CAS message that is associated with a checklist, pilots may simply tap the message to open the appropriate checklist with a single touch. The checklists can also now sense indications and show within the checklist that the item is in the correct position, value or configuration – or provide pilots with the option to quickly view detailed synoptics. Integration with Garmin-designed Electronic Power Distribution Systems replaces traditional switches with intuitive electronic circuit breakers, providing enhanced automation and ensuring a streamlined and modern cockpit experience.
Unmatched safety-enhancing innovations
G2000 PRIME features a wide array of industry-leading advanced safety-enhancing technologies available only from Garmin, including Autonomí, Garmin's family of autonomous safety-enhancing technologies. Collier Trophy recipient, Garmin Autoland, can take complete control of the flight to land the aircraft in an emergency situation where the pilot is unable to do so1. Additional safety tools such as Smart Glide™, Smart Rudder Bias, Electronic Stability Protection (ESP™), Emergency Descent Mode (EDM) and Garmin Autothrottle further ensure confidence in every flight.
Garmin's terminal safety solutions add even more capabilities to G2000 PRIME-equipped aircraft. Award-winning Runway Occupancy Awareness (ROA) technology analyzes GPS and ADS-B traffic information relevant to the airport's runways and taxiways to assess and alert the flight crew of a possible runway incursion or collision. ROA builds upon Garmin's other terminal safety solutions including 3D SafeTaxi® and Garmin SurfaceWatch™.
Seamless connectivity and integration
Stay fully connected while flying behind G2000 PRIME using a variety of supported connectivity options such as Connext Satellite Services, LTE, SiriusXM, Wi-Fi, Bluetooth® and more. Garmin's PlaneSync™ connected aircraft management system automatically updates databases2, logs flight and engine data and allows aircraft owners and operators to remotely check fuel and systems status via the Garmin Pilot™ app3. Automated cockpit functions such as flight plan uploads over PlaneSync ensure pilots have access to real-time data, enhancing their operational efficiency and decision-making.
Initial aircraft delivering with G2000 PRIME will be announced by aircraft manufacturers. To learn more, visit Garmin.com/G2000PRIME.
Garmin products and services have revolutionized flight and become essential to the lives of pilots and aircraft owners and operators around the world. A leading provider of solutions to general aviation, business aviation, rotorcraft, advanced air mobility, government and defense, and commercial air carrier customers, Garmin believes every day is an opportunity to innovate. Recipient of the prestigious Robert J. Collier Trophy for Garmin Autoland, Garmin developed the world's first certified autonomous system that activates during an emergency to control and land an aircraft without human intervention. Visit the Garmin Newsroom, email our media team, connect with @garminaviation on social, or follow our blog.
1 See Garmin.com/ALuse for Autoland system requirements and limitations.
2 Active PlaneSync and database subscriptions required for automatic database updates. Active PlaneSync subscription plan required for flight log uploading. Features are available on-ground only and requires GDL 60 to have active LTE or Wi-Fi connectivity; signal strength and other factors may apply. See Garmin.com/PlaneSyncCoverage for LTE coverage details.
3 Remote aircraft status requires active PlaneSync subscription. User's smart device must have internet connectivity. Feature is available on-ground only and requires GDL 60 to have LTE connectivity; signal strength and other factors may apply. See Garmin.com/PlaneSyncCoverage for coverage details.
About Garmin International, Inc. Garmin International, Inc. is a subsidiary of Garmin Ltd. (NYSE: GRMN). Garmin Ltd. is incorporated in Switzerland, and its principal subsidiaries are located in the United States, Taiwan and the United Kingdom. Garmin, G2000 and SafeTaxi are registered trademarks and SVT, Smart Glide, ESP, SurfaceWatch, PlaneSync and Garmin Pilot are trademarks of Garmin Ltd. or its subsidiaries. All other brands, product names, company names, trademarks and service marks are the properties of their respective owners. All rights reserved.
Notice on Forward-Looking Statements:
This release includes forward-looking statements regarding Garmin Ltd. and its business. Such statements are based on management's current expectations. The forward-looking events and circumstances discussed in this release may not occur and actual results could differ materially as a result of known and unknown risk factors and uncertainties affecting Garmin, including, but not limited to, the risk factors listed in the Annual Report on Form 10-K for the year ended December 27, 2025, filed by Garmin with the Securities and Exchange Commission (Commission file number 0-31983). Copies of such Form 10-K are available at https://www.garmin.com/en-US/investors/sec/. No forward-looking statement can be guaranteed. Forward-looking statements speak only as of the date on which they are made, and Garmin undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
MEDIA CONTACT:
Mikayla Rudolph
913-397-8200
[email protected]
AIRO oznámila dokončení velké dodávky dronů RQ-35 Heidrun globálnímu obrannému zákazníkovi ve 2. čtvrtletí 2026. Firma tím ukázala schopnost škálovat výrobu autonomních systémů.
MCLEAN, Va.--(BUSINESS WIRE)--AIRO Group Holdings, Inc. (Nasdaq: AIRO), a next-generation aerospace and defense company, today announced the successful delivery of a major unmanned aircraft systems (UAS) order to a global defense customer. Completed during the second quarter of 2026, the delivery highlights the continued expansion of AIRO’s autonomous systems business.
“Because we build the sensor, the autonomy and the airframe in-house, we control quality, cost and delivery in a way competitors relying on outside suppliers cannot.” - Joe Burns, CEO of AIRO
ShareThe delivery marks another milestone in AIRO’s strategy to expand its portfolio of proprietary technologies, increase the value delivered on each platform, and strengthen its ability to scale production for allied defense customers. Importantly, this significant delivery demonstrates AIRO’s ability to respond rapidly to large-volume customer demand, leveraging the strength of its SkyWatch brand’s supply chain, manufacturing capabilities, and operational execution.
The RQ-35 Heidrun is a battle-proven, fixed-wing UAS that gives soldiers and decision-makers real-time intelligence, surveillance and reconnaissance capabilities. Its onboard mission-centric AI supports detection, recognition and identification, along with customer-specific edge applications.
“Getting proven systems into operators’ hands quickly is what matters most in today’s environment, and this delivery reflects our ability to do exactly that at scale,” said AIRO Executive Chairman Dr. Chirinjeev Kathuria. “As demand for unmanned ISR accelerates across allied forces, our focus is on being the partner that delivers reliable capability when and where it is needed.”
Continuously refined through battlefield feedback and validated in Ukraine, the RQ-35 Heidrun offers up to three hours of endurance, a 50 km operational range, onboard AI processing, electronic warfare-resilient navigation support and a low visual and acoustic profile. The platform is designed for time-sensitive ISTAR, target observation, route reconnaissance and terrain awareness missions.
“This delivery underscores AIRO’s strategy to build and scale advanced unmanned systems that meet the urgent needs of allied defense and security customers,” said Joe Burns, Chief Executive Officer of AIRO. “Because we build the sensor, the autonomy and the airframe in-house, we control quality, cost and delivery in a way competitors relying on outside suppliers cannot. That vertical integration is what let us convert this order into a fielded capability on schedule, and it is how we intend to keep executing against our backlog.”
This major RQ-35 drone delivery demonstrates the continued scaling of AIRO’s unmanned systems production and the growing role of its platforms in allied defense and security operations. The Company remains focused on expanding production capacity, increasing the amount of proprietary technology across its platform, and delivering mission-critical systems that support future growth opportunities across U.S., NATO, and allied markets.
About AIRO Group Holdings, Inc.
AIRO Group Holdings is a next-generation aerospace and defense platform driving innovation across defense and commercial markets. Headquartered in McLean, Va., with operations in the U.S., Canada and Denmark, AIRO combines global reach with deep technical expertise. Through a vertically integrated model, AIRO delivers mission-critical solutions centered on drone platforms, advanced avionics, integrated training capabilities and embedded autonomy.
Forward looking statements
The statements contained in this press release that are not historical facts are forward-looking statements. You can identify forward-looking statements because they contain words such as “believes,” “expects,” “may,” “will,” “should,” “seeks,” “intends,” “plans,” “estimates,” or “anticipates,” or similar expressions which concern our strategy, plans, projections or intentions. These forward-looking statements may be included throughout this press release and include, but are not limited to, the expected timing of full-scale production of the RQ-35; AIRO's ability to leverage its existing manufacturing infrastructure and supply chain capabilities; the development, testing, scaling, production, deployment, performance and capabilities of the RQ-35; customer interest in, demand for, market acceptance of and deployment opportunities for the RQ-35 and AIRO's other drone platforms; AIRO’s ability to compete across a broader set of mission requirements and grow its global defense platform; AIRO’s ability to execute its strategic initiatives across U.S., NATO, and allied markets; and other statements that are not historical fact. By their nature, forward-looking statements are not statements of historical fact or guarantees of future performance and are subject to risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify, including those described in the section titled “Risk Factors” in AIRO’s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (“SEC”), as well as other filings AIRO may make with the SEC in the future. Forward-looking statements represent AIRO’s management’s beliefs and assumptions only as of the date such statements are made. AIRO undertakes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
AMD klesá už druhou seanci po sobě, i když analytici dál zvyšují cílové ceny. Investory znepokojuje vysoké ocenění a zpomalující AI rally v polovodičích. Akcie za dvě seance odepsaly zhruba 6 %.
Advanced Micro Devices stock (NASDAQ: AMD) was heading for a second straight decline on Thursday despite bullish Wall Street research.
AMD fell about 3.2% to $513 in premarket trading after dropping 3.5% on Wednesday, putting the stock on course for a two-session fall of about 6%.
The weakness reflected a wider retreat from semiconductor stocks and concern that AMD’s elevated valuation leaves little room for delays in its ambitious AI roadmap.
The Philadelphia Semiconductor Index fell 2.6% on Wednesday and ended about 16.5% below its June 22 high.
The Roundhill Memory ETF dropped roughly 7%, extending its decline from the recent peak to around 30%.
Those moves suggest investors are reducing exposure across the AI-hardware trade rather than responding only to AMD.
TSMC’s decision to raise capital spending after record earnings also revived questions about whether the industry is building capacity faster than customers can eventually monetise it.
Semiconductor shares delivered enormous gains in 2026 as chip shortages, rising prices and artificial-intelligence investment drove earnings forecasts higher.
That success has made the group vulnerable whenever investors question how long that growth can continue.
As per market data, the semiconductor index remained sharply higher for the year even after its July correction, while short interest and exchange-traded fund outflows had risen.
Alexander Lis, chief investment officer at SD Ventures, cautioned that target increases may partly reflect share-price momentum rather than guarantee future returns.
Rosenblatt Securities analyst Kevin Cassidy raised his AMD target to $665 from $490 and retained a Buy rating.
“We recommend owning AMD shares into the earnings report,” Cassidy said, according to TipRanks, citing EPYC server strength and AMD’s advantage following delays to Intel’s Diamond Rapids product.
UBS analyst Timothy Arcuri lifted his target to $700 from $670 and kept a Buy rating.
In a note reported, Arcuri said AMD’s July 22-23 AI event should highlight durable CPU and GPU roadmaps, possible partnerships and a broader data-centre market, while supply-chain checks remained supportive.
KeyBanc analyst John Vinh made the most aggressive call, raising his target to $725 from $530.
Vinh expects AMD’s AI GPU revenue to rise from $16.8 billion in 2026 to $48.5 billion in 2027 as additional server-processor capacity and the MI455 and Helios ramps support growth.
William Blair analyst Sebastien Naji provides the clearest explanation for the sell-off.
He initiated coverage at Market Perform, warning that AMD’s rally had left the shares “priced at a premium to peers with little room for error.”
Naji estimated AMD was trading at 33 times 2027 earnings.
He also questioned how long server-CPU share gains can continue as Arm-based processors, Qualcomm, Nvidia and a recovering Intel increase competition.
In accelerators, AMD must still prove it can take durable share from Nvidia while hyperscalers develop their own chips.
Performance remains strong as first-quarter revenue rose 38% to $10.3 billion, while Data Center revenue jumped 57% to $5.8 billion.
AMD guided for second-quarter revenue of approximately $11.2 billion.
The concern is therefore not weak demand today, but how much success the valuation already assumes.
Nvidia představila nový model Cosmos 3 Edge pro roboty a vision AI agenty a rozšiřuje tak své působení v japonské fyzické AI. Firma zároveň buduje koalici s Fujitsu, Hitachi a Kawasaki Heavy Industries.
Nvidia unveiled a new AI model for robots and vision AI agents on Wednesday, deepening its push into the physical AI market in Japan.
The company's new model, Cosmos 3 Edge, is a so-called world model, designed to help systems perceive and navigate physical environments in real time. Cosmos 3 edge is a World models are systems that can learn from a wider range of inputs compared to large language models (LLMs). The rollout follows the launch of Cosmos 3 in May.
The regional expansion takes center stage during CEO Jensen Huang's two-day visit to Japan, where the Silicon Valley chip giant is expanding its physical AI footprint by forming a coalition that local industrial giants, including Fujitsu, Hitachi, and Kawasaki Heavy Industries, intend to join, according to Nvidia.
"The next frontier of AI is in the physical world, and this is a once-in-a-generation opportunity for Japan," Nvidia CEO Jensen Huang said in a Wednesday statement. "Japan invented modern manufacturing. Now, it has the opportunity to reinvent it for the age of intelligent industries."
The tech giant's partnership with Japanese firms comes just months after Microsoft's $10 billion investment in the country, which aims to build out AI infrastructure and beef up cybersecurity. Japanese investment giant SoftBank has bet heavily on the boom in AI. It's looking to partner with Microsoft and Sakura Internet to develop AI in Japan.
Japan's AI market is expected to reach $27.9 billion by 2029, opening doors for U.S. firms to invest, according to the International Trade Administration. This growth is driven by Tokyo's active push to promote AI adoption across industries, coupled with the eagerness of local firms to forge international partnerships.
Ajay Rajadhyaksha, global chairman of research at Barclays, told CNBC last month that the country holds an advantage in Asia, driven by its diverse AI and clean structural growth stories.
Nvidia's partnership pushNvidia is also aggressively expanding its AI footprint into Japan's healthcare and biotechnology sectors by extending its reach into agentic AI for advanced sciences through new drug discovery and medical robotics initiatives.
When it comes to agentic AI, Nvidia highlighted the ongoing expansion of Tokyo-1, the AI drug discovery consortium operated by Xeureka, a Mitsui subsidiary. The platform, which has steadily grown since its initial announcement in 2023, is powered by the Nvidia BioNeMo Agent Toolkit, a platform for accelerating autonomous AI drug discovery.
Japan's pharmaceutical heavyweights are already scaling their involvement. Major drugmakers, including Astellas Pharma Inc, Daiichi Sankyo, and Ono Pharmaceutical are utilizing Nvidia's specialized biology toolkit to streamline their workflows, the U.S. company said in a blog post.
Beyond biotech, Nvidia said it is making inroads into industrial automation through a partnership with Kawasaki Heavy Industries.
Dryden Gold získala povolení k vrtům v Mud Lake, které jí umožní vrtat nové cíle po loňském programu. Povrchové vzorky v zóně podobné Elora ukázaly 93,00 g/t zlata.
Vancouver, British Columbia--(Newsfile Corp. - July 16, 2026) - Dryden Gold Corp. (TSXV: DRY) (OTCQX: DRYGF) (FSE: X7W) ("Dryden Gold" or the "Company") is pleased to announce that it has received the exploration permit for its Mud Lake target. The permit allows Dryden Gold to drill test extension targets identified through its 2025 drill program and geological mapping. Surface samples collected on a high-grade shear zone similar to Elora, where a significant fold in the mineralized structure occurs, assayed 93.00 g/t gold (Figure 1). This target is north of the previously permitted area and indicates a repetition that demonstrates the potential to extend the known mineralized system providing the foundation for a much larger gold-bearing district (Figure 2). This type of structural periodicity is typical of many high-performing gold camps in Northwest Ontario, including Red Lake.
Trey Wasser, CEO of Dryden Gold stated, "Based on the data and strong geological similarities, our team believes that Mud Lake has the potential to emerge as a significant extension within the Gold Rock Camp. We are increasingly encouraged by the prospect that the Manitou Dinorwic deformation zone ("MDdz") could host multiple gold deposits along strike. Securing this drill permit is an important step toward testing the discovery potential at Mud Lake to prove periodicity, at the deposit scale. With our strong treasury providing a robust 2026 field program, our exploration teams will continue mapping and prospecting at several additional high-priority targets across the Gold Rock Camp."
Recent geological mapping at the Mud Lake target has identified a mineralized structural corridor that shares several key characteristics with Big Master and Elora at Gold Rock. The 2026 mapping program also identified an en-echelon structural trend, where high-grade gold mineralization was discovered, further strengthening the Company's geological interpretation of the target. The approved drill permit also includes the Wamsley target; another high-priority area identified during the 2025 mapping campaign (Figure 2).
At Gold Rock, exploration drilling continues to advance several high-priority targets, including a newly interpreted central mineralized corridor located between the Elora and Big Master systems. A second drill is now operating and is testing the depth extensions of the known high-grade gold zones while the other drill is expanding the structural footprint at Gold Rock. One rig will be deployed to drill Mud Lake in early August.
Figure 1. Detailed map of the Mud Lake target highlighting key 2025 results
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/9776/305379_0309969564d53a30_001full.jpg
Figure 2. Geology map Gold Rock Camp (left side), detailed map of Gold Rock and
Mud Lake drill targets (right side)
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/9776/305379_0309969564d53a30_002full.jpg
Qualified Person
The technical disclosure in this news release has been reviewed and approved by Maura Kolb, M.Sc., P. Geo., President of Dryden Gold and a Qualified Person as defined by National Instrument 43-101 of the Canadian Securities Administrators.
Analytical Laboratory and QA/QC Procedures
The Company is drilling NQ size core. Samples are cut in half, with half going to the lab for analysis and half kept as a record. True thickness/widths of the mineralization is unknown, result intervals are reported as the drilled core lengths unless otherwise stated. All sampling completed by Dryden Gold Corp. within its exploration programs is subject to a Company standard of internal quality control and quality assurance (QA/QC) programs which include the insertion of certified reference materials, blank materials, and a level of duplicate analysis. Drill samples from the 2024, 2025 and 2026 programs were sent to Activation Laboratories, with sample preparation and analysis in Dryden, where they were processed for gold analysis by 50-gram fire assay with an atomic absorption finish and over limits determined by Fire Assay with a gravimetric finish. Select samples were analyzed using metallic screens. Activation Laboratories systems conform to requirements of ISO/IEC Standard 17025 guidelines and meets assay requirements outlined for NI 43-101.
ABOUT DRYDEN GOLD CORP.
Dryden Gold is an exploration company focused on the discovery of high-grade gold mineralization listed on the TSX-V ("DRY") and traded on the OTCQX ("DRYGF") and FSE ("X7W"). The Company has a strong management team and Board of Directors comprised of experienced individuals with a track record of building shareholder value through property acquisition and consolidation, exploration success, and mergers and acquisitions. Dryden Gold controls 100% interest in mining claims in a dominant strategic land position in the Dryden District of Northwestern Ontario. The property hosts high-grade gold mineralization over 50km of potential strike length along the Manitou-Dinorwic deformation zone. The property has excellent infrastructure, enjoys collaborative relationships with First Nations communities and benefits from proximity to an experienced mining workforce. Dryden Gold is committed to building respectful, collaborative relationships with Indigenous Nations and communities throughout our area of operations. We recognize the importance of ongoing dialogue, mutual understanding, and meaningful engagement as we advance our exploration activities.
For more information go to our website www.drydengold.com.
Cautionary Note Regarding Forward-Looking Statements
The information contained herein contains "forward-looking statements" within the meaning of applicable securities legislation. Forward-looking statements include, but are not limited to, statements with respect to: receipt of corporate and regulatory approvals, issuance of common shares; future development plans; and the business and operations of Dryden Gold. Forward-looking statements relate to information that is based on assumptions of management, forecasts of future results, and estimates of amounts not yet determinable which include the number of metres of drilling the company may complete in 2026 and the timing of certain exploration programs during the coming year. Any statements that express predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be "forward-looking statements." Forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ from those reflected in the forward-looking statements, including, without limitation: risks related to failure to obtain adequate financing on a timely basis and on acceptable terms; political and regulatory risks associated with mining and exploration; risks related to the maintenance of stock exchange listings including receipt of TSX Venture Exchange approval for the offering; risks related to environmental regulation and liability; the potential for delays in exploration or development activities; the uncertainty of profitability; risks and uncertainties relating to the interpretation of drill results, the geology, grade and continuity of mineral deposits; risks related to the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; the possibility that future exploration, development or mining results will not be consistent with the Company's expectations; risks related to commodity price fluctuations; and other risks and uncertainties related to the Company's prospects, properties and business detailed elsewhere in Dryden Gold's and the Company's disclosure record. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements. Investors are cautioned against attributing undue certainty to forward-looking statements. These forward-looking statements are made as of the date hereof and Dryden Gold and the Company do not assume any obligation to update or revise them to reflect new events or circumstances. Actual events or results could differ materially from Dryden Gold's and the Company's expectations or projections.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305379
Source: Dryden Gold Corp.
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Thunder Gold oznámila na cíli UV v Tower Mountain průnik 45,0 metru s 1,793 g/t Au, včetně 1,5 metru s 44,100 g/t Au. Výsledky potvrzují pokračování mineralizace v hloubce i nové mělké zóny poblíž současné jámy.
Thunder Bay, Ontario--(Newsfile Corp. - July 16, 2026) - Thunder Gold Corp. (TSXV: TGOL) (FSE: Z25) (OTCQB: TGOLF) ("Thunder Gold" or the "Company") is pleased to announce exploration diamond drill results from the UV Target, at the Company's flagship Tower Mountain Property, 40 kilometres west of Thunder Bay, Ontario.
Six (6) holes totaling 2,937 metres targeted the down-dip projection of the main mineralized trend observed in historical diamond drill holes completed from 2002 to 2005. Three (3) holes, TM26-198, 199 and 200 targeted the projected trend 100 to 150 metres below the current bottom of the optimized pit constraining the Company's 2026 Mineral Resource Estimate (the "MRE"). The remaining holes targeted gaps in the MRE where there was insufficient drill data to estimate gold grades.
Key results from the program include:
TM26-204: 142.0 metres averaging 0.668 g/t Au, including 45.0 metres averaging 1.793 g/t Au and 1.5 metres averaging 44.100 g/t Au, within and immediately adjacent to the 2026 MRE optimized pit limit.TM26-200: 238.5 metres averaging 0.259 g/t Au from 361.5 metres to 600.0 metres, consistent with historical results in TM11-63, TM04-13 and TM04-12. TM26-198: 39.0 metres averaging 0.320 g/t Au within 100 metres of surface, in a new mineralized zone immediately adjacent to the current optimized pit limit. TM26-203: 13.5 metres averaging 0.612 g/t Au from 3.0 to 16.5 metres depth in previously un-estimated rock. Full assay results, including hole locations, orientations and section references, are provided in Tables 1 and 2 below.
Drilling has confirmed that the main mineralized trend at UV continues at depth and remains open, with grades and widths consistent with historical drilling and the 2026 MRE. Importantly, multiple new zones of mineralization above the 2026 MRE cut-off grade of 0.19 g/t Au were intersected in areas previously modeled as waste, providing potential to reduce the current 1.8:1 waste-to-ore strip ratio defined within the optimized pit.
Wes Hanson, President and CEO states, "These results materially advance our understanding of the UV Target and reinforce the continuity of gold mineralization below and adjacent to the current pit shell. The step-out holes confirm that the low-grade core at UV continues at depth and remains open, while the shallow holes have identified new zones of near-surface mineralization in areas previously modeled as waste. Together, this work supports our objective of growing and upgrading the Tower Mountain resource, improving the strip ratio and enhancing the overall economics of a potential open-pit operation."
"We are now completing exploration drilling at the Bench Target along the eastern margin of the optimized pit, which will conclude the current phase of drilling focused on un-estimated areas within the 2026 MRE pit shell. We plan to commence resource definition drilling on August 1, targeting conversion of Inferred Resources to Indicated, with completion expected by September 30 and results anticipated by mid-October in advance of an updated MRE, subject to any delays related to extreme forest fire conditions in northwestern Ontario."
Table 1.0 - UV Target Drill Hole Location and Alignment
Figure 1.0 - Diamond Drill Plan, UV Target, February to June 2026
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/5364/305365_810560a624a59bf8_001full.jpg
Section A - A' TM26-198
TM26-198 was designed to test the downward continuation of the high-grade results reported in historical drill holes TM04-09, TM04-24 and TM21-90. The current optimized pit was unable to recover the mineralization associated with TM04-24 (88.5m @ 0.989 g/t Au) and TM21-90 (138.0 m @ 0.313 g/t Au) due to the unfavourable waste : ore strip ratio to access that mineralization. TM26-198 was drilled parallel to the southwestern edge of the optimized pit limit with two objectives:
Evaluate the down-dip continuity of the interpreted sub-vertical low-grade envelope; andEvaluate the potential for "new" mineralization external to the current optimized pit limit.
The UV low-grade mineralization was projected between 400 and 600 metres downhole. TM26-198 intersected a flat lying fault at the predicted upper contact of the low-grade trend and there is a definite increase in the number of individual samples above the targeted cutoff grade of 0.20 g/t Au. However, results are scattered and inconsistent throughout the projected target. The higher grade (1.0 to 10.0 g/t Au) feldspar porphyries, common in the upper drill holes, were absent throughout the target horizon, suggesting that TM26-198 is drilled parallel to the high-grade feldspar porphyry intrusives. From 400 metres onward, silicification ranged from strong to intense and there is a notable decrease in both carbonate-sericite alteration and pyrite, two key factors associated with the MRE gold distribution. Further drilling is necessary to evaluate the northern edge of the UV system.
TM26-198 successfully identified a new mineralized zone immediately adjacent to the current optimized pit limit intersecting 39.0 metres averaging 0.32 g/t Au within 100 metres of surface, immediately under the current optimized pit limit. Further shallow drilling is planned to expand this zone as it has the potential to increase the inferred resource.
Section B - B' TM26-199
TM26-199 was designed to test the downward continuation of the mineralization reported in historical drill holes TM04-03 (262.5 m @ 0.405 g/t Au), TM04-07 (168.0 m @ 0.237 g/t Au) and TM05-49 (243.0 m 2 0.241 g/t Au). TM26-199 was drilled parallel to the southwestern edge of the optimized pit limit with two objectives:
Evaluate the down-dip continuity of the interpreted sub-vertical low-grade envelope; andEvaluate the potential for "new" mineralization external to the current optimized pit limit.
TM26-199 intersected scattered, narrow intervals greater than 0.20 g/t Au from surface to 390 metres depth, parallel to the southwestern edge of the 2026 MRE optimized pit limit.
TM26-199 intersected the projected low-grade core of the UV Target from 390.0 to 598.5 metres, almost exactly as predicted, 100 metres below the 2026 MRE optimized pit limit. Gold grades are consistently above 0.10 g/t Au and average 0.220 g/t across the 208.5 metre interval. These results are consistent with the historical drill results from 2002 through 2005.
Section C - C' TM26-200 and TM26-203
As with holes TM26-198 and 199, TM26-200 was designed to test the downward continuation of the low-grade core UV mineralization, 100 to 150 metres below the 2026 MRE optimized pit limit while also testing areas that were not estimated due to insufficient drill hole density.
TM26-203, a shallow hole, targeted gaps in the 2026 MRE model that were the result of insufficient drill coverage.
TM26-200 intersected 34.5 metres @ 0.282 g/t Au from the bottom of casing at 6.0 metres depth to 40.5 metres depth. The mineralization lies external to the current MRE optimized pit, in an area previously un-estimated due to insufficient drill hole density. From 40.5 metres to 361.5 metres, TM26-200 intersected scattered, narrow intervals above the 0.20 g/t Au. TM26-200 intersected 238.5 metres @ 0.282 g/t Au from 361.5 metres to the end of the hole at 600 metres. The results are consistent with the historical results in holes TM11-63 (231.0 metres @ 0.468 g/t Au), TM04-13 (246.0 metres @ 0.177 g/t Au) and TM04-12 (108.0 metres @ 0.530 g/t Au).
TM26-203 intersected 13.5 metres @ 0.612 g/t Au from the bottom of casing at 3.0 metres to `16.5 metres depth. The remaining 271.5 metres intersected scattered, narrow intervals greater than 0.20 g/t Au in what was previously un-estimated rock due to insufficient data.
Section D - D' TM26-202 and TM26-204
Holes TM26-202 and TM26-204 were drilled as 50-metre step out holes surrounding TM23-143 which reported 109.0 metres averaging 0.317 g/t Au.
TM26-202 intersected 38.0 metres @ 0.207 g/t Au over the final 38 metres of the hole. The mineralization projects vertically under TM23-143 (109.0 metres @ 0.317 g/t Au) and is interpreted to represent the southwestern contact of the low-grade core of the UV Target defined in drill sections A-A', B-B' and C-C').
TM26-204 intersected 142.0 metres @ 0.668 g/t Au including 45.0 metres @ 1.793 g/t Au within and immediately adjacent to the 2026 MRE optimized pit limit. This intersection offers excellent potential to increase the overall inferred resource as the 2026 MRE estimated this area to be waste, due to lack of drill hole coverage. Shallow follow-up drill holes are planned before September to expand this newly identified trend.
Qualified Person
Technical information in this news release has been reviewed and approved by Wes Hanson, P.Geo., President and CEO of Thunder Gold Corp., who is a Qualified Person under the definitions established by NI 43-101.
About the Tower Mountain Gold Property
The 7,625-hectare, 100%-owned Tower Mountain Property is beside the Trans-Canada highway, 40-km west of Thunder Bay, Ontario (pop. 110,000). Gold mineralization occurs in variably brecciated and altered rocks surrounding the calc-alkalic Tower Mountain Intrusive Complex. Drilling to date has established an initial mineral resource of 500,000 ozs (Indicated) with an additional 3,000,000 ozs (Inferred), parallel to the western contact of the intrusion. The remaining 75% of the contact demonstrates similar geology, alteration, and geophysical signatures and is untested by drilling. A second gold trend, identified at surface in 2026, outcrops at surface and is continuously mineralized over a 100-metre width. The gold mineralization occurs within Timiskaming-type conglomerates that can be traced along a southwest trend for over 5.0 kilometres. Both targets offer opportunity to materially increase the total resource through systematic drilling.
About Thunder Gold Corp.
Thunder Gold is advancing the Tower Mountain project in Thunder Bay, Ont. -- an emerging gold system with the scale, consistency and quality to support a long-life, open-pit operation. Results from the disciplined drill programs have consistently reinforced confidence in the continuity and predictability of the discovery while highlighting significant potential for expansion across multiple zones of the Tower Mountain intrusive complex. With industry-leading drilling costs, existing infrastructure and a skilled local work force, Tower Mountain represents a rare combination of size, scalability and cost-effective growth.
At Thunder Gold, our vision is clear: to unlock a discovery that has the potential to become a transformational gold project, delivering long-term value for shareholders while contributing to the future of Canada's mining industry.
For more information about the Company please visit: www.thundergoldcorp.com.
On behalf of the Board of Directors,
Wes Hanson, P.Geo., President and CEO
NEITHER THE TSXV NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSXV) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
The information contained herein contains "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation (collectively, "forward-looking statements"). Forward-looking statements relate to information that is based on assumptions of management, forecasts of future results, and estimates of amounts not yet determinable. All statements, other than statements of historical fact, are forward-looking statements and are based on predictions, expectations, beliefs, plans, projections, objectives and assumptions made as of the date of this news release, including without limitation: the size of the Offering and other statements concerning the Offering; the anticipated use of proceeds from the Offering; the renunciation to the purchasers of FT Shares and timing thereof; the tax treatment of the FT Shares and the Company's plans regarding exploring its mineral exploration properties; anticipated results of geophysical drilling programs, geological interpretations and potential mineral recovery. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.
Forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ from those reflected in the forward-looking statements, including, without limitation: risks related to failure to obtain adequate funding on a timely basis and on acceptable terms; risks related to the outcome of legal proceedings; political and regulatory risks associated with mining and exploration; risks related to the maintenance of stock exchange listings; risks related to environmental regulation and liability; the potential for delays in exploration or development activities or the completion of feasibility studies; the uncertainty of profitability; risks and uncertainties relating to the interpretation of drill results, the geology, grade and continuity of mineral deposits; risks related to the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; results of prefeasibility and feasibility studies, and the possibility that future exploration, development or mining results will not be consistent with the Company's expectations; risks related to the gold price and other commodity price fluctuations; and other risks and uncertainties related to the Company's prospects, properties and business detailed elsewhere in the Company's disclosure record. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements. Investors are cautioned against attributing undue certainty or reliance on forward-looking statements. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise any forward-looking statements, other than as required by applicable law, to reflect new information, events or circumstances, or changes in management's estimates, projections or opinions. Actual events or results could differ materially from those anticipated in the forward-looking statements or from the Company's expectations or projections.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305365
Source: Thunder Gold Corp.
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Moderna oznámila první podání dávky v americké studii fáze 1 mRNA-4200 u pacientů s pokročilými nebo metastatickými solidními nádory. Studie bude hodnotit bezpečnost a snášenlivost v kombinaci s inhibitorem kontrolních bodů.
CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced or metastatic solid tumors. mRNA-4200 encodes for seven antigens commonly shared across patients and tumor types and is designed to help induce and expand T-cell responses against selected tumor targets.
"mRNA-4200 represents our third off-the-shelf cancer antigen therapy candidate and builds on our efforts to explore broad applicability across multiple cancer types," said David Berman, M.D., Ph.D., Chief Development Officer of Moderna. "By encoding multiple shared tumor targets, this investigational therapy reflects our ongoing efforts to expand the potential of cancer immunotherapy beyond single-target approaches as we continue working to transform cancer care for patients."
The first dose was administered by Dr. William McKean, Clinical Investigator at START Mountain Region in Salt Lake City, Utah, part of The START Center for Cancer Research, the world's largest community-based early-phase oncology site network.
"The first patient dosed in a study represents far more than an operational milestone--it marks the beginning of evaluating a new therapeutic approach that has the potential to impact patients with advanced cancer," said Dr. McKean. "We are proud to continue our collaboration with Moderna and to support the clinical development of mRNA-4200 by providing patients with early access to promising investigational treatments while generating the clinical evidence needed to advance cancer research."
The Phase 1 trial (ClinicalTrials.gov identifier: NCT06880549) is an open-label, multicenter, dose-escalation study that will evaluate the safety and tolerability of mRNA-4200 administered with checkpoint inhibitor therapy in adult participants with advanced solid tumors.
mRNA-4200 was developed in collaboration with Immatics under the Database Program. mRNA-4200 incorporates targets identified using Immatics' XPRESIDENT® target discovery and validation platform and its bioinformatics and AI platform XCUBE®.
About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
Moderna Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the ability for mRNA-4200 to help induce and expand T-cell responses against selected tumor targets; and the potential of Moderna's mRNA platform in oncology. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
Media:
Chris Ridley
Vice President, Global Head of Communications
+1 617-800-3651 [email protected]
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834 [email protected]
--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) today reported second quarter 2026 results and raised guidance for full year 2026.
“Our results and outlook reflect the continuing progress in our work to simplify how we operate, improve both affordability and the health care experience for patients and care providers and apply modern technology to create real improvement for people,” said Stephen Hemsley, chief executive officer of UnitedHealth Group.
The company now expects full year 2026 adjusted net earnings between $19.50 to $20.00 per share resulting from performance year-to-date and an improved outlook for the remainder of the year. A table outlining the company’s updated outlook is below, with additional detail on page 7 of this release.
Consolidated revenues for the second quarter 2026 were $112.0 billion and earnings from operations were $8.0 billion, with a net margin of 4.9%. Cash flows from operations were $11.1 billion, or 1.9x net income, and the debt-to-capital ratio was 41.2% as of June 30, 2026.
UnitedHealth Group’s medical cost ratio was 86.7% for the second quarter 2026, reflecting cost and pricing discipline, as well as mix changes across all benefit offerings. The operating cost ratio of 12.7% in the second quarter 2026 compared to 12.3% in the second quarter 2025, reflecting targeted investments in technology, operations and the community.
Over the last year, the company has advanced a broad set of reforms and commitments to improve affordability, transparency and simplicity for care providers and consumers. These actions reflect the company’s deep commitment to helping people live healthier lives and helping make the health system work better for everyone. These actions are outlined in more detail on page 3 of this release.
Second Quarter 2026 Key Performance Metrics
Second quarter 2026 adjusted net earnings were $6.38 per share. The medical care ratio was 86.7% and reflected product design changes, improved medical management and better aligned pricing. MCR was affected by $860 million of net favorable prior period development, with the majority related to 2026 dates of service. The operating cost ratio of 12.7% included targeted investments in infrastructure, artificial intelligence, care delivery enhancements, consumer experience and community support. UnitedHealthcare served 48.5 million consumers and reported revenues of $86.0 billion and earnings of $3.9 billion, with operating margins of 4.6%. Optum supported more than 120 million consumers and generated revenues of $65.7 billion and earnings of $4.0 billion, representing 160 basis points of margin expansion year-over-year. UnitedHealth Group Updated 2026 Full Year Guidance
($ in millions, except per share data)
Reported Operating
Earnings
Adjusted Operating
Earnings
UnitedHealthcare
> $12,000
> $12,000
Optum Health
> $2,275
> $2,215
Optum Insight
> $4,925
> $4,750
Optum Rx
> $6,250
> $6,250
Optum (a)
> $13,450
> $13,215
UnitedHealth Group
> $25,450
> $25,215
Medical Care Ratio
88.1% ± 25 bps
Tax Rate
~18.5%
Cash Flows from Operations
~$24,000
Share Repurchase
At Least $5,000
Net Earnings to UNH Shareholders
> $16,750
Diluted
Adjusted (b)
Net Earnings per Share
$18.45 - $18.95
$19.50 - $20.00
Addressing America’s Healthcare Challenges with Sustainable Solutions
UnitedHealth Group remains committed to addressing the issues that make health care costly and complicated for the people and providers we serve. Recent actions taken to address these issues include:
UnitedHealth Group Second Quarter 2026 Results
Quarterly Financial Performance
Three Months Ended
June 30,
2026
June 30,
2025
March 31,
2026
Revenues
$112.0 billion
$111.6 billion
$111.7 billion
Earnings from Operations
$8.0 billion
$5.2 billion
$9.0 billion
Net Margin
4.9%
3.1%
5.6%
UnitedHealth Group’s second quarter 2026 revenues were $112.0 billion compared to $111.6 billion in the year ago quarter. Second quarter 2026 earnings from operations of $8.0 billion compared to $5.2 billion in the year ago quarter, driven by strong performance across both UnitedHealthcare and Optum. The second quarter 2026 medical care ratio was 86.7% compared to 89.4% in the second quarter 2025. The year-over-year decrease was driven by benefit design and pricing discipline, member mix and medical cost management initiatives. Net medical reserve development was $860 million in the quarter. Days claims payable were 47.0 compared to 48.6 in the first quarter 2026 and 44.5 in the second quarter 2025. The sequential variation was driven by normal seasonality. Days sales outstanding of 17.7 compared to 21.6 in the first quarter 2026 and 19.9 in the year ago quarter, with the sequential and year-over-year decrease due to payment timing. The second quarter 2026 operating cost ratio of 12.7% compared to 12.3% in second quarter 2025, reflecting incremental investments in technology, processes and people to improve care delivery and customer experiences and advance community health. Cash flows from operations were $11.1 billion, or 1.9 times net income, reflecting the timing of a substantial government payment, along with strong earnings performance and disciplined working capital management. Debt-to-capital ratio was 41.2% as of June 30, 2026, compared to 42.9% in the first quarter 2026 and 44.1% in the second quarter 2025. The company continues to target a long-term debt-to-capital ratio of approximately 40.0% by year-end. The company repurchased $4.0 billion of its common stock through mid-July 2026 and is on track to repurchase at least $5.0 billion for the full year 2026. UnitedHealthcare Second Quarter 2026 Results
UnitedHealthcare provides health care benefits to individuals and employers, as well as Government Program beneficiaries. UnitedHealthcare is dedicated to improving the value customers and consumers receive by improving health and wellness, enhancing the quality of care received, simplifying the health care experience and reducing the total cost of care.
Quarterly Financial Performance
Three Months Ended
June 30,
2026
June 30,
2025
March 31,
2026
Revenues
$86.0 billion
$86.1 billion
$86.3 billion
Earnings from Operations
$3.9 billion
$2.1 billion
$5.7 billion
Operating Margin
4.6%
2.4%
6.6%
UnitedHealthcare
UnitedHealthcare continues to improve the consumer experience, including by expanding care access and digital services, simplifying prior approvals and offering greater support to rural hospitals and care providers. UnitedHealthcare second quarter 2026 revenues of $86.0 billion compared to $86.1 billion in the second quarter 2025. UnitedHealthcare served 48.5 million people in the second quarter 2026, down 525,000 sequentially. UnitedHealthcare’s second quarter 2026 earnings from operations were $3.9 billion and operating margin was 4.6% compared to $2.1 billion and 2.4% in second quarter 2025. The year-over-year increase was driven by medical and operating cost management, pricing discipline and benefit design changes. UnitedHealthcare Employer & Individual
UnitedHealthcare Employer & Individual second quarter 2026 revenues were $20.0 billion compared to $19.8 billion in the second quarter 2025. The number of people served contracted by 145,000 in the second quarter 2026 due to attrition in employer self-funded and fully-insured products. UnitedHealthcare Medicare & Retirement
UnitedHealthcare Medicare & Retirement second quarter 2026 revenues were $42.4 billion compared to $42.6 billion in the second quarter 2025 due to fewer seniors served. Seniors served through Medicare Advantage, including programs serving complex populations included in Medicaid, have contracted by 965,000 since year-end 2025. UnitedHealthcare Community & State
UnitedHealthcare Community & State second quarter 2026 revenues were $23.6 billion compared to $23.7 billion in the second quarter 2025. People served contracted by 380,000 in the second quarter 2026 primarily due to the planned exit from the Louisiana health plan, as well as ongoing Medicaid eligibility requirements. Optum Second Quarter 2026 Results
The Optum businesses serve participants throughout health care, including payers, care providers, employers, governments, life sciences companies and consumers. Using market-leading information, analytics and technology to yield clinical insights, Optum helps improve overall health system performance by optimizing care quality, reducing care costs and improving the consumer experience.
Quarterly Financial Performance
Three Months Ended
June 30,
2026
June 30,
2025
March 31,
2026
Revenues
$65.7 billion
$67.2 billion
$63.7 billion
Earnings from Operations
$4.0 billion
$3.1 billion
$3.3 billion
Operating Margin
6.2%
4.6%
5.2%
Optum Health
Optum Health continues to show steady momentum, with ongoing improvements in access to care and clinical and operational discipline driving better patient outcomes, increased provider satisfaction and cost management savings as the business recenters on its integrated value-based care delivery model. Optum Health’s second quarter 2026 revenues of $23.5 billion decreased 5% year-over-year due to ~700,000 fewer value-based care patients served. Second quarter 2026 earnings from operations were $1.2 billion, representing a 5.1% operating margin. The year-over-year increase was driven by strong operational improvements and medical cost management. Optum Insight
Optum Insight continues to bring AI-enabled products and services to the market, including autonomous coding and digital prior authorization tools, and completed its acquisition of Alegeus on July 2, 2026, expanding the company's consumer-directed healthcare account capabilities. Optum Insight reported second quarter 2026 revenues of $5.4 billion. Second quarter 2026 earnings from operations were $1.4 billion compared to $1.2 billion in the second quarter 2025. The year-over-year increase was driven by operational improvements and timing of contracts. Optum Rx
Optum Rx is leading an industry-wide shift toward greater transparency and affordability through a modern pharmacy care model that eliminates spread pricing, replaces volume-based incentives with clearly defined per-member fees and provides full disclosure of manufacturer payments. Optum Rx’s second quarter 2026 revenues were $38.3 billion compared to $38.5 billion in second quarter 2025. Earnings from operations for the second quarter 2026 were $1.5 billion compared to $1.4 billion in the second quarter 2025, reflecting specialty generics adoption and continued operational improvements. Adjusted scripts were 387 million compared to 414 million last year due to membership declines within UnitedHealthcare and other customers. UnitedHealth Group 2026 Outlook
($ and weighted-average shares in millions; except per share data)
As of
January 27, 2026
As of
July 16, 2026
Operating Earnings
UnitedHealthcare
> $10,800
> $12,000
Optum Health
> $2,200
> $2,275
Optum Insight
> $4,750
> $4,925
Optum Rx
> $6,250
> $6,250
Optum
> $13,200
> $13,450
UnitedHealth Group
> $24,000
> $25,450
Net Earnings to UNH Shareholders
> $15,600
> $16,750
Diluted Net Earnings per Share to UNH Shareholders
> $17.10
$18.45 - $18.95
Adjusted Earnings per Share (1)
> $17.75
$19.50 - $20.00
Medical Care Ratio
88.8% ± 50 bps
88.1% ± 25 bps
Tax Rate
~19.25%
~18.5%
Cash Flows from Operations
> $18,000
~$24,000
Share Repurchase
~$2,500
At Least $5,000
(1) Refer to page 16 of this release for a reconciliation of non-GAAP measures.
Below outlines the 2026 Reported to Adjusted Earnings Bridge for Optum as of July 16, 2026.
Optum 2026 Reported to Adjusted Earnings Bridge
($ in millions)
Optum Health
Optum Insight
Optum Rx
Total Optum
2026 Reported Operating Earnings Guidance
> $2,275 (1)
> $4,925
> $6,250
> $13,450
Net Portfolio Divestitures, Restructuring and Other
$345
$(175)
-
$170
Net Change in Third Party Loss Contracts
$(405)
-
-
$(405)
2026 Adjusted Operating Earnings
> $2,215
> $4,750
> $6,250
> $13,215
Adjusted Operating Earnings as of January 27, 2026
> $1,577
> $4,750
> $6,250
> $12,577
(1) Optum Health includes $405 million of 2026 operating earnings related to the net change in loss contracts reserve, which will be excluded from adjusted operating earnings and adjusted earnings per share.
About UnitedHealth Group
UnitedHealth Group (NYSE: UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at www.unitedhealthgroup.com and follow UnitedHealth Group on LinkedIn.
Earnings Conference Call
As previously announced, UnitedHealth Group will discuss the company’s results, strategy and future outlook on a conference call with investors at 8:00 a.m. Eastern Time today. UnitedHealth Group will host a live webcast of this conference call from the Investor Relations page of the company’s website (www.unitedhealthgroup.com). Following the call, a webcast replay will be on the Investor Relations page through July 30, 2026. This earnings release and the Form 8-K dated July 16, 2026, can also be accessed from the Investor Relations page of the company’s website.
Non-GAAP Financial Information
This news release presents non-GAAP financial information provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America (“GAAP”). A reconciliation of the non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release.
Forward-Looking Statements
The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements which are intended to take advantage of the “safe harbor” provisions of the federal securities laws. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” and similar expressions identify forward-looking statements. These statements may contain information about financial prospects, economic conditions and trends and involve risks and uncertainties. Actual results could differ materially from those that management expects, depending on the outcome of certain factors including: our ability to effectively estimate, price for and manage medical costs; new or changes in existing health care laws or regulations, or their enforcement or application; cyberattacks, other privacy/data security incidents, or our failure to comply with related regulations; reductions in revenue or delays to cash flows received under government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data validation audits; our ability to successfully execute initiatives designed to simplify and improve the consumer healthcare experience; our ability to effectively execute our value-based care strategies; the DOJ’s legal actions concerning our participation in the Medicare program; our ability to maintain and achieve improvement in quality scores impacting revenue; failure to maintain effective and efficient information systems or if our technology products do not operate as intended; risks and uncertainties associated with our businesses providing pharmacy care services; competitive pressures, including our ability to maintain or increase our market share; changes in or challenges to our public sector contract awards; failure to achieve targeted operating cost productivity improvements; failure to develop and maintain satisfactory relationships with health care payers, physicians, hospitals and other service providers; the impact of potential changes in tax laws and regulations; increases in costs and other liabilities associated with litigation, government investigations, audits or reviews; risks and uncertainties associated with our increasing use of artificial intelligence and other emerging technologies; failure to complete, manage or integrate strategic transactions; risks and uncertainties associated with the sale of our remaining operations in South America; risks associated with public health crises arising from large-scale medical emergencies, pandemics, natural disasters and other extreme events; failure to attract, develop, retain, and manage the succession of key employees and executives; our investment portfolio performance; impairment of our goodwill and intangible assets; failure to protect proprietary rights to our databases, software and related products; downgrades in our credit ratings; and our ability to obtain sufficient funds from our regulated subsidiaries or from external financings to fund our obligations, reinvest in our business, maintain our debt to total capital ratio at targeted levels, maintain our quarterly dividend payment cycle, or continue repurchasing shares of our common stock.
This above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial condition and results of operations, more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations expressed or implied in this document or any of our prior communications. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-looking statements, except as required by law.
UNITEDHEALTH GROUP
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in millions, except per share data; unaudited)
Three Months Ended
June 30,
Six Months Ended
June 30,
2026
2025
2026
2025
Revenues
Premiums
$86,956
$87,905
$174,517
$174,439
Products
13,835
13,564
27,085
26,600
Services
10,018
9,039
19,797
18,011
Investment and other income
1,223
1,108
2,354
2,141
Total revenues
112,032
111,616
223,753
221,191
Operating costs
Medical costs
75,358
78,585
148,847
151,996
Operating costs
14,268
13,778
29,658
27,372
Cost of products sold
13,375
13,019
26,198
25,409
Depreciation and amortization
1,040
1,084
2,069
2,145
Total operating costs
104,041
106,466
206,772
206,922
Earnings from operations
7,991
5,150
16,981
14,269
Interest expense
(962)
(1,027)
(1,917)
(2,025)
Loss on sale of subsidiary and subsidiaries held for sale
(61)
(41)
(133)
(56)
Earnings before income taxes
6,968
4,082
14,931
12,188
Provision for income taxes
(1,298)
(510)
(2,780)
(2,142)
Net earnings
5,670
3,572
12,151
10,046
Earnings attributable to noncontrolling interests
(186)
(166)
(387)
(348)
Net earnings attributable to UnitedHealth Group common shareholders
$5,484
$3,406
$11,764
$9,698
Diluted earnings per share attributable to UnitedHealth Group common shareholders (a)
$6.04
$3.74
$12.94
$10.61
Adjusted earnings per share attributable to UnitedHealth Group common shareholders (b)
$6.38
$4.08
$13.61
$11.29
Diluted weighted-average common shares outstanding
906
910
908
914
UNITEDHEALTH GROUP
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions; unaudited)
June 30,
2026
December 31,
2025
Assets
Cash and short-term investments
$31,468
$28,121
Accounts receivable, net
21,573
23,018
Other current assets
33,819
39,443
Total current assets
86,860
90,582
Long-term investments
57,716
54,251
Other long-term assets
165,151
164,748
Total assets
$309,727
$309,581
Liabilities, redeemable noncontrolling interests and equity
Medical costs payable
$38,930
$39,337
Short-term borrowings and current maturities of long-term debt
3,827
6,069
Other current liabilities
69,063
69,491
Total current liabilities
111,820
114,897
Long-term debt, less current maturities
69,501
72,320
Other long-term liabilities
22,457
20,666
Redeemable noncontrolling interests
1,436
1,608
Equity
104,513
100,090
Total liabilities, redeemable noncontrolling interests and equity
$309,727
$309,581
UNITEDHEALTH GROUP
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions; unaudited)
Six Months Ended
June 30,
2026
2025
Operating Activities
Net earnings
$12,151
$10,046
Noncash items:
Depreciation and amortization
2,069
2,145
Deferred income taxes and other
176
40
Share-based compensation
624
572
Loss on sale of subsidiary and subsidiaries held for sale
133
56
Net changes in operating assets and liabilities
4,811
(215)
Cash flows from operating activities
19,964
12,644
Investing Activities
(Purchases of investments, net of sales and maturities) sales and maturities of investments, net of purchases
(2,751)
1,327
Purchases of property, equipment and capitalized software
(1,562)
(1,784)
Cash paid for acquisitions and other transactions, net
(98)
(734)
Repayment of care provider loans - cyberattack
197
1,293
Other, net
(31)
(1,618)
Cash flows used for investing activities
(4,245)
(1,516)
Financing Activities
Common share repurchases
(1,646)
(5,545)
Dividends paid
(4,092)
(3,912)
Net change in short-term borrowings and long-term debt
(4,813)
1,566
Other, net
(1,064)
43
Cash flows used for financing activities
(11,615)
(7,848)
Effect of exchange rate changes on cash and cash equivalents
(3)
29
Increase in cash and cash equivalents, including cash within businesses held for sale
4,101
3,309
Less: net change in cash within businesses held for sale
119
(25)
Net increase in cash and cash equivalents
4,220
3,284
Cash and cash equivalents, beginning of period
24,365
25,312
Cash and cash equivalents, end of period
$28,585
$28,596
UNITEDHEALTH GROUP
REVENUES BY BUSINESS - SUPPLEMENTAL FINANCIAL INFORMATION
(in millions; unaudited)
Optum
UnitedHealth
Group
Consolidated (a)
UnitedHealthcare
Optum
Health (c)
Optum
Insight (c)
Optum
Rx
Total
Optum (a)
Three Months Ended June 30, 2026
Total revenues
$86,017
$23,472
$5,402
$38,292
$65,663
$112,032
Restructuring and other (2)
—
(1)
—
—
(1)
(1)
Adjusted revenues (b)
$86,017
$23,471
$5,402
$38,292
$65,662
$112,031
Three Months Ended June 30, 2025
Total revenues
$86,103
$24,725
$5,232
$38,459
$67,225
$111,616
Six Months Ended June 30, 2026
Total revenues
$172,282
$47,581
$10,527
$74,028
$129,412
$223,753
Restructuring and other (2)
—
2
(77)
—
(75)
(75)
Adjusted revenues (b)
$172,282
$47,583
$10,450
$74,028
$129,337
$223,678
Six Months Ended June 30, 2025
Total revenues
$170,720
$49,562
$10,259
$73,591
$131,110
$221,191
UnitedHealthcare Revenues
(in millions; unaudited)
Three Months Ended
June 30,
Six Months Ended
June 30,
2026
2025
2026
2025
UnitedHealthcare Employer & Individual - Domestic
$19,048
$18,950
$38,254
$38,016
UnitedHealthcare Employer & Individual - Global
944
819
1,856
1,601
UnitedHealthcare Employer & Individual - Total
19,992
19,769
40,110
39,617
UnitedHealthcare Medicare & Retirement
42,390
42,623
84,472
84,328
UnitedHealthcare Community & State
23,635
23,711
47,700
46,775
Total UnitedHealthcare revenues
$86,017
$86,103
$172,282
$170,720
(a)
Optum and consolidated revenues for the three months ended June 30, 2026 and 2025 include Optum eliminations of $1,503 and $1,191; and corporate eliminations of $39,648 and $41,712, respectively. Optum and consolidated revenues for the six months ended June 30, 2026 and 2025 include Optum eliminations of $2,724 and $2,302; and corporate eliminations of $77,941 and $80,639, respectively.
(b)
See page 16 for description of non-GAAP measures.
(c) Prior period amounts have been recast to reflect the realignment of Optum Financial. Note: See end notes for further information regarding non-GAAP adjustments.
UNITEDHEALTH GROUP
EARNINGS BY BUSINESS - SUPPLEMENTAL FINANCIAL INFORMATION
(in millions, except percentages; unaudited)
Optum
UnitedHealth
Group
Consolidated
UnitedHealthcare
Optum
Health (b)
Optum
Insight (b)
Optum
Rx
Total
Optum
Three Months Ended June 30, 2026
Earnings from operations
$3,942
$1,190
$1,369
$1,490
$4,049
$7,991
Net portfolio divestitures and South American impacts (1)
—
35
4
—
39
39
Restructuring and other (2)
—
(51)
—
—
(51)
(51)
Adjusted earnings from operations (a)
$3,942
$1,174
$1,373
$1,490
$4,037
$7,979
Operating margin
4.6 %
5.1 %
25.3 %
3.9 %
6.2 %
7.1 %
Adjusted operating margin (a)
4.6 %
5.0 %
25.4 %
3.9 %
6.1 %
7.1 %
Three Months Ended June 30, 2025
Earnings from operations
$2,075
$429
$1,205
$1,441
$3,075
$5,150
Operating margin
2.4 %
1.7 %
23.0 %
3.7 %
4.6 %
4.6 %
Six Months Ended June 30, 2026
Earnings from operations
$9,636
$2,331
$2,332
$2,682
$7,345
$16,981
Net portfolio divestitures and South American impacts (1)
—
341
(524)
(8)
(191)
(191)
Restructuring and other (2)
—
(186)
339
—
153
153
Adjusted earnings from operations (a)
$9,636
$2,486
$2,147
$2,674
$7,307
$16,943
Operating margin
5.6 %
4.9 %
22.2 %
3.6 %
5.7 %
7.6 %
Adjusted operating margin (a)
5.6 %
5.2 %
20.5 %
3.6 %
5.6 %
7.6 %
Six Months Ended June 30, 2025
Earnings from operations
$7,301
$1,840
$2,369
$2,759
$6,968
$14,269
Operating margin
4.3 %
3.7 %
23.1 %
3.7 %
5.3 %
6.5 %
UNITEDHEALTH GROUP
PEOPLE SERVED AND PERFORMANCE METRICS - SUPPLEMENTAL FINANCIAL INFORMATION
(unaudited)
UnitedHealthcare Customer Profile
(in thousands)
People Served
June 30, 2026
March 31, 2026
December 31, 2025
June 30, 2025
Commercial:
Risk-based
7,655
7,725
8,165
8,440
Fee-based
22,265
22,340
21,485
21,530
Total Commercial
29,920
30,065
29,650
29,970
Medicare Advantage
7,565
7,555
8,445
8,350
Medicaid
6,780
7,160
7,380
7,490
Medicare Supplement (Standardized)
4,260
4,270
4,285
4,305
Total Community and Senior
18,605
18,985
20,110
20,145
Total UnitedHealthcare - Medical
48,525
49,050
49,760
50,115
Supplemental Data
Medicare Part D stand-alone
2,710
2,740
2,770
2,800
South American businesses held for sale
1,145
1,160
1,160
1,165
Optum Performance Metrics
June 30, 2026
March 31, 2026
December 31, 2025
June 30, 2025
Optum Health Consumers Served (in millions) (a)
93
93
92
95
Optum Rx Quarterly Adjusted Scripts (in millions)
387
383
424
414
UNITEDHEALTH GROUP
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
(in millions, except per share data; unaudited)
Adjusted Net Earnings Per Share
Three Months Ended
June 30,
Six Months Ended
June 30,
Projected
Year Ended
December 31,
2026
2025
2026
2025
2026
Net earnings attributable to UnitedHealth Group common shareholders
$5,484
$3,406
$11,764
$9,698
> $16,750
Intangible amortization
346
409
680
826
~1,345
Net portfolio divestitures and South American impacts (1)
100
—
(58)
—
~(35)
Restructuring and other (2)
(51)
—
153
—
~(50)
Tax effect of adjustments
(87)
(99)
(169)
(201)
~(285)
Adjusted net earnings attributable to UnitedHealth Group common shareholders
$5,792
$3,716
$12,370
$10,323
> $17,725
Diluted earnings per share
$6.04
$3.74
$12.94
$10.61
$18.45 to $18.95
Intangible amortization per share
0.38
0.45
0.75
0.90
~1.50
Net portfolio divestitures and South American impacts per share
Merck získal od FDA schválení přípravku LIPFENDRA, prvního a jediného jednorázového perorálního inhibitoru PCSK9 ke snížení LDL-C u dospělých s hypercholesterolemií. Ve studiích ve 24. týdnu snížil LDL-C o 56 % a 59 % oproti placebu.
At week 24 in the CORALreef Lipids and CORALreef HeFH trials, LIPFENDRA significantly reduced LDL-C by a placebo-adjusted 56% and 59%, respectively
LIPFENDRA is a novel macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved LIPFENDRA® (enlicitide) tablets 20 mg as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). LIPFENDRA is a novel macrocyclic peptide and is the first FDA-approved oral PCSK9 inhibitor shown to lower LDL-C, also known as bad cholesterol.
“By harnessing the innovative science of PCSK9 inhibitors and novel macrocyclic peptide technology, LIPFENDRA was designed to significantly lower LDL-C in the form of a convenient once-daily pill,” said Dr. Dean Y. Li, president, Merck Research Laboratories. “This is a pivotal moment as we bring the first U.S. FDA-approved oral PCSK9 inhibitor to adults with high LDL-C, offering patients an important new option. We’re proud of our work with regulators on this rigorous and efficient review process.”
The approval is based on two Phase 3 trials from the CORALreef clinical program: CORALreef Lipids and CORALreef HeFH. In CORALreef Lipids, LIPFENDRA reduced LDL-C by 56% compared to placebo at week 24. A 60% decrease from baseline in LDL-C was observed with LIPFENDRA when biologically impossible baseline LDL-C values were removed according to revised data handling rules (post-hoc). In CORALreef HeFH, LIPFENDRA reduced LDL-C by 59% at week 24 compared to placebo. Results from these Phase 3 trials showed treatment with LIPFENDRA resulted in reductions across other atherogenic lipoproteins associated with atherosclerotic cardiovascular disease (ASCVD) risk including non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B (ApoB). The safety profile of LIPFENDRA in CORALreef Lipids was similar to placebo. In CORALreef HeFH, the most common adverse reactions in adults with HeFH treated with LIPFENDRA that occurred at higher frequencies compared to placebo were diarrhea (LIPFENDRA 7%, placebo 2%) and dizziness (LIPFENDRA 9%, placebo 4%). In both trials, similar proportions of LIPFENDRA-treated patients and placebo-treated patients discontinued treatment because of an adverse reaction. For additional information on results from the CORALreef trials, see “Clinical data supporting FDA approval” below.
“High LDL-C is a major risk factor for atherosclerotic cardiovascular disease, which is the leading cause of death globally,” said Dr. Ann Marie Navar, a lead author of the CORALreef Lipids study and associate professor of medicine in the Division of Cardiology at UT Southwestern Medical Center. “In two Phase 3 trials, LIPFENDRA led to impressive reductions in LDL-C. Now, for the first time, patients have an oral PCSK9 inhibitor for LDL lowering.”
An ongoing clinical trial is studying the effect of LIPFENDRA on cardiovascular morbidity and mortality. It is not yet known if LIPFENDRA can reduce the risk of cardiovascular morbidity and mortality.
“One of the greatest opportunities to help manage the risk of ASCVD lies in the timely identification and appropriate treatment of risk factors, such as LDL-C,” said Katherine Wilemon, CEO of the Family Heart Foundation. “We are encouraged by the approval of a new oral PCSK9 inhibitor option for adults who need additional LDL-C lowering.”
Clinical data supporting FDA approval
LIPFENDRA was approved based on results from two pivotal Phase 3 trials from the CORALreef clinical trial program:
At week 24, in the CORALreef Lipids trial, treatment with LIPFENDRA resulted in: A statistically significant and clinically meaningful reduction in LDL-C of 56% compared to placebo at week 24 (95% CI: -61, -51; p<0.001), with a reduction from baseline (primary endpoint) in LDL-C of 57% for LIPFENDRA compared to an increase of 3% for placebo; When LDL-C values ≤0 were removed according to revised data handling rules (post-hoc), a statistically significant and clinically meaningful reduction in LDL-C of 60% for LIPFENDRA compared to an increase of 3% for placebo at week 24 (95% CI: -62, -57%). Statistically significant reductions in secondary endpoints from baseline to week 24 compared to an increase of 3% for placebo: 54% mean reduction in non-HDL-C for LIPFENDRA; 50% mean reduction in ApoB for LIPFENDRA. At week 24, in the CORALreef HeFH trial, treatment with LIPFENDRA resulted in: A statistically significant and clinically meaningful reduction in LDL-C of 59% compared to placebo (95% CI: -66, -53; p<0.001), with a reduction from baseline (primary endpoint) in LDL-C of 58% for LIPFENDRA compared to an increase of 3% for placebo; Statistically significant reductions in secondary endpoints from baseline to week 24 compared to an increase of 2% for placebo: 52% mean reduction in non-HDL-C for LIPFENDRA; 48% mean reduction in ApoB for LIPFENDRA. In CORALreef Lipids, the frequencies of adverse reactions in adults with hypercholesterolemia were similar between those treated with LIPFENDRA and those receiving placebo. Similar proportions of LIPFENDRA-treated patients and placebo-treated patients discontinued treatment because of an adverse reaction. In CORALreef HeFH, the most common adverse reactions in adults with HeFH treated with LIPFENDRA that occurred at higher frequencies compared to placebo were diarrhea (LIPFENDRA 7%, placebo 2%) and dizziness (LIPFENDRA 9%, placebo 4%). Similar proportions of LIPFENDRA-treated patients and placebo-treated patients discontinued treatment because of an adverse reaction. The safety profile observed in adults with HeFH in CORALreef HeFH was otherwise generally consistent with that observed in adults with hypercholesterolemia in CORALreef Lipids.
About CORALreef Lipids and HeFH
CORALreef Lipids (NCT05952856) was a Phase 3, multicenter, double-blind, randomized, placebo-controlled study in which 2,904 patients with hypercholesterolemia (including those with and without HeFH) and a history of a major ASCVD event or increased risk for development of a first major ASCVD event were randomized in a 2:1 ratio to receive LIPFENDRA 20 mg orally once daily (n=1,935) or placebo (n=969) for 52 weeks. Patients required additional LDL-C reduction despite stable lipid-lowering treatment with moderate- or high-intensity statins (unless statin intolerance was documented) with or without other lipid-modifying therapy. Patients taking PCSK9 inhibitors were excluded from the trial. The primary efficacy outcome measure was the mean percent change from baseline to week 24 in LDL-C.
CORALreef HeFH (NCT05952869) was a Phase 3, multicenter, double-blind, randomized, placebo-controlled study in which 303 patients with HeFH were randomized in a 2:1 ratio to receive LIPFENDRA 20 mg orally once daily (n=202) or placebo (n=101) for 52 weeks. Patients required additional LDL-C reduction despite stable lipid-lowering treatment with moderate- or high-intensity statins, with or without other lipid-modifying therapy. The diagnosis of HeFH was made by clinical criteria or genotyping. The primary efficacy outcome measure was the mean percent change from baseline to week 24 in LDL-C.
About CORALreef clinical trial program
The efficacy and safety profile of LIPFENDRA continues to be evaluated through the comprehensive CORALreef Clinical Trial program evaluating over 19,000 participants who have hypercholesterolemia. LIPFENDRA was FDA approved based on two pivotal Phase 3 studies: CORALreef Lipids (NCT05952856) and CORALreef HeFH (NCT05952869). LIPFENDRA is continuing to be evaluated in the large cardiovascular outcomes trial, CORALreef Outcomes (NCT06008756), which has completed enrollment with over 14,500 participants. Additional CORALreef clinical trials include CORALreef Extension (NCT06492291), CORALreef Pediatric (NCT07058077), and CORALreef Combination (NCT07216482).
About LIPFENDRA® (enlicitide) tablets 20 mg
LIPFENDRA is an oral proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor FDA-approved as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Cardiovascular outcomes trials have demonstrated that reducing LDL-C lowers the risk for major adverse cardiovascular events (MACE) in adults at increased risk, when treated with statins or monoclonal antibody PCSK9 inhibitors as an add-on to statin therapy. LIPFENDRA is the first oral PCSK9 inhibitor approved to reduce LDL-C and is a novel macrocyclic peptide that inhibits the binding of PCSK9 to LDL receptors.
Selected Safety Information
In the CORALreef Lipids trial the frequencies of adverse reactions were similar between adults treated with LIPFENDRA and those receiving placebo. Similar proportions of LIPFENDRA-treated patients and placebo-treated patients discontinued treatment because of an adverse reaction.
In the CORALreef HeFH trial the most common adverse reactions that occurred at higher frequencies compared to placebo were diarrhea (LIPFENDRA 7%, placebo 2%) and dizziness (LIPFENDRA 9%, placebo 4%). Similar proportions of LIPFENDRA-treated patients and placebo-treated patients discontinued treatment because of an adverse reaction. The safety profile was otherwise generally consistent with that observed in adults with hypercholesterolemia in the CORALreef Lipids trial.
Merck’s focus on cardiometabolic and respiratory diseases
Merck has a long history of developing treatments for cardiometabolic and respiratory diseases. Building on a legacy that began nearly 70 years ago with the introduction of our first cardiovascular therapy, we are committed to advancing research for patients impacted by cardiometabolic and respiratory diseases. Our focus spans a range of diseases, including atherosclerotic cardiovascular disease, heart failure, pulmonary hypertension and chronic obstructive pulmonary disease (COPD).
Advancements in the treatment of cardiometabolic and respiratory diseases can make a critical difference for patients and health systems around the world. At Merck, we strive for scientific excellence and innovation in all stages of research, from discovery through approval and life cycle management.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Please see Prescribing Information for LIPFENDRA (enlicitide) at https://www.merck.com/product/usa/pi_circulars/l/lipfendra/lipfendra_pi.pdf and Patient Information/Medication Guide for LIPFENDRA (enlicitide) at https://www.merck.com/product/usa/pi_circulars/l/lipfendra/lipfendra_ppi.pdf.
MINNEAPOLIS--(BUSINESS WIRE)--U.S. Bancorp reported its second quarter 2026 results today. The earnings release, earnings supplement and slide presentation can be accessed online at ir.usbank.com/investor-relations/financial-information.
At 7 a.m. Central Time, Chief Executive Officer Gunjan Kedia and Vice Chair and Chief Financial Officer John Stern will host a conference call to review the financial results. The conference call will be available online or by telephone. To access the webcast and presentation, visit U.S. Bancorp’s website at usbank.com and click on “About Us,” “Investor Relations” and choose “Webcasts & Presentations” from the “News & events” dropdown menu To access the conference call from locations within the United States and Canada, please dial 888-210-4659. Participants calling from outside the United States and Canada, please dial 646-960-0383. The access code for all participants is 7269933.
About U.S. Bancorp
Headquartered in Minneapolis, U.S. Bancorp is the parent company of U.S. Bank National Association the fifth-largest commercial bank in the United States. The company’s three major business lines serve 15 million clients globally, and its team of nearly 70,000 people invest their hearts and minds to power human potential every day. Ranked 110th in the Fortune 500, U.S. Bancorp is deeply respected for its culture and long-term stewardship and admired for its diversified business mix and product capabilities.
Správkyně fondu Ankur Crawfordová uvedla, že by teď koupila jedině Micron, protože firma může v příštích 18 měsících vytvořit cash flow odpovídající zhruba 30 % tržní kapitalizace.
Nasdaq futures fell 0.21%, while S&P 500 futures slipped 0.04%. The decline appeared to reflect broader weakness in technology stocks and profit-taking after Micron’s strong rally over the past year.
The softer futures market weighed on higher-beta chip stocks before the opening bell. Micron remains well above its longer-term trend levels, but investors have become more cautious following signs that the stock’s recent momentum has slowed.
Cash Flow Outlook Draws Bullish ViewAlger Executive Vice President Ankur Crawford said Wednesday that Micron’s earnings power remains underappreciated. Crawford said that if she were buying just one stock right now, it would be Micron.
Speaking on CNBC, Crawford said the company could generate cash flow equivalent to roughly 30% of its current market capitalization over the next 18 months and as much as 50% over a longer period.
She attributed that outlook to persistent shortages in high-end DRAM, which continue to support pricing. Although China could eventually emerge as a larger competitor in memory, Crawford said she does not expect that risk to materially affect the market until 2029 or 2030.
She added that investors are prematurely assuming the memory cycle is nearing its peak, arguing that supply constraints could keep earnings growing into 2027 or 2028.
Technical Picture Remains MixedMicron continues to trade in a long-term uptrend. The stock is 31.4% above its 100-day simple moving average and 86.2% above its 200-day average.
However, shares have fallen 14.9% below the 20-day moving average and 4% below the 50-day moving average. That suggests the stock is experiencing a short-term pullback within a broader bullish trend.
The moving averages remain in a positive alignment, with the 20-day average above the 50-day average and the 50-day average above the 200-day average. Still, the stock is trading below its shorter-term averages, indicating buyers have become more selective.
Momentum indicators also point to cooling strength. The MACD remains below its signal line, suggesting upside momentum has weakened.
A key support level sits near $854.50. A break below that level could increase selling pressure.
Earnings And Analyst OutlookWall Street expects Micron to report quarterly results around Sept. 22.
Analysts project earnings of $31.24 per share, up sharply from $3.03 a year earlier. Revenue is expected to increase to $50.72 billion from $11.31 billion.
The stock carries a consensus Buy rating with an average price target of $1,548.86. Recent analyst actions include:
KeyBanc raised its price target to $1,750 and maintained an Overweight rating on July 14. Cantor Fitzgerald raised its price target to $2,000 and maintained an Overweight rating on June 29. Cantor Fitzgerald maintained its Overweight rating and $1,500 price target on June 25. ETF ExposureAs a result, strong inflows or outflows in those funds can affect demand for Micron shares.
MU Stock Price Activity: Micron Technology shares were down 1.97% at $886.45 during premarket trading on Thursday, according to Benzinga Pro data.
Image via Shutterstock
Market News and Data brought to you by Benzinga APIs
TSMC zveřejnila konferenční hovor k výsledkům za 2. čtvrtletí 2026 a následný výhled na 3. čtvrtletí 2026. CFO Wendell Huang měl shrnout provozní výsledky a vedení klíčové zprávy společnosti.
Taiwan Semiconductor Manufacturing Company Limited (TSM) Q2 2026 Earnings Call July 16, 2026 2:00 AM EDT
Company Participants
Jeff Su - Director of Investor Relations
Jen-Chau Huang - Senior VP & CFO
C.C. Wei - Chairman & CEO
Conference Call Participants
Sunny Lin - UBS Investment Bank, Research Division
Charlie Chan - Morgan Stanley, Research Division
Yu Jang Lai - Macquarie Research
Gokul Hariharan - JPMorgan Chase & Co, Research Division
Jim Fontanelli - Arete Research Services LLP
Mehdi Hosseini - Susquehanna Financial Group, LLLP, Research Division
Chia Yi Chen - Citigroup Inc., Research Division
Haas Liu - BofA Securities, Research Division
Robert Sanders - Deutsche Bank AG, Research Division
Evelyn Yu - Goldman Sachs Group, Inc., Research Division
Junhong Pan - KGI Securities Co. Ltd., Research Division
Presentation
Jeff Su
Director of Investor Relations
Good afternoon, everyone. And welcome to TSMC's Second Quarter 2026 Earnings Conference and Conference Call. This is Jeff Su, TSMC's Director of Investor Relations and your host for today.
Today's event is being webcast live through TSMC's website at www.tsmc.com, where you can also download the earnings release materials. [Operator Instructions]
The format for today's event will be as follows: First, TSMC's Senior Vice President and CFO, Mr. Wendell Huang, will summarize our operations in the second quarter 2026, followed by our guidance for the third quarter 2026. Afterwards, Mr. Huang and TSMC's Chairman and CEO, Dr. C.C. Wei, will jointly provide the company's key messages. Then we will open both the floor and the line for the question-and-answer session.
As usual, I'd like to remind everybody that today's discussions may contain forward-looking statements that are subject to significant risks and uncertainties, which could cause actual results to differ materially from those contained in the forward-looking statements. Please refer to the safe harbor notice that appears in our press release.
Eli Lilly koupí AtaiBeckley za 6,75 USD za akcii v hotovosti a až o 2,50 USD více prostřednictvím CVR. Cílem je posílit vývoj léčby deprese odolné vůči léčbě.
AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression
Acquisition expands Lilly's neuroscience pipeline to address some of the most challenging conditions in mental health
, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing innovative therapeutics for mental health conditions, today announced a definitive agreement for Lilly to acquire AtaiBeckley.
AtaiBeckley is advancing a pipeline of rapid-acting neuroplastogens, including multiple clinical-stage programs and a discovery pipeline of next-generation compounds. The lead asset, BPL-003 (mebufotenin benzoate), is a synthetic form of 5-MeO-DMT administered intranasally for treatment-resistant depression, which affects millions of people in the United States.
Emerging research indicates that treatment-resistant depression and other serious mental health conditions may involve a loss of synaptic plasticity, the brain's ability to form and strengthen connections in regions critical to mood regulation. AtaiBeckley's therapies are designed to restore synaptic connectivity and aim to promote the growth of new neural connections, offering a distinct mechanism from conventional antidepressants that primarily target neurotransmitter levels.
"Treatment-resistant depression persists even after multiple treatments have failed. Millions of people are still searching for relief and desperately need a therapy that works," said Carole Ho, executive vice president and president, Lilly Neuroscience. "Advancing AtaiBeckley's investigational therapies gives us a real chance to change that."
In a Phase 2b study, BPL-003 demonstrated rapid and durable reductions in depressive symptoms following an in-clinic visit lasting approximately two hours on average, with beneficial effects persisting for months. BPL-003 has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration and has initiated Phase 3 activities. VLS-01, the second most advanced program of the pipeline, is a buccal film formulation of DMT advancing in an ongoing Phase 2b study.
"Across our portfolio, we're seeking to demonstrate that psychiatric illness is treatable at its biological root, not just its symptoms," said Srinivas Rao, co-founder and chief executive officer of AtaiBeckley. "Lilly's expertise and reach are expected to accelerate that work for people whose conditions have not responded to existing treatments."
"From Atai's founding, our mission has been to bring transformative mental health treatments to the patients who need them most. Joining Lilly gives this pipeline, and the patients waiting for it, the benefit of the resources and scale Lilly has to potentially advance therapies faster than we could alone. I am confident this transaction represents the best path forward for patients and shareholders," said Christian Angermayer, founder, largest shareholder, and chairman of the board, AtaiBeckley.
Under the terms of the agreement, Lilly will acquire all outstanding shares of AtaiBeckley common stock for $6.75 per share in cash upon closing; plus up to $2.50 per share in the form of a Contingent Value Right (CVR) entitling the holder to additional cash payments upon achievement of specified development and regulatory milestones related to the BPL-003 and VLS-01 programs as follows: (a) $1.00 per share upon initiation of a Phase 3 clinical trial of VLS-01 prior to the fourth anniversary of closing; (b) $0.50 per share upon U.S. regulatory approval and DEA rescheduling of BPL-003 prior to the fifth anniversary of closing; and (c) $1.00 per share upon U.S. regulatory approval and DEA rescheduling of VLS-01 prior to the seventh anniversary of closing. The upfront cash consideration represents an aggregate equity value of approximately $2.8 billion and the CVR represents an additional potential aggregate equity value of approximately $1.0 billion. There can be no assurance that any payments will be made with respect to the CVR.
The transaction is not subject to any financing condition and is expected to close in the third quarter, subject to approval by AtaiBeckley stockholders and satisfaction of other customary closing conditions, including regulatory approvals. The purchase price payable at closing represents a premium of approximately 40% to the 30-day volume-weighted average trading price of AtaiBeckley's common stock ended on July 15, 2026. The boards of directors of both companies have approved the transaction.
To demonstrate their commitment to the transaction, Apeiron Investment Group, Ltd and all directors and officers of AtaiBeckley have signed voting and support agreements pursuant to which each has agreed to vote to approve the transaction. The shares subject to the voting agreements represent a total of approximately 15% of AtaiBeckley's outstanding common stock.
Lilly will determine the accounting treatment of this transaction in accordance with Generally Accepted Accounting Principles (GAAP) upon closing. This transaction will thereafter be reflected in Lilly's financial results and financial guidance.
Goldman Sachs is acting as exclusive financial advisor and Ropes & Gray is acting as legal counsel to Lilly. Moelis & Company LLC and Centerview Partners LLC are acting as financial advisors and Latham & Watkins is acting as legal counsel to AtaiBeckley. Citi also provided financial advice to the AtaiBeckley Board of Directors in the transaction.
About AtaiBeckley
AtaiBeckley is a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. BPL-003 was granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration and has initiated Phase 3 activities; VLS-01 and EMP-01 are in Phase 2 clinical development. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists. These programs aim to create breakthroughs in mental health through transformative interventional psychiatry therapies that can integrate seamlessly into healthcare systems.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY
Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
No Offer or Solicitation
This communication is for informational purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.
Additional Information about the Acquisition and Where to Find It
AtaiBeckley plans to file a proxy statement (the "Proxy Statement") with the Securities and Exchange Commission (the "SEC") in connection with the solicitation of proxies to approve the agreement and plan of merger (the "Merger Agreement") relating to Lilly's proposed acquisition of AtaiBeckley (the "Merger"). Promptly after filing the definitive Proxy Statement with the SEC, AtaiBeckley will mail the definitive Proxy Statement and a proxy card to each stockholder entitled to vote at the special meeting to consider the adoption of the Merger Agreement. Stockholders are urged to read the proxy statement (including any amendments or supplements thereto) and any other relevant documents that AtaiBeckley will file with the SEC when they become available because they will contain important information. Stockholders may obtain, free of charge, the preliminary and definitive versions of the Proxy Statement, any amendments or supplements thereto, and any other relevant documents filed by AtaiBeckley with the SEC in connection with the Merger at the SEC's website (http://www.sec.gov). Copies of AtaiBeckley's definitive Proxy Statement, any amendments or supplements thereto, and any other relevant documents filed by AtaiBeckley with the SEC in connection with the Merger will also be available, free of charge, at AtaiBeckley's investor relations website (https://ir.ataibeckley.com), or by writing to AtaiBeckley Inc., Attention: Investor Relations, 250 West 34th Street, New York, NY 10119.
Participants in the Solicitation
Under SEC rules, AtaiBeckley and certain of its directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from stockholders in connection with the Merger. Information about the directors and executive officers of AtaiBeckley and their ownership of AtaiBeckley's common stock is set forth in the definitive proxy statement for AtaiBeckley's 2026 Annual Meeting of Stockholders (the "2026 Proxy Statement"), which was filed with the SEC on April 22, 2026, including the sections captioned "Director Compensation," "Executive Employment Agreements" and "Security Ownership of Certain Beneficial Owners and Management," or its Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 6, 2026, and in other documents filed by AtaiBeckley with the SEC. To the extent holdings of such participants in AtaiBeckley's securities have changed since the amounts described in the 2026 Proxy Statement, such changes have been reflected on Forms 3 or Forms 4 filed with the SEC by AtaiBeckley's directors and executive officers. These documents can be obtained free of charge from the sources indicated below. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Proxy Statement and other relevant materials to be filed with the SEC in respect of the Merger when they become available.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding: the Merger; the prospective benefits of the Merger; the parties' ability to satisfy the conditions to the consummation of the Merger and the expected timetable for the Merger; the anticipated occurrence, manner and timing of the closing of the Merger; potential milestone payment amounts and terms pursuant to the CVRs; AtaiBeckley's product candidates and ongoing clinical and preclinical development; Lilly's development of programs targeting treatment-resistant depression and mental health conditions; and the accounting treatment of the potential acquisition under GAAP and its potential impact on Lilly's financial results and financial guidance. All statements other than statements of historical facts are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on current beliefs and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to: the possibility that AtaiBeckley's shareholders may not approve the adoption of the Merger agreement; AtaiBeckley's receipt of any competing offers or acquisition proposals; a failure to (or delay in) receiving the required regulatory clearances for the Merger; a condition to closing of the Merger may not be satisfied (or waived); the ability of each party to consummate the Merger; the closing of the Merger might be delayed or not occur at all; the diversion of management time and attention from ongoing business operations and opportunities; the response of competitors to the Merger; the effect of the Merger and the public announcement of the Merger on AtaiBeckley's operations and its relationships with its suppliers, business partners, management and employees, including its ability to attract and retain key personnel; Lilly's ability to successfully integrate AtaiBeckley and execute on the continued development of AtaiBeckley's programs following the closing of the Merger; that all or any of the potential milestone payments pursuant to the CVRs will become payable on the terms described herein or at all; the outcome of any legal proceedings that could be instituted against the parties to the Merger; the risks inherent in drug research, development and commercialization; disruption in AtaiBeckley's plans and operations attributable to the Merger; changes in AtaiBeckley's business during the period between announcement and closing of the Merger; Lilly's evaluation of the accounting treatment of the potential acquisition and its potential impact on its financial results and financial guidance; the effects of the Merger (or the announcement thereof) on AtaiBeckley's stock price; relationships with key third parties or governmental entities; regulatory changes and developments; and the impact of global macroeconomic conditions, including trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions. For further discussion of these and other risks and uncertainties, see Lilly's and AtaiBeckley's periodic reports filed with the SEC. There can be no assurance that the Merger will in fact be consummated. All forward-looking statements in this communication are based on information available to Lilly and AtaiBeckley as of the date of this communication. Lilly and AtaiBeckley each expressly disclaim any obligation to publicly update or revise the forward-looking statements, except as required by law.
Rocket Lab se dostal mezi uchazeče o program Space Force v hodnotě až 5,6 miliardy USD do roku 2029. O zakázky ale může soutěžit až po úspěšném prvním letu rakety Neutron.
The U.S. military's most sensitive satellites have long ridden to orbit on a short list of trusted rockets. Now Rocket Lab (RKLB 3.36%) has forced its way into that conversation, earning a spot to compete in the Space Force's National Security Space Launch (NSSL) Phase 3 Lane 1 program, an arrangement with a maximum value of $5.6 billion through 2029.
But being invited to compete and actually winning work are two very different things, and the entire opportunity hinges on one machine: the Neutron rocket.
Why Neutron is the linchpin Rocket Lab built its business on the small Electron rocket, but Electron is far too small for the heavy national-security payloads the Space Force needs to launch. Neutron, its larger reusable medium-lift vehicle, is the rocket designed to carry them. The program's structure makes this crystal clear: Rocket Lab has been on-ramped as an eligible bidder, but it cannot win any individual task orders until Neutron completes a successful first flight. In other words, no working Neutron means no share of the $5.6 billion in available contracts, full stop.
Image source: Getty Images.
The path to winning task orders Being a contender requires passing a handful of milestones. First, Neutron has to fly, with a debut currently targeted for the fourth quarter of 2026. A clean flight would let Rocket Lab pursue formal certification and then compete for specific missions, and the program plans to award at least 30 launches over its life, with a possible extension into the next decade. Rocket Lab is trying to build credibility ahead of that debut, having already lined up a commercial launch backlog for Neutron and drawn interest from the military for a cargo-transport test. Each contract signed before the first flight strengthens the case that the rocket will have steady demand once it's flying.
Objectively, investors should know that the obstacles are significant. Neutron's timeline has already slipped once after a test failure on its first-stage tank, and new rockets are notoriously prone to delays and early setbacks. Rocket Lab is also arriving late to a field where Space Exploration Technologies (aka SpaceX) and United Launch Alliance are already securing task orders, so it will compete for missions against established providers with proven vehicles. Until Neutron flies, Rocket Lab remains on the outside looking in.
Today's Change
(
-3.36
%) $
-2.65
Current Price
$
76.16
The takeaway for potential investors Rocket Lab's inclusion in a $5.6 billion program is a genuine vote of confidence, but it is best understood as an option rather than a guaranteed payday. The value of that option rests almost entirely on Neutron's debut going well. A successful first flight would open the door to years of high-value government work and validate Rocket Lab's push to become a serious defense-launch player.
Rocket Lab podle článku vypadá nyní jako lepší akcie z vesmírného sektoru k nákupu. SpaceX má vyšší ocenění, zatímco tržby Rocket Lab rostou o 64 % na 200 milionů USD.
Space stocks are on many investors' minds these days, but going all-in on this sector right now comes with considerable risk, as most rocket stocks are volatile.
Still, two stocks that are no doubt near the top of many investors' watch lists are Space Exploration Technologies (SPCX 0.59%) and Rocket Lab (RKLB 3.36%). Here's which one looks like the better buy right now.
Image source: Getty Images.
The case for SpaceX What was once just a rocket company has morphed into an expanding technology behemoth with its sights set on both the space and artificial intelligence (AI) markets.
SpaceX has highly ambitious goals for both, including colonizing Mars, launching orbital data centers, expanding its Starlink satellite internet business, and building what some analysts are calling a "sovereign AI" platform in which the company controls the AI model, chip designs, processor manufacturing, and everything in between.
That's part of the appeal of SpaceX for some investors -- the company is trying big things, like developing its Starship rocket, which it says will reduce the costs of putting payloads into orbit by at least 90%, or deploying a constellation of data center satellites. Morningstar research puts the total addressable market for its Starlink connectivity business at $129 billion.
And the company is making headway on some of its goals. It has 12 million Starlink internet subscribers and generated $1.9 billion in operating profit from that business in the most recent quarter.
SpaceX is also making progress with its neocloud business, which leases data center capacity (Earth-bound, for now) to tech companies including Alphabet and Anthropic. That business has already signed more than $81 billion in contracts.
And then there's the potential for SpaceX to merge with Elon Musk's other large company, Tesla. That could expand SpaceX's opportunities into the autonomous vehicle and humanoid robot markets, the latter of which could be worth $3 trillion by 2050, according to a Morgan Stanley forecast.
Today's Change
(
-0.59
%) $
-0.81
Current Price
$
135.27
The case for Rocket Lab There's some overlap between Rocket Lab and SpaceX, though Rocket Lab isn't building AI data centers or planning to merge with a humanoid robotics company (as of now).
The company is instead mostly focused on launching rockets for its customers and on expanding its satellite communications network through its recently announced purchase of Iridium Communications.
Rocket Lab has agreed to pay $8 billion for Iridium, and is expected to close on the deal next year, giving it 2.5 million satellite-based mobile subscribers. The service is mainly geared toward the private and government sectors, in contrast to Starlink, which caters more to customers who want at-home internet service.
Iridium is profitable, with $114 million in net earnings last year, and the deal will help Rocket Lab expand its satellite communications network to better compete with SpaceX.
But Rocket Lab's primary business is sending payloads into space, and in the first quarter, the company signed 31 new deals, selling more launches than it did in all of 2025.
The company also has some major launch contracts already signed, including with the U.S. government to establish the satellite system for the proposed Golden Dome missile defense system. It also has contracts for missile tracking and military communications.
Today's Change
(
-3.36
%) $
-2.65
Current Price
$
76.16
While Rocket Lab isn't profitable, its loss of $0.07 per share in Q1 was an improvement from its loss of $0.12 per share in the prior-year quarter. Revenue is also growing at a healthy clip, rising 64% to $200 million.
In contrast, SpaceX's sales rose just 15% in Q1 to $4.7 billion, and the company's loss of $3.29 per share was dramatically worse than its $0.41 per share loss in the year-ago quarter.
SpaceX's massive losses have been fueled by sharp increases in its capital expenditures, which reached $10 billion in Q1 2026 alone, compared to $27 billion for all of 2025.
That heavy spending should give investors pause, and so should the lofty valuation of its stock. SpaceX trades at a price-to-sales (P/S) ratio of about 94 compared to Rocket Lab's P/S ratio of 66.
While neither stock is cheap, SpaceX's shares trade at a much higher premium even as the company ramps up spending and its losses widen. All of which means that Rocket Lab looks like the better space stock to buy right now.
Viasat experts demonstrate satellite-enabled voice call capabilities as part of research collaboration
during this week’s 5G Automotive Association Meeting Week in Munich, Germany: for the first time integrated with the infotainment system of a BMW iX3.
Showcase highlights what might be possible in future and the potential for reliable voice and messaging connectivity beyond the reach of traditional terrestrial networks.
MUNICH, July 16, 2026 (GLOBE NEWSWIRE) -- Viasat, Inc. (NASDAQ: VSAT), a global leader in satellite communications, today announced a landmark technology demonstration showcasing the first automotive satellite voice call demonstration fully integrated into a BMW Group vehicle’s platform.
It marks a significant step forward as Viasat brings Non-Terrestrial Network (NTN) communications into the connected vehicle ecosystem: enabling drivers and passengers to stay connected in remote or underserved areas where cellular coverage may be limited or unavailable.
Building on an earlier demonstration with eSIM capabilities from Cubic³, a leading provider of software-defined vehicle (SDV) solutions, Viasat experts in Munich utilized advanced technology including Qualcomm Technologies Inc.’s Snapdragon® Auto 5G Modem-RF Gen 2 solution, and the Fraunhofer IIS NESC AI voice codec. This enables voice communications to be sent using the NB-IoT communications protocol over Viasat’s highly reliable, L-band satellite network.
For the first time, this technology was integrated with BMW Group’s in-vehicle architecture, allowing voice calls to be initiated and managed directly through the vehicle interface. By extending messaging and voice services beyond cellular coverage, automakers like BMW Group can ensure drivers remain connected for emergency assistance and critical safety applications, regardless of location.
“This demonstration reflects broader industry excitement to ensure consistent, resilient satellite capabilities for next-generation vehicles,” said Sandeep Moorthy, Senior Vice President, Advanced Non-Terrestrial Solutions at Viasat. “By bringing standards-based NTN to vehicles, we can integrate satellite voice and messaging and ultimately enable a future where drivers can remain connected — wherever the journey takes them.”
Viasat, BMW Group, Cubic3, and Fraunhofer IIS are active members of the 5GAA (5G Automotive Association), which brings together technology and automotive partners to develop real-world, scalable connectivity solutions for all road users. Satellite-enabled automotive connectivity applications include voice and messaging emergency services, fleet management, and over-the-air updates in low-connectivity regions.
The NB-IoT protocol, which can support lower data-rate applications, is enabled by global 3GPP standards. Future releases are expected to pave the way for 5G-New Radio (5G-NR) satellite services, which could support video streaming and seamless roaming between terrestrial and satellite networks.
About Viasat
Viasat is a global communications company that believes everyone and everything in the world can be connected. With offices in 24 countries around the world, our mission shapes how consumers, businesses, governments and militaries around the world communicate and connect. Viasat is developing the ultimate global communications network to power high-quality, reliable, secure, affordable, fast connections to positively impact people’s lives anywhere they are - on the ground, in the air or at sea, while building a sustainable future in space. In May 2023, Viasat completed its acquisition of Inmarsat, combining the teams, technologies and resources of the two companies to create a new global communications partner. Learn more at www.viasat.com, the Viasat News Room or follow us on LinkedIn, X, Instagram, Facebook, Bluesky, Threads, and YouTube.
Viasat, Inc. Contacts
Richard Jones, External Communications, Corporate & Commercial Services, [email protected]
Lisa Curran/Peter Lopez, Investor Relations, [email protected]
About 5GAA
The 5G Automotive Association (5GAA) is a global, cross-industry organisation of companies from the automotive, technology, and telecommunications industries (ICT), working together to develop end-to-end solutions for future mobility and transportation services. Created in September 2016, 5GAA has rapidly expanded to include key players with a global footprint in the automotive, technology and telecommunications industries. This includes automotive manufacturers, tier-1 suppliers, chipset/communication system providers, mobile operators and infrastructure vendors. More information.
About Cubic3
Cubic³ brings cellular and satellite connectivity together on one platform for the automotive industry, giving software-defined vehicles (SDVs) seamless coverage across more than 200 countries and territories. With access to over 550 mobile networks, Cubic³ helps automotive OEMs navigate the complexities of global connectivity and compliance, so drivers stay connected whether they're within reach of a cellular network or relying on satellite.
Snapdragon and Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries.
Qualcomm, Qualcomm Dragonwing and Snapdragon are trademarks or registered trademarks of Qualcomm Incorporated.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to the safe harbors created under the Securities Act of 1933 and the Securities Exchange Act of 1934. Forward-looking statements include, among others, statements that refer to the expected benefits, capabilities, performance, availability, and future development of Viasat’s satellite-enabled automotive connectivity solutions; the successful integration and commercialization of satellite voice technology within BMW Group or any other company’s vehicles; the anticipated expansion of NTN services for automotive applications; and the connectivity to be provided by Viasat L-band satellites. Readers are cautioned that actual results could differ materially from those expressed in any forward-looking statements. Factors that could cause actual results to differ include: our ability to successfully develop, integrate, and commercialize satellite-enabled automotive technologies; risks associated with demonstrating and scaling new technologies; our ability to realize the anticipated benefits of our satellite network, including the ViaSat-3 class satellites and any future satellite we may construct or acquire; unexpected expenses related to our satellite projects; our ability to successfully implement our business plan for new and existing services on our anticipated timeline or at all; risks associated with the construction, launch and operation of satellites, including the effect of any anomaly, operational failure or degradation in satellite performance; changes in relationships with key partners, including automotive OEMs; our reliance on third parties to manufacture, supply, or integrate our solutions; increased competition and introduction of new technologies in the communications and automotive industries; changes in the global business environment and economic conditions; regulatory and spectrum-related risks, including changes affecting spectrum availability or permitted uses; our inability to access or expand use of spectrum or orbital locations; and other factors affecting the communications and automotive industries generally. In addition, please refer to the risk factors contained in our SEC filings available at www.sec.gov, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. We undertake no obligation to update or revise any forward-looking statements for any reason.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/19addb9d-bccf-4b68-9bff-fde2f0b7700e
Viasat experts demonstrate satellite-enabled voice call capabilities Viasat experts demonstrate satellite-enabled voice call capabilities as part of research collaborati...
Catholic Health a GE HealthCare uzavřely desetileté partnerství za zhruba 500 milionů USD, které má na Long Islandu rozšířit přístup k pokročilému zobrazování, přesné diagnostice a technologiím umělé inteligence.
ROCKVILLE CENTRE, N.Y.--(BUSINESS WIRE)--Catholic Health, an integrated health system located on Long Island, NY, and GE HealthCare (Nasdaq: GEHC) announced today a 10-year strategic partnership, known as a Care Alliance, valued at approximately $500 million, to help expand access to advanced imaging, precision diagnostics and AI-enabled technology across Catholic Health in support of innovative, compassionate and patient-centered care. This will be one of the largest Care Alliances between GE HealthCare and a leading healthcare system in the United States to date; spanning equipment, service, digital solutions, cloud solutions and AI-enabled technologies.
The Care Alliance centers on system-wide technology and equipment modernization across key Catholic Health service lines, including cardiology, oncology, neurology, and women’s health. Through this modernization, Catholic Health aims to:
Expand Catholic Health’s renowned cardiology practice by extending advanced cardiac imaging to multiple outpatient and ambulatory sites, helping improve access to high-quality cardiac services closer to home. Reduce delays in the oncology care journey by adding MR, CT, and PET technologies equipped with on-device AI solutions, with the goal of decreasing the time from diagnostic imaging to treatment. Expand nuclear medicine capabilities at Catholic Health’s St. Francis Hospital & Heart Center® and Good Samaritan University Hospital flagship locations to enhance diagnostic confidence in oncology. Add hundreds of ultrasound systems to help increase department efficiency and support clinician confidence at the point of care, including at the bedside. Enhance women's health with expanded capabilities in OB/GYN and maternal fetal medicine. A unique aspect of the Care Alliance is an embedded cardiovascular scientist that can work directly with Catholic Health clinicians to help highlight physician perspectives, clinical insights and patient care needs, potentially informing future equipment and technology considerations.
“This Care Alliance represents an important investment in the future of health care on Long Island and reflects Catholic Health’s commitment to innovating in ways that improve how care is delivered,” said Gary Havican, Interim President and CEO and Chief Operating Officer of Catholic Health. “By combining Catholic Health’s clinical expertise and commitment to compassionate, high-quality care with GE HealthCare’s advanced technology, AI-driven tools, and digital capabilities, we are enhancing our ability to deliver precision care, expand access to specialized services closer to home, and create a more seamless experience for patients and clinicians. The partnership also gives our physicians and care teams a meaningful voice in shaping the future of care so innovation is guided by real clinical and patient needs.”
As part of the 10-year Care Alliance, approximately 50% of equipment additions will arrive at Catholic Health clinical sites during the first three years of the agreement. The agreement is also expected to generate capital savings compared with traditional equipment purchasing approaches thanks to unitary payments and accelerators, which can allow Catholic Health to reinvest resources in technology modernization, expanded patient access and clinical program growth.
For patients, the partnership is designed to have a tangible impact on their clinical experience. AI-enabled tools, standardized equipment and more consistent workflows can help Catholic Health to increase capacity, reduce delays in diagnosis and treatment, improve appointment availability, and bring specialized services — including cardiology, neurology, women’s health and cancer care — closer to home.
Patients may begin to see benefits during the first year of the agreement with equipment additions expected to arrive within months, including contrast-enhanced mammography to improve access to breast imaging and biopsy services; expanded diagnostic imaging capabilities across multiple modalities; and upgraded maternal-infant care monitoring technologies at Good Samaritan University Hospital.
Clinicians will also benefit from enhanced operational support and ongoing collaboration with GE HealthCare experts to help optimize workflows, strengthen clinical decision-making and support innovation.
Beyond equipment additions and service line expansion, the Care Alliance includes comprehensive imaging, biomedical maintenance, and service support. A 10-year, multivendor service agreement will cover delivery and maintenance of equipment across 40+ sites, including lifecycle and fleet management, as well as comprehensive education and training. The agreement is designed to support Catholic Health as it maximizes uptime, boosts asset utilization, lowers lifecycle costs, increases operational efficiency, and enhances patient care. This service component helps distinguish the Care Alliance from a traditional equipment agreement, positioning GE HealthCare as a long-term partner in supporting equipment performance and reliability across the system.
The Care Alliance will also emphasize AI, cloud, and software solutions designed to deliver actionable insights and drive operational efficiency. Digital solutions included in the Care Alliance aim to reduce manual tasks, ease cognitive load for clinicians, improve clarity for patients, and create a more seamless clinical environment. One example is Imaging 360, a cloud-based radiology operations platform that unifies radiology workflows, centralizes performance insights, and enables remote scanning support. By providing a system-wide view of imaging operations, it can help multi-site health systems improve efficiency, patient access, and care consistency.
“This Care Alliance with Catholic Health is grounded in deep collaboration to expand access and advance high-quality care across Long Island,” said Rachel Gilbreath, region president, East, U.S. and Canada at GE HealthCare. “Over the next decade, we will work side-by-side to implement innovative technology and processes across the enterprise, integrate AI, cloud, and software solutions, and support clinical excellence, including cardiology, to position Catholic Health to improve outcomes and operational performance. Together, we are aligning people, process, and technology to deliver measurable impact for patients and clinicians.”
Over the course of the Care Alliance, Catholic Health will add expanded capabilities and service lines at St. Francis Hospital & Heart Center®, St. Charles Hospital, Good Samaritan University Hospital, St. Joseph Hospital, St. Catherine of Siena Hospital, and Mercy Hospital, as well as 36 other sites. Equipment will span modalities including CT, PET/CT, nuclear medicine, MR, mammography, X-ray, surgery, ultrasound, women’s health, anesthesia, diagnostic cardiology, and maternal infant care.
Catholic Health and GE HealthCare relationship
Outside of this agreement, Catholic Health and GE HealthCare have a history of working together on precision care capabilities, including Catholic Health’s early adoption of GE HealthCare’s proprietary PET agent Flyrcado™ (flurpiridaz F 18), which supports greater diagnostic confidence and more personalized care planning. In April 2025, St. Francis Hospital & Heart Center® was the first U.S. site to perform an exercise stress PET myocardial perfusion imaging study using GE HealthCare’s Flyrcado™ (flurpiridaz F 18).
For more information about GE HealthCare’s Care Alliances, visit: https://info.gehealthcare.com/carealliance
About Catholic Health
Catholic Health is an integrated system encompassing some of the region’s finest health and human services agencies. The health system has over 17,000 employees, six acute care hospitals, three nursing homes, a home health service, hospice and a network of physician practices. Under the sponsorship of the Diocese of Rockville Centre, Catholic Health serves hundreds of thousands of Long Islanders each year, providing care that extends from the beginning of life to helping people live their final years in comfort, grace and dignity. For more information, visit: https://www.catholichealthli.org.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.
Important Safety Information and Usage of Flyrcado™ (flurpiridaz F 18) injection
FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION) ™ (flurpiridaz F 18) injection, for intravenous use important safety information
Indications and Usage
FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.
Contraindications
None
Warnings and Precautions
· Risk associated with exercise or pharmacologic stress: Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, stroke, and seizure. Perform stress testing in the setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent’s prescribing information.
· Radiation risks: FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void.
Adverse Reactions
· Most common adverse reactions occurring during FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.
Use in Specific Populations
· Pregnancy
There are no data on use of flurpiridaz F 18 in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. If considering FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION administration to a pregnant woman, inform the patient
about the potential for adverse pregnancy outcomes based on the radiation dose from flurpiridaz F 18 and the gestational timing of exposure.
FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION contains ethanol (a maximum daily dose of 337 mg anhydrous ethanol). If considering FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes associated with ethanol exposure during pregnancy.
· Lactation
Temporarily discontinue breastfeeding. A lactating woman should pump and discard breastmilk for at least 8 hours after FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION administration.
· Pediatric Use
Safety and effectiveness of FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION in pediatric patients have not been established.
To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2 then option 1) or by email at [email protected] or FDA at 800-FDA-1088 or www.fda.gov/medwatch
For full prescribing information, click here. For important safety information, please click here.
CoreWeave je asi 49 % pod 52týdenním maximem 153,20 USD po zprávách, že Meta chce budovat vlastní AI cloud. Firma přitom v 1. čtvrtletí 2026 zvýšila výnosy o 112 % na 2,1 miliardy USD.
Few stocks capture the AI infrastructure boom -- and its risks -- quite like CoreWeave (CRWV 3.58%). The company rents out the high-end computing power that trains and runs AI models, and demand for it has been ferocious. Yet as of this writing, shares sit near $77 -- about 49% below the 52-week high of $153.20.
The latest leg down has a specific cause. Earlier this month, reports surfaced that Meta Platforms plans to build its own AI cloud business and sell excess capacity to outside customers. Meta happens to be one of CoreWeave's largest customers, so the news raised an uncomfortable possibility: one of the company's biggest buyers may be about to become a competitor.
Shares have fallen for four straight sessions since. For dip buyers, a decline like this is tempting. But a lower price only helps if the business underneath it can support the stock. So, which is this, a bargain or a value trap?
Image source: The Motley Fool.
Staggering growth The top line leaves no doubt about demand. In the first quarter of 2026, CoreWeave's revenue more than doubled, rising 112% year over year to $2.1 billion. That followed 168% growth for full-year 2025, so even as the rate cools, the company is still expanding at a pace almost no business its size can match.
The backlog is just as eye-catching. CoreWeave signed more than $40 billion of new contracts during the quarter, lifting its revenue backlog to $99.4 billion. That figure dwarfs the roughly $12.5 billion in revenue it expects to generate this year, and on paper it offers years of visibility.
Today's Change
(
-3.58
%) $
-2.86
Current Price
$
77.08
Management still guides for $12 billion to $13 billion in revenue this year, with the exit rate climbing toward $18 billion to $19 billion annualized. Few companies grow into their promises this fast.
The physical footprint is scaling to match. The company now holds more than 3.5 gigawatts of contracted power and recently surpassed 1 gigawatt of actual capacity, a milestone only a handful of cloud operators have ever reached.
The trouble is what all of this costs. CoreWeave is borrowing heavily to buy graphics processing units, lease data centers, and secure power, and the bills are climbing faster than sales.
Its first-quarter net loss more than doubled to $740 million, from $315 million a year earlier, and it widened from a $452 million loss in the prior quarter. Net interest expense alone more than doubled year over year, to $536 million, as the debt load grew.
The spending, meanwhile, is only accelerating. Management expects capital expenditures of $31 billion to $35 billion this year, against that same roughly $12.5 billion in revenue. The demand is not in doubt. The economics are.
The Meta problem and the price The Meta news sharpens the risk considerably. CoreWeave holds a roughly $21 billion agreement with Meta that runs through 2032, so one of its largest customers is reportedly building the very capability CoreWeave sells.
To be fair, that agreement still binds Meta as a paying customer for now, which limits the near-term damage. CoreWeave's customer base is broadening, too, with recent deals signed alongside AI labs such as Anthropic and Cohere.
But those customers share a trait -- they are deep-pocketed enough to build their own capacity over time, exactly as Meta is now doing. When one of your biggest buyers decides it can do the job itself, the long-term pricing power of the whole industry arguably starts to look shakier.
Then there's the valuation. CoreWeave isn't profitable, so there's no price-to-earnings ratio to lean on. Measured against sales, its roughly $42 billion market capitalization works out to about 3.3 times this year's expected revenue.
That might look reasonable for a fast-growing software company. But CoreWeave isn't software. It's a capital-intensive, heavily indebted infrastructure business with no profits in sight and a customer list that now includes its newest rival.
So is the sell-off an opportunity or a warning? To me, it's a warning. CoreWeave is executing an ambitious plan in a booming market, and its top-line growth is hard to fault. But the road to durable profits runs through tens of billions in spending, a mountain of debt, and pricing power that its own customers are working to erode. That is more uncertainty than I want to underwrite. I'd stay on the sidelines and look for AI exposure where the path to profitability is clearer.
These days, investors have valid concerns about the stock market's valuation. The ongoing artificial intelligence boom also adds fears about possible disruption. It doesn't help that the broader economy is characterized by heightened uncertainty.
This supports the view that it's time for investors to consider opportunities that generate consistent income. If this sounds like the approach you're interested in, look at Coca-Cola (KO 0.76%).
This Dividend King stock yields 2.55%, more than double the yield of the S&P 500 index, and it just raised its dividend for the 64th straight year.
Image source: Getty Images.
Showing a firm commitment to shareholders In February of this year, Coca-Cola's board of directors gave investors a reason to cheer. The business hiked its quarterly dividend payout 4% to $0.53. This is the 64th consecutive year that such a move was made. That shows an incredible commitment to the company's shareholders.
Since the start of 2010, Coca-Cola has returned almost $102 billion to investors via dividend payments. This equals 28% of the current market cap.
If a business is able to build a monster streak like this one, it's a clear sign of its consistency and staying power. Coca-Cola has stood the test of time, operating through numerous periods of uncertainty, including wars, recessions, and technology cycles, only to continue its success. Investors have every reason to be confident that this business will still be dominating the beverage market a century from now.
Coca-Cola's impressive profits also virtually eliminate the risk of the dividend being suspended. In the past decade, the company has reported an average quarterly operating margin of 26.9%. It generates sizable cash flow, giving it the financial horsepower to continue returning capital to shareholders. Not even the black swan event of the pandemic that derailed the global economy in 2020 disrupted Coca-Cola's ability to pay its dividend.
Today's Change
(
-0.76
%) $
-0.63
Current Price
$
82.45
Set the right expectations You've now decided that adding Coca-Cola to your portfolio is the right move. This is a safe stock to buy and hold. It will certainly provide valuable peace of mind.
However, it's important for investors to set the right expectations. Coca-Cola's shares are unlikely to beat the market over the long term. In the past decade, the beverage giant produced a total return of 152%, meaningfully lagging the S&P 500 index. There's no reason to believe the future will be any different.
That's because Coca-Cola is an extremely mature company. It essentially has universal adoption, as it's in more than 200 countries and territories. This naturally limits growth potential.
Don't be discouraged, though. This is a competitively advantaged, predictable, and highly stable business that dividend investors can own with confidence.
Coca-Cola zvýšila čtvrtletní dividendu o zhruba 4 % na 53 centů na akcii v únoru a letos vyplácí už 64. rokem v řadě více. Akcie jsou jen 3,8 % pod rekordem a obchodují se za téměř 26násobek trailing earnings.
One of Wall Street’s most dependable income stocks has quietly become a market outperformer trading close to a record high.
Its dividend yield is roughly twice that of the broader market, while its payout has increased every year for more than six decades.
The company is Coca-Cola NYSE:KO. Investors have embraced its defensive demand, pricing power and dependable cash returns during an uncertain economic period.
Yet after the shares closed at $82.45 on Wednesday, only 3.8% below their July 7 record, even bullish analysts are divided over how much upside remains.
A 64-year payout streak is only part of the storyCoca-Cola raised its quarterly dividend by about 4% in February, from 51 cents to 53 cents per share.
That marked its 64th consecutive annual increase and lifted the annualised payout to $2.12. At Wednesday’s close, the shares yielded about 2.6%.
The attraction extends beyond income. First-quarter net revenue increased 12% to $12.5 billion, organic revenue advanced 10% and global unit-case volume rose 3%.
Those figures suggest the dividend is being supported by continuing business growth rather than borrowing or financial engineering.
Coca-Cola also enjoys structural advantages few consumer companies can match.
Its brands have global recognition, management can adjust prices and package sizes across markets, and independent bottlers handle much of the capital-intensive production and distribution.
That asset-light structure helps explain why investors have favoured the company during economic uncertainty.
Consumers may postpone expensive purchases, but relatively inexpensive drinks remain accessible, giving Coca-Cola a defensive quality that many cyclical businesses lack.
Citigroup analyst Filippo Falorni delivered the most aggressive recent call on July 14, raising his Coca-Cola price target to $97 from $91 while retaining a Buy rating.
The target implies that Citi believes resilient earnings and brand momentum can justify a further valuation premium.
JPMorgan analyst Andrea Faria Teixeira is also positive, but more measured. She raised her target to $90 from $85 on July 10 and maintained an Overweight rating.
Bank of America analyst Peter Galbo has maintained a Buy rating and a $95 target.
The bank sees the FIFA World Cup as a useful near-term catalyst because the tournament creates repeated beverage-consumption occasions across homes, bars and restaurants, while giving Coca-Cola an unusually broad global marketing platform.
The tournament may support volumes and brand visibility, but it is temporary.
The longer-term case still depends on Coca-Cola protecting demand as consumers become more selective and input costs remain unpredictable.
Coca-Cola now trades at nearly 26 times trailing earnings, a demanding multiple for a mature consumer-staples company.
Its Wednesday's close was also only a few dollars below the record $85.68 reached earlier this month.
Bernstein SocGen provides the clearest cautious counterpoint.
The firm cut its target to $83 from $84 and kept a Market Perform rating, citing an uneven consumer environment, affordability spending, Mexican tax pressures and the possibility that elevated aluminium costs could weigh on bottlers in 2027 and 2028.
The broader analyst picture reinforces that tension.
Twenty-five analysts tracked by Stock Analysis carry an average target of $86.85, implying only about 5% upside, despite an overall Buy consensus.
Coca-Cola reports second-quarter results on July 28. Investors will watch organic sales, volumes, North American demand, commodity costs and World Cup-related commentary.
Founded in 2011, Delivery Hero now operates in over 60 markets and is one of the world's biggest food delivery groups . German food delivery group Delivery Hero said Thursday it has agreed to be acquired by U.S. ride-hailing giant Uber in a 12.7 billion euro ($14.6 billion) deal.
Founded in 2011, the German firm now operates in more than 60 markets and is one of the world's biggest food delivery groups.
It has also expanded beyond its traditional food business to quick commerce, delivering small packages to customers.
Uber is offering 41.50 euros per share for Delivery Hero, valuing the deal at 12.7 billion euros.
Delivery Hero's shares were down 0.5% in Frankfurt after the announcement, trading at 37.9 euros.
"Uber's global mobility and delivery platform and our shared commitment to innovation make this the right partnership to build on Delivery Hero's strengths in local food delivery and quick commerce," said Niklas Oestberg, CEO and co-founder of Delivery Hero.
Uber CEO Dara Khosrowshahi said a merger would "extend affordable, reliable delivery to many millions more people in some of the world's most dynamic economies, while creating more opportunities for merchants and couriers."
Uber is acquiring Delivery Hero's businesses in 50 markets worldwide across Asia, Europe, Latin America and the Middle East.
A U.S. investment firm, SSW Partners, is acquiring the German group's operations in another 14 markets, where Uber and Delivery Hero compete, for around 1.4 billion euros.
Delivery Hero said its management recommends that shareholders accept the deal and that it is expected to be finalized in the second half of 2027.
Who's behind this story?
Andrew Zinin Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Germany's Delivery Hero agrees 12.7-bn-euro takeover by Uber (2026, July 16) retrieved 16 July 2026 from https://techxplore.com/news/2026-07-germany-delivery-hero-bn-euro.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
Amazon testuje software pro řízení směn ve skladech, ale část manažerů jeho doporučení obchází a žádá vypnutí automatických kontrol. Firma přesto plánuje širší nasazení napříč desítkami severoamerických fulfillment a sort center a do roku 2026 tvrdší vynucování.
An Amazon fulfillment center Bloomberg/Getty Images Amazon is testing software to decide where warehouse workers should go. Some managers keep ignoring it.
Internal planning documents show the tech giant intends to expand these labor-management systems across dozens of its North American fulfillment centers and sort centers, where they could save hundreds of millions of dollars a year.
However, some warehouse managers have been overriding the software recommendations, asking engineers to disable automated features, and finding other ways around the systems, according to internal Slack conversations and the documents from earlier this year.
The pushback has been enough for Amazon to conclude that software recommendations alone aren't enough to get the new technology working as designed.
"Providing managers with optimized recommendations is necessary but insufficient," Amazon said in one of the documents. "Without system-enforced guardrails, manual overrides and habits erode even the best science."
The conflict highlights a broader challenge in automating warehouse management: software can make decisions, but people still have to follow the guidance. The documents and internal communications reviewed by Business Insider suggest getting managers to trust the software, and ultimately defer to its decisions, is proving more difficult than Amazon expected.
Competing philosophiesAmazon uses a growing mix of machine learning, computer vision, and other AI tools that increasingly guide staffing decisions traditionally made by managers.
Initially, those systems functioned as advisory tools. A program called DOPLERS calculates staffing plans, Full Facility Load Balancing recommends labor moves, and Right Link Station automatically tracks and captures check-in data for support staff.
But the internal documents reviewed by Business Insider show Amazon came to see manager discretion as an obstacle.
"Algorithm accuracy cannot be meaningfully measured without enforcement," one of the documents stated.
The documents reveal two competing philosophies of warehouse management. Some managers believe warehouses are still too dynamic for algorithms to understand every situation. Amazon, however, saw that too much human judgment prevented those algorithms from working as intended.
As a result, Amazon's strategy evolved to broader tracking of overrides and stricter enforcement planned over time.
"Hard enforcement is the end goal for 2026," one planning document stated.
"Iterate on the logic"
Amazon CEO Andy Jassy Bloomberg/Getty Images In an email ahead of publication, an Amazon spokesperson called this story's premise "wrong," saying the company is only piloting the technology at a small number of US facilities to help managers adjust staffing as package volumes change.
Managers still make staffing decisions, the spokesperson added, while the software system provides "better information" and is being refined based on testing and employee feedback before any broader rollout.
"As with all new systems, we continuously iterate on the logic — it takes time, testing, and iteration to get there — which is why it's inappropriate to draw broad conclusions during initial testing phases," the spokesperson said. "We always want to learn what's working for our employees, and what isn't, so we can make adjustments to get things right. That's what pilots are all about."
The spokesperson said the quotes and sentiments cited in the story came from an "early-stage planning document" that captured anecdotal observations during a pilot and "don't reflect how the system operates today." The issues were "not a widespread or ongoing concern," the spokesperson said, adding that the tools are intended to help managers make more consistent staffing decisions, not replace their judgment.
An Amazon spokesperson previously told Business Insider that broader expansion plans remain subject to change and that projected savings estimates are hypothetical because the systems are still being tested.
"Please turn if off"Still, the documents and internal communications reviewed by Business Insider suggest a deeper disagreement over who should make staffing decisions inside Amazon's warehouses.
Some managers often wanted to keep more workers assigned to their areas to maintain productivity or because they believed operations required more staffing than the software recommended, according to Slack messages from inside Amazon that were obtained by Business Insider.
Several managers overstaffed warehouse support roles and "hid hours through manual time edits," as some sites found "loopholes," Amazon said in the official internal documents.
The Amazon spokesperson told Business Insider that managers make staffing decisions based on what the company has learned about shopping patterns over the years, but "there will always be variations."
Internal Amazon Slack conversations from earlier this year show some managers at the company repeatedly asking to disable some of the automated staffing controls, or give warehouse leaders authority to do it themselves.
"Please turn it off now and I will explain," one warehouse manager wrote shortly after Amazon's enforcement effort launched at an early test site.
Minutes later, an Amazon product manager replied, "We will disable enforcement for now."
Some managers argued the software often lacked the context they had on the warehouse floor, noting that the system overreacted to a brief slowdown in package volume, recommending staffing cuts that didn't reflect real-time conditions.
Other managers complained the system pulled workers away from urgent areas, prevented them from reassigning idle employees, or left workers temporarily locked out of new assignments while different systems synchronized.
One manager said automated staffing changes caused packages to repeatedly circulate through the warehouse instead of being processed the first time, prompting a request to "disable the system until it gets fixed."
Another manager questioned whether the software could account for differences between workers. "Does it understand 6 foot three Henry that weighs 250 pounds is way better at chasing than 67-year old Henrietta that weighs under 100 pounds and doesn't reach 5 foot?" this person wrote in Amazon's internal Slack.
The Amazon spokesperson told Business Insider that the Slack channel included a "small handful of managers" and the comments "don't reflect the current state of the technology, since they're from a channel that was intended to provide constructive feedback on this initial pilot."
Amazon wants to double downThe conflict reveals something larger than a disagreement over warehouse software.
Historically, supervisors balanced labor using experience and local knowledge. Amazon wants software to make more of these decisions.
The official internal documents show Amazon interpreted manager workarounds less as evidence that automation had limits than as proof that recommendations alone wouldn't change behavior.
Internal Amazon roadmaps call for progressively tighter controls, including limits on how far managers can deviate from the algorithm. Amazon's own "Success Metrics" for 2026 mention a "reduction in manual staffing interventions by managers."
"Enforcement is our highest-leverage mechanism and we're doubling down," Amazon stated in one of the documents.
Have a tip? Contact this reporter via email at [email protected] or Signal, Telegram, or WhatsApp at 650-942-3061. Use a personal email address, a nonwork WiFi network, and a nonwork device; here's our guide to sharing information securely.
Read next
Eugene Kim You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.
Eugene is Business Insider’s Chief Tech Correspondent, where he leads coverage of Amazon. His reporting spans the company’s retail operations, AWS, Alexa, and its secretive internal work culture.Previously, he worked at CNBC, Fortune Magazine Korea, and Japan's Yomiuri Shimbun. He holds degrees from NYU and Columbia University’s Graduate School of Journalism.In 2022, Eugene broke a story uncovering Amazon’s practice of deceptively enrolling customers in Prime and deliberately making cancellation difficult. A year later, the Federal Trade Commission sued the company, citing his reporting. That case culminated in a record $2.5 billion settlement in 2025.His reporting has earned multiple honors, including the SF Press Club’s Bay Area Journalism Award and SPJ NorCal’s Excellence in Journalism Award.Eugene lives in the Bay Area. Contact him via email at [email protected], or Signal, Telegram, or WhatsApp at 650-942-3061. Use a personal email address, a nonwork WiFi network, and a nonwork device; here's our guide to sharing information securely. ExpertiseAmazon, Jeff Bezos, Andy Jassy, e-commerce, and cloud computing.Popular ArticlesAmazon:Internal Amazon emails give an exclusive look at how CEO Andy Jassy has started to run the company, with obsessive attention to the retail business and what some employees feel is micromanagingAndy Jassy will be the next CEO of Amazon. Insiders dish on what it's like to work for Jeff Bezos' successor, who built AWS into a $40 billion business.Internal documents show Amazon has for years knowingly tricked people into signing up for Prime subscriptions. 'We have been deliberately confusing,' former employee says.Inside Amazon's flailing brick-and-mortar ambitions: missed projections, pressure to cut costs, and a war with Whole FoodsInside Amazon's complex employee-review system, where workers feel left in the dark and managers expect to give 5% of reports bad reviewsAfter 28 years, 'Day 2' finally arrives at AmazonAWS, Alexa, healthcare:Inside Amazon's struggle to break into the lucrative market for SaaS business applications, including an internal pitch to buy $38 billion HubSpotInside Amazon's struggle to crack Nvidia's AI-chip dominanceAmazon's AI data center dream runs into the reality of 'zombie' facilities, higher costs, and labor shortagesAmazon is gutting its voice assistant, Alexa. Employees describe a division in crisis and huge losses on 'a wasted opportunity.'Amazon is working on a new 'Remarkable Alexa,' but internal politics and technical issues plague the projectAmazon projected huge losses from its healthcare business in 2024, but strong sales growth, internal document reveals
Fujitsu s FANUC, Yaskawa Electric a Kawasaki Heavy Industries zkoumá platformu fyzické AI s technologií Nvidia pro továrny, logistiku a nemocnice. Zatím jde jen o průzkum bez objednávek či závazků ohledně tržeb.
Nvidia’s latest Japanese collaboration may not change earnings forecasts overnight, but it offers a glimpse of where the chipmaker expects artificial intelligence to travel next.
Fujitsu is bringing together FANUC, Yaskawa Electric and Kawasaki Heavy Industries to explore a physical-AI control platform using Nvidia technology, with applications across factories, logistics networks and hospitals.
For investors, the attraction is not a robot order. It is the possibility that Nvidia can extend its dominance from data centres into machines operating throughout the physical economy.
No orders, deployment targets, or revenue commitments were disclosed.
Fujitsu will lead business discussions around a common platform designed to connect enterprise systems with autonomous robots.
Proposed uses include optimising factory production, automating warehouse material handling and deploying robots to transport medicines, specimens or patients inside hospitals.
Nvidia’s role extends beyond supplying processors. Fujitsu plans to use Cosmos world models to understand and predict real environments.
Omniverse, the Isaac robotics platform and the Newton physics engine will support digital twins, robot learning, simulation, verification and the transition from virtual testing to physical deployment.
The partners also bring experience that Nvidia cannot build alone.
Yaskawa said its MOTOMAN NEXT autonomous robot already carries Nvidia GPUs as standard, while FANUC and Kawasaki contribute established expertise in factory automation, control systems, mobility and healthcare robotics.
Still, the announcement remains exploratory. Fujitsu said the companies will begin by discussing business opportunities and formulating a roadmap for technology development and expansion.
Also read: Nvidia’s Jensen Huang hints at Korea’s next trillion-dollar AI opportunity
The investment argument is that Nvidia could capture several layers of future robotics spending.
Customers may train models on their data-centre GPUs, create synthetic environments with Cosmos, test machines through Omniverse and Isaac, and run intelligence at the edge using Nvidia processors.
That would make robotics another full-stack ecosystem opportunity, rather than a narrow chip market.
A shared development environment used by multiple manufacturers could also strengthen switching costs: the more engineers train, simulate and validate robots through Nvidia software, the harder it becomes to replace that stack.
Wedbush analyst Dan Ives told CNBC’s “Squawk Box” that Nvidia remained the foundation of the physical-AI ecosystem and was four to five years ahead of serious competitors.
His comments preceded the Japan announcement, but the collaboration supports his broader argument that Nvidia’s moat increasingly spans hardware, models and development tools.
Nvidia stock NASDAQ:NVDA was recently trading around $212.50. KeyBanc analyst John Vinh this week raised his price target to $330 from $310 and retained an Overweight rating, citing strong demand and competitive barriers created by CUDA.
He viewed a slight delay in the Vera Rubin ramp as posing limited risk because additional Blackwell B300 shipments could offset the timing shift.
Bank of America analyst Vivek Arya has likewise described Nvidia’s relative underperformance as an “enhanced” buying opportunity.
Arya argues that investors are overemphasising higher memory costs and custom-chip competition while underestimating Nvidia’s pricing power, supply-chain execution and share of hyperscaler infrastructure spending.
Neither call depended on Japan robotics revenue. Wall Street’s current bull case still rests overwhelmingly on data centres, CUDA, Blackwell and Rubin.
The Fujitsu-led initiative adds longer-dated optionality rather than near-term earnings visibility.
NVIDIA a Noetra Corp. spouštějí v Japonsku první národní AI infrastrukturu pro fyzickou AI. Projekt podpořený METI má dodat 140 megawattů kapacity datového centra.
NVIDIA to partner with Noetra Corp. to build the NVIDIA Vera Rubin AI factory with 13,750 Vera CPUs and 27,500 Rubin GPUs to deliver 140 megawatts of data center capacity based on the NVIDIA DSX platform.The initiative, supported by Japan’s Ministry of Economy, Trade and Industry (METI), will provide the computing foundation for Japan’s FRONTia Project to strengthen the country’s ecosystem across manufacturing, logistics, healthcare and more.AI factory to create open multimodal foundation models to develop AI agents, digital twins, robotics and physical AI applications. TOKYO, July 16, 2026 (GLOBE NEWSWIRE) -- NVIDIA today announced it is working with Noetra Corp. to launch an NVIDIA Vera Rubin AI factory with 13,750 NVIDIA Vera CPUs and 27,500 NVIDIA Rubin GPUs for national physical AI. Supported by Japan’s AI and industry leaders, the initiative marks the world’s first national AI infrastructure for physical AI, strengthening the country’s AI ecosystem across manufacturing, logistics, healthcare, telecommunications and more.
The new AI factory, established by Noetra, will be architected with NVIDIA Vera Rubin NVL72 racks using the NVIDIA DSX™ platform, connected and scaled with NVIDIA Spectrum-X™ Ethernet networking. It will enable the development of open multimodal foundation models that power AI agents, digital twins, robotics and other physical AI applications.
The NVIDIA Vera Rubin AI factory will provide the computing foundation for Japan’s FRONTia Project, which refers to the project titled, “Development of Multimodal Foundation Models with a View to AI Robotics and Physical AI,” launched by METI. The project brings together the country’s manufacturing expertise, real-world industrial data and global technology leaders to develop highly reliable multimodal foundation models for physical AI.
The pretrained weights of Noetra’s multimodal foundation models will be made broadly available to domestic model developers and enterprises alongside software such as NVIDIA Nemotron™, NVIDIA Cosmos™, NVIDIA Isaac™ GR00T open models, NVIDIA NeMo™ libraries and more. This will accelerate the development of agentic AI and physical AI applications.
“Japan invented modern manufacturing. Now, it is building the AI factories that will power the next industrial revolution,” said Jensen Huang, founder and CEO of NVIDIA. “NVIDIA is honored to partner with Japan and its industrial leaders to build the AI infrastructure that will power the country’s industries, its economy and a new generation of innovation.”
“Japan has launched the FRONTia Project, which will serve as the core of the country’s physical AI ecosystem,” said Ryosei Akazawa, Japan’s Minister of Economy, Trade and Industry. “By fostering collaboration between Japan and leading global innovators — including NVIDIA — and leveraging Japan’s strengths, such as its onsite expertise and manufacturing technology infrastructure, we will build highly reliable multimodal foundation models and contribute to solving global social challenges.”
“Bringing physical AI into the real world requires enormous computing, data and foundational technologies — challenges no single company can solve alone,” said Hironobu Tamba, CEO of Noetra. “Together with partners across Japan and around the world, Noetra will advance Japan-developed multimodal foundation models and accelerate the deployment of physical AI across Japanese industries by broadly sharing the results of our research.”
Built on the NVIDIA Vera Rubin DSX AI factory architecture, the AI factory will deliver 140 megawatts of data center capacity combined with the NVIDIA Spectrum-X Ethernet networking platform, NVIDIA BlueField® DPUs, and tightly codesigned silicon, systems and software to provide breakthrough AI performance, lower token costs and massive scale for frontier AI training.
NVIDIA DSX provides a reference design and platform for AI factories, helping infrastructure builders accelerate time to production, increase token throughput per megawatt and operate with greater reliability and efficiency.
Advancing Japan’s Physical AI Ambitions
Japan’s AI Robotics Strategy, released in March, sets a goal for the country to capture more than 30% of the global AI robotics market by 2040, representing an estimated $133 billion opportunity. To help achieve the goal, METI is advancing a multimodal foundation model program for robotics and physical AI as part of Japan’s broader industrial AI policy.
As the AI factory expands, it will support training trillion-parameter-scale AI models, giving organizations across Japan access to one of the world’s most advanced AI environments and laying the foundation for the next era of intelligent manufacturing and robotics.
About NVIDIA
NVIDIA (NASDAQ: NVDA) is the world leader in AI and accelerated computing.
For further information, contact:
Kristin Uchiyama
Corporate Communications
NVIDIA Corporation [email protected]
Certain statements in this press release including, but not limited to, statements as to: Japan building the AI factories that will power the next industrial revolution; NVIDIA to partner with Japan and its industrial leaders to build the AI infrastructure that will power the country’s industries, its economy and a new generation of innovation; expectations with respect to growth, performance, availability, and benefits of NVIDIA’s products, services and technologies, and related trends and drivers; expectations with respect to NVIDIA’s third party arrangements, including with its collaborators and partners; expectations with respect to technology developments, and related trends and drivers; projected market growth and trends; expectations with respect to AI and related industries; and other statements that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections based on management’s beliefs and assumptions and on information currently available to management and are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic and political conditions; NVIDIA’s reliance on third parties to manufacture, assemble, package and test NVIDIA’s products; the impact of technological development and competition; development of new products and technologies or enhancements to NVIDIA’s existing products and technologies; market acceptance of NVIDIA’s products or NVIDIA’s partners’ products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of NVIDIA’s products or technologies when integrated into systems; NVIDIA’s ability to realize the potential benefits of business investments or acquisitions; and changes in applicable laws and regulations, as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company’s website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/322eb6fb-fe24-4ea5-a123-2c076a6fa629
NVIDIA Vera Rubin AI Factory for Japan Physical AI NVIDIA today announced it is working with Noetra Corp. to launch an NVIDIA Vera Rubin AI factory wit...
, /PRNewswire/ -- Baidu, Inc. ("Baidu" or the "Company") (Nasdaq: BIDU; HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)), a leading AI company with strong Internet foundation, today announced that the board of directors of the Company (the "Board") approved a motion to pursue the voluntary conversion to dual-primary listing (the "Primary Conversion") on the Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange"). The Primary Conversion is expected to become effective within this year. The Board also authorized the Company's management to proceed with the relevant preparatory work and undertake the necessary procedures to complete the Primary Conversion.
After the Primary Conversion, the Company will become a dual-primary listed company on the Main Board of the Hong Kong Stock Exchange and the Nasdaq Global Select Market, and its Class A ordinary shares and American depositary shares will continue to be traded on both stock exchanges (as the case may be) and remain mutually fungible. The Company believes that the dual-primary listing, once effective, will enhance the liquidity of its securities, broaden its investor base and provide greater flexibility in accessing both capital markets.
The Primary Conversion is conditional upon and subject to, among other things, market conditions and the obtaining of the necessary regulatory approvals. The Company will make further announcement(s) to disclose any material updates and progress with respect to the Primary Conversion in accordance with applicable laws and regulations as and when appropriate. This announcement is for information purposes only and does not constitute, or form part of, any invitation or offer to acquire, purchase or subscribe for any securities of the Company. Shareholders and potential investors should exercise caution when dealing in the securities of the Company.
About Baidu
Founded in 2000, Baidu's mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong Internet foundation, trading on Nasdaq under "BIDU" and HKEX under "9888". One Baidu ADS represents eight Class A ordinary shares.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "future," "intend," "plan," "believe," "estimate," "is/are likely to" and similar statements. Baidu may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in announcements made on the website of the Hong Kong Stock Exchange, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about Baidu's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Baidu's growth strategies; its future business development, including development of new products and services; its ability to attract and retain users and customers; competition in the Chinese Internet search and newsfeed market; competition for online marketing customers; changes in the Company's revenues and certain cost or expense items as a percentage of its revenues; the outcome of ongoing, or any future, litigation or arbitration, including those relating to intellectual property rights; the expected growth of the Chinese-language Internet search and newsfeed market and the number of Internet and broadband users in China; Chinese governmental policies relating to the Internet and Internet search providers, and general economic conditions in China and elsewhere. Further information regarding these and other risks is included in the Company's annual report on Form 20-F and other documents filed with the SEC, and announcements on the website of the Hong Kong Stock Exchange. Baidu does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this announcement is as of the date of the announcement, and Baidu undertakes no duty to update such information, except as required under applicable law.
Oracle si ve fiskálním roce 2026 zvýšila čistý zisk o 37 % a backlog vzrostl na 638 miliard USD. To podle článku naznačuje, že firma může růst i bez plného naplnění dohody s OpenAI.
Oracle (ORCL +3.56%) stock has trended downward since the tech giant struck a deal with OpenAI last September. The $300 billion size of the deal led to a 36% one-day gain in the stock price immediately following the deal's announcement and stoked investor optimism. Still, investors began to doubt whether OpenAI could fulfill its part of the deal.
Moreover, Oracle has borrowed nearly $130 billion as of the end of fiscal 2026 (ended May 31) to build the necessary infrastructure, a considerable burden for a company with a $43 billion book value. Consequently, the stock price has fallem 60% from that high.
Given these price swings, it is increasingly likely that the market is underestimating the massive growth potential of Oracle. These two reasons explain why investors should look at Oracle as a possible buying opportunity.
Oracle Chairman and CTO Larry Ellison. Image source: Oracle.
1. Oracle's valuation is more reasonable now The aforementioned pullback in the stock may have changed Oracle's investment thesis, particularly regarding its valuation. Last September's stock surge lifted Oracle's P/E ratio to 76. At the time, investors seemed willing to pay this premium amid the OpenAI deal.
However, a combination of the falling stock price and a 37% increase in net income during fiscal 2026 reduced its earnings multiple to 22, well below the 32 average P/E ratio for the S&P 500.
Additionally, analysts forecast a continued increase in profits, taking its forward P/E ratio to 16. Hence, despite its considerable debt, that low valuation has made Oracle stock increasingly attractive.
Today's Change
(
3.56
%) $
4.55
Current Price
$
132.49
2. RPO growth is not all tied to OpenAI deal Those rising profits are also a result of the growth in its remaining performance obligations (RPO), or backlog. At the time of the OpenAI announcement, it accounted for about two-thirds of Oracle's $455 billion RPO.
Admittedly, losing all or part of the OpenAI deal would be a huge setback for Oracle. Nonetheless, in the nine months since the announcement, its backlog has risen to $638 billion.
In other words, Oracle has booked the equivalent of 60% of an OpenAI deal, helping to justify its borrowing and the $56 billion it spent on capital expenditures (capex) in fiscal 2026. That success in attracting additional business implies that Oracle could survive losing the OpenAI deal.
A potential double for Oracle The above factors set Oracle stock up to double in value by 2028, if not before.
Thanks to a lower stock price and higher profits, its P/E ratio has fallen well below S&P averages, and its forward P/E ratio will take that multiple into the teens if the stock does not rebound soon.
Moreover, the stock sell-off implied the OpenAI deal was an end-all, be-all for Oracle's AI infrastructure business. However, the fact that it signed almost $200 billion in additional deals in nine months indicates that this business could still thrive if the OpenAI deal does not fully materialize.
Thus, investors who can handle Oracle's debt risk should consider this AI stock.
BlackBerry se posunula od smartphonů k fyzické AI a její software QNX už pohání více než 275 milionů vozidel. Ve 1. fiskálním čtvrtletí 2027 (za tři měsíce končící 31. května 2026) tržby meziročně vzrostly o 26 % a firma dosáhla kladného provozního peněžního toku.
BlackBerry (BB 3.36%) has reinvented itself from a smartphone company to a key player in physical AI -- AI that interacts with the physical world -- and the stock's 180% year-to-date surge through July 13 isn't a meme rally like its brief moment in 2021. BlackBerry's QNX software helps robots interact with the world safely and effectively. That's a critical feature for autonomous vehicles, drones, and humanoid robots.
The company has been securing partnerships and agreements with Nvidia, BMW, and the federal government. That's just the beginning, which makes now the right time to assess BlackBerry's long-term potential for investors.
Image source: Getty Images.
Winning deals now that will be transformative later QNX isn't speculative. The software is already powering BlackBerry to meaningful growth and profits, and more than 275 million vehicles on the road use this technology. The company reported 26% year-over-year revenue growth in its fiscal 2027 first quarter (the three months ended May 31, 2026) and achieved its first fiscal quarter of positive operating cash flow in nine years, excluding a patent sale in fiscal 2024.
Today's Change
(
-3.36
%) $
-0.37
Current Price
$
10.64
"We are particularly encouraged by the multiyear growth opportunities ahead in software-defined vehicles, as well as broad opportunities in the general embedded market, especially physical AI," BlackBerry CEO John J. Giamatteo told investors.
While BlackBerry is already positioned to post significant sales growth thanks to autonomous vehicles, the Nvidia partnership showcases the company's true potential. The QNX OS (operating system) was integrated with Nvidia IGX Thor and the Nvidia Halos Safety Stack, which will assist with physical AI across robotics, medical, and industrial systems.
The global humanoid robot market alone may be enough for BlackBerry to become a long-term wealth multiplier. That market is expected to maintain a 50% compound annual growth rate through 2034 and become a $165 billion industry in the process, according to Fortune Business Insights.
The backlog is steadily growing BlackBerry wrapped up its fiscal 2022 with a $460 million backlog for QNX, and that backlog had more than doubled by the end of fiscal 2026, reaching $940 million.
Revenue for this critical segment has been accelerating as well. BlackBerry's QNX software delivered 20% year-over-year revenue growth in its fiscal 2026 fourth quarter. That growth rate jumped to 26% in BlackBerry's fiscal 2027 first quarter.
BlackBerry is currently guiding for $607.5 million in fiscal 2027 revenue, with approximately half of that coming from QNX. The company reported $549.1 million in fiscal 2026 revenue, so that would be 10.6% year-over-year growth if it hits its estimate. That's a big improvement from the company's 3% year-over-year revenue growth in its fiscal 2026.
Financials are already moving in the right direction, and BlackBerry's positioning in the physical artificial intelligence industry suggests revenue can continue to accelerate in the years ahead. That setup can help BlackBerry continue to deliver on its recent gains.
Apple rozšířil partnerství s Broadcomem a zavázal se odebrat více než 30 miliard USD do roku 2031. Tim Cook označil čipy Broadcomu za zásadní pro dodání neuvěřitelného výkonu a konektivity, které zákazníci očekávají.
Broadcom (AVGO +1.28%) has performed well over the past 12 months. The company's strong position in the market for custom artificial intelligence (AI) chips is proving to be a massive growth driver. What's more, Broadcom recently announced a deal with Apple (AAPL +4.01%) that arguably strengthens the bull thesis for the stock. Here's what investors need to know.
A long-term deal removes major uncertainty Broadcom has designed and produced chips for Apple's devices for years. But recently, the two companies announced an expanded partnership. Apple committed over $30 billion to Broadcom through 2031, which is expected to lead to the production of 15 billion chips. Tim Cook, Apple's CEO, praised Broadcom's chips, calling them "essential to delivering the incredible performance and connectivity our customers expect."
Image source: The Motley Fool.
This is great news for Broadcom, and not necessarily because of the dollar amount. After all, extended over five years, the $30 billion deal comes out to an average of $6 billion annually. Meanwhile, in the second quarter of its fiscal year 2026, ending on May 3, Broadcom's revenue was $22.2 billion. So, the money Broadcom will get from this deal, while not insignificant, isn't exactly a game changer.
However, there are other dynamics at play that investors should pay attention to. For instance, one of the strongest arguments against Broadcom's bull thesis is customer concentration. According to some estimates, Apple alone accounts for roughly 20% of the company's revenue. What would happen if Apple suddenly stopped buying chips from Broadcom? The company's shares would almost certainly fall off a cliff. But investors no longer have to worry about that, at least for the foreseeable future.
The expanded partnership provides a degree of security that Broadcom lacked before, by reducing the risk of sudden revenue loss from one of the company's biggest customers. And that's great news for the company and its shareholders.
Today's Change
(
1.28
%) $
4.99
Current Price
$
394.10
Why Broadcom stock is a buy Broadcom has signed other deals that provide it with significant revenue visibility over the next few years, including with Meta Platforms (META +3.06%). The chipmaker's revenue and earnings are also growing at a good clip, primarily thanks to its work in custom AI chips. Broadcom's second-quarter revenue of $22.2 billion jumped by 48% year over year, with revenue from its AI semiconductor segment soaring 143%.
The company expects sales growth to accelerate within this unit. Broadcom projected that its AI chip revenue would soar by over 200% year over year during its upcoming quarter. It could be just the beginning. As companies increasingly seek cost-effective alternatives to GPUs (Graphics Processing Units), demand for Broadcom's products should remain strong in the medium term. Broadcom's shares jumped after it announced its expanded deal with Apple, and the stock is up 40% over the past 12 months. But it isn't too late to invest.
DeltaDeFi, první DEX na Cardanu poháněný Hydra, okamžitě pozastavil provoz kvůli vyčerpání provozní rezervy. Tým chce později vrátit zbývající prostředky uživatelům.
The Cardano ecosystem has suffered another setback after a decentralized exchange powered by Hydra announced that it is suspending operations indefinitely due to operational constraints.
DeltaDeFi, the first Hydra Layer 2-powered DEX on Cardano, confirmed the decision in an operational update. The announcement has reignited concerns across the Cardano community, with many viewing it as the latest addition to a growing list of ecosystem projects that have either shut down or reduced operations in recent months.
DeltaDeFi Suspends Development and Maintenance In an update shared with its community, the DeltaDeFi team revealed that it had exhausted its operational runway. This left it with no choice but to pause the project effectively immediately.
As a result, the team will suspend both platform development and active maintenance until further notice. During the downtime, the developers plan to evaluate strategies that could enable the project to resume operations in the future.
Meanwhile, DeltaDeFi announced plans to return its remaining funds to users once sufficient minimum UTXO becomes available to process withdrawals. The team also advised users who do not automatically receive their funds to contact the developers through the project’s X account or Discord server for assistance.
How DeltaDeFi Advanced Cardano’s Hydra Ecosystem DeltaDeFi stands out from many decentralized exchanges by building on Hydra, Cardano’s Layer-2 scaling solution designed to increase transaction throughput while reducing settlement times.
Unlike most Cardano DEXs that rely primarily on automated market makers (AMMs), DeltaDeFi adopted an order-book-based trading model. This approach delivered a trading experience closer to traditional financial markets while preserving the benefits of decentralized infrastructure.
The platform promoted features such as sub-second transaction settlement, high-speed order execution, and improved trading efficiency through Hydra’s scaling capabilities. With the project’s suspension, Cardano loses one of its most prominent real-world demonstrations of Hydra’s decentralized finance (DeFi) potential.
It bears mentioning that Hydra recently introduced v2.2.0, focused on real-world use cases, enhanced benchmarking, and optimized snapshot latency.
Another Challenge for Cardano Builders DeltaDeFi’s decision adds to a growing list of Cardano projects that have recently scaled back operations or exited the ecosystem altogether. Projects including JPG Store, TapTools, and contributors such as Chicken have previously cited challenges ranging from rising operational expenses and limited funding to long-term developer sustainability.
Although each project has faced its own circumstances, several common themes have emerged. These include shrinking funding opportunities, increasing operating costs, prolonged market weakness, and ongoing ecosystem governance challenges.
DeltaDeFi’s operational pause reinforces concerns that even technically innovative projects on Cardano continue to face significant sustainability hurdles despite ongoing protocol upgrades and ecosystem development.
DisClamier: This content is informational and should not be considered financial advice. The views expressed in this article may include the author's personal opinions and do not reflect The Crypto Basic opinion. Readers are encouraged to do thorough research before making any investment decisions. The Crypto Basic is not responsible for any financial losses.
Podobně jako ve středu ASML přikročila o den později k výraznému zlepšení výhledu také Taiwan Semiconductor Manufacturing Co. (TSMC). Největší smluvní výrobce čipů na světě zvýšil pro letošní rok jak výhled investičních výdajů, tak i tržeb. Firma tím investorům vyslala jasný signál, že očekává pokračující silnou poptávku po AI čipech a datová centra ještě několik dalších let.
TSMC pro letošek nově počítá s kapitálovými výdaji v rozmezí 60 až 64 miliard dolarů. Předchozí odhad přitom počítal s 52 až 56 miliardami dolarů. Část zvýšených investic má zamířit do USA, konkrétně do rozšiřování výroby v Arizoně, kde firma investuje celkem 265 mld. USD.
TSMC zároveň zvýšila očekávání růstu tržeb v dolarovém vyjádření na více než 40 procent, zatímco dříve předpokládala růst přesahující 30 procent. Pro třetí kvartál počítá s tržbami mezi 44,6 mld. USD a 45,8 mld. USD s provozní marží mezi 56 a 58 procenty. "Poptávka po AI je stále velmi silná," oznámil předseda podniku C.C. Wei.
Firma navíc uvedla, že investiční tempo by mohlo v nadcházejících třech letech nabrat ještě větší obrátky. Podle vedení společnosti stojí za tím přesvědčení, že technologičtí giganti včetně Mety Platforms nebo Alphabetu budou pokračovat v rozsáhlém budování infrastruktury pro umělou inteligenci.
Čtyři největší američtí provozovatelé cloudových a AI platforem, označovaní jako hyperscaleři, mají letos investovat do datových center a související infrastruktury více než 725 miliard dolarů. Právě tato vlna investic byla jedním z hlavních motorů růstu technologických akcií v letošním roce. TSMC je přitom investory vnímána jako jeden z nejdůležitějších indikátorů vývoje celého odvětví, protože vyrábí většinu nejpokročilejších čipů na světě, píše agentura Bloomberg.
Rychlý růst sektoru však zároveň vyvolává otázky ohledně udržitelnosti současných valuací. Investoři stále častěji přemítají nad tím, zda zmíněné společnosti nebudují větší výpočetní kapacitu, než budou v budoucnu skutečně potřebovat.
Finanční ředitel TSMC Wendell Huang má ale jasno. Během konferenčního hovoru s analytiky zdůraznil, že důvěra firmy v dlouhodobý trend rozvoje umělé inteligence zůstává velmi silná. „Kapitálové výdaje v příštích třech letech budou ještě větší, výrazně vyšší než v uplynulých třech letech,“ řekl.
Podobný optimismus zaznívá i od dalších klíčových hráčů v polovodičovém řetězci. Třeba jihokorejská SK Hynix očekává, že nedostatek paměťových čipů by mohl přetrvávat i po roce 2030. Rostoucí poptávka po AI systémech zvyšuje zájem jak o tradiční paměťové čipy, tak o pokročilé HBM paměti, které jsou nezbytnou součástí moderních AI akcelerátorů.
Co se týče samotných výsledků za druhé čtvrtletí, tak v něm TSMC vykázala meziroční růst čistého zisku o 77,4 procenta na 22,36 mld. USD při očekávání 19,74 mld. USD. Tržby vzrostly oproti stejnému období minulého roku o 33,7 procenta na 40,2 mld. USD.
FirstCash zvýšil hotovostní nabídku za Ramsdens na 675 p za akcii z 600 p, celkově až na 684 p včetně dividend. Ramsdens po zprávě vzrostl o 13,6 % na 670 p.
Ramsdens Holdings PLC (AIM:RFX) shares jumped 13.6% to 670p after an improved takeover offer was secured after shareholder feedback prompted US pawnbroking group FirstCash to raise its recommended bid.
FirstCash increased the cash consideration to 675p a share from 600p. Including dividends of up to 9p a share that shareholders will receive or be compensated for, the total value of the offer rises to as much as 684p a share.
The revised proposal values the pawnbroker, jewellery retailer and foreign exchange business at up to £232 million on a fully diluted basis.
The new cash offer represents a 49% premium to Ramsdens' closing share price on 22 June, before the original bid was announced, and a 37% premium to the company's record closing price before the start of the offer period.
The companies said they had engaged with Ramsdens shareholders following the original recommended offer announced last month and had agreed the higher price in response.
FirstCash also declared the revised proposal to be its final offer under Takeover Panel rules, meaning it cannot increase the bid unless a competing bidder emerges or the Panel grants permission in exceptional circumstances.
The takeover remains structured as a scheme of arrangement and continues to have the unanimous backing of the Ramsdens board.
LG Chem zahájila masovou výrobu a dodávky odstraňovačů polovodičových vrstev pro Amkor, čímž poprvé vstoupila na tento trh. Nový produkt má zkrátit dobu procesu přibližně o 50 %.
SEOUL, South Korea--(BUSINESS WIRE)--LG Chem (KRX: 051910) announced on July 16 that it has begun mass production and supply of semiconductor strippers to Amkor Technology, marking the company’s first entry into the semiconductor stripper market and accelerating its strategy to expand its semiconductor materials business.
Through our collaboration with Amkor, a world-class semiconductor packaging and testing company, we will further strengthen our competitiveness in delivering customized materials optimized for customers’ manufacturing processes.
Share Amkor Technology is a global leader in outsourced semiconductor assembly and test (OSAT), providing semiconductor packaging and testing services to leading semiconductor manufacturers worldwide.
A semiconductor stripper is a critical process material used to remove photoresist (PR) and residue remaining on semiconductor substrates after circuit patterning. As semiconductor circuits continue to shrink, residue removal performance has become increasingly important, directly affecting manufacturing yield and product reliability. As a result, stripper performance is considered a key factor in determining semiconductor quality.
LG Chem entered the semiconductor stripper market by leveraging the technological expertise and customer support capabilities it developed through its display stripper business. The company demonstrated its technology’s competitiveness by successfully passing the rigorous qualification process required by Amkor, a leading global OSAT customer, with its first semiconductor stripper product.
The stripper supplied to Amkor has been customized and optimized for the company’s new production line. Compared with existing products, it reduces the process time required to remove photoresist and process residue by approximately 50%, significantly improving manufacturing efficiency.
Demand for advanced process materials continues to grow as artificial intelligence (AI) investments and high-bandwidth memory (HBM) demand drive the expansion of advanced semiconductor packaging technologies.
Kim Dong Choon, CEO of LG Chem, said, “Through our collaboration with Amkor, a world-class semiconductor packaging and testing company, we will further strengthen our competitiveness in delivering customized materials optimized for customers’ manufacturing processes.”
Earlier this year, LG Chem announced a strategy to more than double the size of its electronics materials business. As part of this initiative, the company is expanding its semiconductor packaging materials portfolio — including copper-clad laminates (CCL), die attach films (DAF), and photo imageable dielectric (PID) — while accelerating the growth of its high-value-added electronic materials business.
Calix má po uzavření trhu v pondělí zveřejnit výsledky za 2. čtvrtletí; analytici čekají EPS 41 centů oproti 33 centům loni a tržby 289,95 milionu USD.
Calix, Inc. (NYSE:CALX) will release its second quarter earnings report after the closing bell on Monday, July 20.
Analysts expect the San Jose, California-based company to report quarterly earnings of 41 cents per share, up from 33 cents per share in the year-ago period. The consensus estimate for Calix’s quarterly revenue is $289.95 million. It reported $241.88 million last year, according to Benzinga Pro.
On April 21, Calix posted upbeat first-quarter earnings and announced an additional $100 million buyback plan.
Calix shares rose 1.1% to close at $39.47 on Wednesday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
Considering buying CALX stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
Tchajwanský výrobce čipů TSMC zveřejnil výsledky hospodaření za druhé čtvrtletí roku 2026 a zároveň představil výhled tržeb na třetí čtvrtletí, který překonal průměrný odhad analytiků. Společnost oznámila také dodatečnou investici 100 mld. USD do rozšíření výroby v americké Arizoně.
Výsledky společnosti TSMC (TSM) za 2Q 2026 2Q 2026 2Q 2025 Tržby (mld. USD) 40,20 30,07 Čistý zisk (mld. USD) 22,36 12,58 Zisk na ADR* (ADR, USD/akcie) 4,31 2,43 * Akcie TSMC se obchodují formou amerických depozitních certifikátů (ADR), jeden odpovídá pěti akciím.
Výsledky za 2Q Tržby dosáhly 1,27 bil. TWD (40,20 mld. USD), meziročně vzrostly o 36,0 % v tchajwanských dolarech, resp. o 33,7 % v USD, a byly v souladu s odhadem 1,27 bil. TWD.
Hrubá marže dosáhla 67,7 %, nad odhadem 67,1 %.
Provozní zisk činil 766,6 mld. TWD (24,26 mld. USD), nad odhadem 742,75 mld. TWD. Provozní marže dosáhla 60,3 %, nad odhadem 58,6 %.
Čistý zisk dosáhl 706,6 mld. TWD (22,36 mld. USD), meziročně vzrostl o 77,4 % a překonal odhad 623,73 mld. TWD. Čistá zisková marže činila 55,6 %.
Ředěný zisk na akcii dosáhl 27,25 TWD (4,31 USD na ADR), meziročně vzrostl o 77,4 %.
V mezikvartálním srovnání tržby vzrostly o 12,0 % a čistý zisk o 23,4 %.
Tržby podle technologie
Tržby společnosti dle jednotlivých technologií, zdroj: TSMC
Tržby podle platformy
Tržby společnosti dle jednotlivých platforem, zdroj: TSMC
Výhled na 3Q 2026 Společnost pro třetí čtvrtletí roku 2026 očekává:
Tržby 44,6–45,8 mld. USD (konsensus: 43,11 mld. USD). Hrubou marži 65–67 % (konsensus: 65,9 %). Provozní marži 56–58 % (konsensus: 57,7 %). Komentář vedení Wendell Huang, finanční ředitel TSMC, uvedl: „Náš byznys ve druhém čtvrtletí byl podpořen silnou poptávkou po našich špičkových procesních technologiích. Do třetího čtvrtletí 2026 očekáváme, že náš byznys bude nadále podporován silnou poptávkou po špičkových procesních technologiích, včetně prudkého náběhu naší 2nanometrové technologie.“
Generální ředitel C.C. Wei zároveň oznámil, že společnost nyní očekává celoroční růst tržeb za rok 2026 mírně nad 40 % meziročně v dolarovém vyjádření. Huang dodal, že TSMC zvýší kapitálové výdaje pro rok 2026 na 60–64 mld. USD, jelikož společnost nadále výrazně investuje na podporu růstu svých zákazníků.
Dodatečné informace TSMC oznámil, že do svého závodu v americké Arizoně investuje dalších 100 mld. USD na výstavbu „čtyř nebo více“ továren, čímž se celkový objem investičních plánů společnosti ve Spojených státech zvýší na 265 mld. USD. Podle Weie má jít o výstavbu několika a více závodů na výrobu logických polovodičových waferů pro technologie 2 nm a novější, stejně jako závodů pro pokročilé pouzdření.
Akcie TSMC Akcie TSMC (TSM) včera v poburzovní fázi obchodování vzrostly o 0,84 % na 423,00 USD.
Taiwan Semiconductor Manufacturing Co Ltd (TSM) před výsledky uzavřely na 419,48 USD Ukazatel Ukazatel Kapitalizace (mld. USD) 2175,6 P/E 28,6 Vývoj za letošní rok (%) +38,0 Očekávané P/E 27,0 52týdenní minimum (USD) 223,7 Prům. cílová cena (USD) 486,8 52týdenní maximum (USD) 479,0 Dividendový výnos (%) 0,8 Zdroj: TSMC, Bloomberg
Nebius představil nový asset-light model, v němž partneři provozují vlastní datová centra pro AI a firma do nich dodává svou full-stack AI cloud platformu. Cílem je rychle rozšířit kapacitu pro zákazníky při minimálních dodatečných kapitálových nárocích.
AMSTERDAM--(BUSINESS WIRE)--Nebius (Nasdaq: NBIS), the AI cloud company, today announced a new business model that lets infrastructure partners deploy Nebius’s full-stack AI cloud platform in their own AI data centers. The model brings additional capacity to Nebius customers, and expands the availability of value-added AI compute globally at a time when demand continues to outstrip supply.
Under the model, partners finance and own the infrastructure and hardware, and operate the data centers. Nebius supplies its systems architecture and supply-chain access; deploys and maintains its hardware design and software and services stack on the partner infrastructure; and takes the resulting capacity to market through its global sales organization.
Partners get fully-owned AI infrastructure assets, designed to Nebius standards, and a fast route to serve the AI cloud market. Nebius’s architecture and platform transform a partner’s raw capacity into a production-ready AI cloud, which Nebius then connects to customers. Because Nebius brings the demand, partners can begin generating a return as soon as the capacity goes live.
For Nebius, this asset-light approach expands the capacity it can offer its customers, such as AI natives and enterprises, with minimal incremental capital requirements. Partners’ data centers will join the Nebius capacity pool, adding incremental capacity to that coming online from Nebius’s owned data centers and colocations.
Arkady Volozh, founder and CEO of Nebius, said:
“Our new asset-light model gives infrastructure partners a flexible way to benefit from the explosive growth of AI. Our software allows partners to reach a much wider customer base with much better margins than conventional wholesale bare-metal contracts. We're inviting data center investors, regional partners and others with capacity or capital to contribute to join us in serving this demand – combining their assets and local strengths with Nebius's technology, platform, operational expertise and customer demand.”
Nebius anticipates pursuing a variety of economic arrangements under this partnership model, including revenue-sharing agreements, licensing fees and commissions, as well as committed capacity arrangements that would provide Nebius with access to additional compute to be sold to customers. The company has already entered into initial arrangements under this asset-light model.
As part of the partnership agreements, Nebius will equip partner teams to run the site and will remain responsible for the cloud software and service levels, while the partner manages the facility and hardware. Customers receive the same standard of service whether they run on Nebius’s own infrastructure or a partner’s.
Prospective partners can learn more at nebius.com/infrastructure-partners or contact [email protected].
About Nebius
Nebius, the AI cloud company, is building the full-stack platform for developers and companies to take charge of their AI future — from data and model training to production deployment. Founded on deep in-house technological expertise and operating at scale with a rapidly expanding global footprint, Nebius serves startups and enterprises building AI products, agents and services worldwide.
Nebius is listed on Nasdaq (Nasdaq: NBIS) and headquartered in Amsterdam.
For more information please visit www.nebius.com.
Media kit nebius.com/media-kit.
Disclaimer
Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our ability to enter into acceptable arrangements with partners, our ability to ensure the same standards of service across both partner and Nebius-owned facilities, our ability to sell this capacity through our global go-to-market organization, our forecast revenue from this service in 2026, our future financial and business performance, strategy, expected growth, planned investments and capital expenditures, capacity expansion plans, anticipated future financing transactions and expected financial results, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “estimate,” “expect,” “guide,” “intend,” “likely,” “may,” “will” and similar expressions and their negatives are intended to identify forward-looking statements.
These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. Actual results may differ materially from the results predicted or implied by such statements, and our reported results should not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from the results predicted or implied by such statements include, among others, our ability to successfully identify appropriate partners; the ability of our identified partners to fully finance their infrastructure and to operate data centers that meet our requirements; market, macroeconomic and geopolitical conditions; competitive pressures; technological developments; our ability to secure and retain customers; our ability to secure additional capital to enable the growth of the business; unpredictable sales cycles; and potential pricing pressures; as well as those risks and uncertainties related to our continuing businesses included under the captions “Risk Factors” and “Operating and Financial Review and Prospects” in our Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on April 30, 2026, which is available on our investor relations website at https://nebius.com/investor-hub and on the SEC website at www.sec.gov.
All information in this press release is as of the date hereof (unless stated otherwise). Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.
In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date hereof and, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.
Ondo Finance spustila první tokenizované akciové reprezentace kryté DTC tokenized entitlements a připojila se k tokenizační iniciativě DTCC. ONDO za posledních 24 hodin vzrostlo o 5,6 %.
Ondo Finance [ONDO] announced the launch of the first tokenized stock representations backed by DTC tokenized entitlements. Through this initiative, Ondo Finance joins a host of other TradFi giants, including BlackRock, J.P. Morgan, and Goldman Sachs, in participating in “DTCC’s largest tokenization initiative to date”.
Source: Ondo Finance on X Ian de Bode, CEO of Ondo Finance, said
Ondo is the only company simultaneously building all pathways for US securities tokenization. Today’s initiative with DTCC demonstrates that Ondo Stocks infrastructure is purpose-built to interoperate with institutional market infrastructure, not to compete with it.
The announcement has helped bolster the bullish sentiment around the decentralized finance platform and its native token, ONDO. The altcoin has rallied 5.6% in the past 24 hours, with an uptick of 51.7% to its daily trading volume.
The triangle pattern and an impending ONDO breakout Source: ONDO/USDT on TradingView The descending triangle pattern [green] came amid ONDO’s inability to flip the long-term bearish swing structure bullishly. The $0.47 swing high was tested but not convincingly breached.
As things stand, the bearish long-term outlook for the altcoin remains intact.
Yet, the descending triangle could change things around. The $0.31 zone has been defended since June. At the time of writing, the $0.336 local resistance zone has kept bulls from taking prices higher.
Neither the CMF nor the OBV signaled steady buying pressure on the altcoin. Unless proven otherwise, it would be prudent for ONDO swing traders to be cautious of a bullish outcome.
Traders’ call to action- Buy if… Source: ONDO/USDT on TradingView The H4 swing structure was also bearish. The local resistance zone coincided with the 50% retracement level at $0.343. This divided the premium and discount areas for swing traders.
A bullish breakout from the descending triangle pattern could still face rejection from the discount area overhead and be unable to climb past $0.372 and $0.394 resistances.
It would be best for traders and investors to wait for the market to show its hand. Trying to go long right now has its risks.
Final Summary News of Ondo’s launch of its first tokenized stock representations based on DTCC tokenized entitlements has buoyed market confidence. Volume trends and overarching price action drew question marks over the token’s ability to rally to $0.40 or higher.
Nvidia oznámila partnerství s japonskými firmami včetně Fanuc a Yaskawa Electric na vývoji robotiky a AI. Jensen Huang řekl, že s AI budou roboti chytří, snadno přizpůsobitelní a dostupní.
Item 1 of 6 Nvidia CEO Jensen Huang, Fujitsu CEO Takahito Tokita, FANUC President and CEO Kenji Yamaguchi, Yaskawa Electric Vice Chairman and Executive Officer Masahiro Ogawa, and Kawasaki Heavy Industries President and CEO Yasuhiko Hashimoto attend a media briefing on the announcement regarding exploring physical AI development and implementation across industries, in Tokyo, Japan, July 16, 2026. REUTERS/Kim Kyung-Hoon
[1/6]Nvidia CEO Jensen Huang, Fujitsu CEO Takahito Tokita, FANUC President and CEO Kenji Yamaguchi, Yaskawa Electric Vice Chairman and Executive Officer Masahiro Ogawa, and Kawasaki Heavy Industries... Purchase Licensing Rights, opens new tab Read more
TOKYO, July 16 (Reuters) - Nvidia (NVDA.O), opens new tab said on Thursday it was partnering with Japanese companies including Fanuc (6954.T), opens new tab and Yaskawa Electric (6506.T), opens new tab to advance the development of robotics and AI.
"With AI, robots will become smart, easily adaptable and accessible," Nvidia CEO Jensen Huang said at a media event in Tokyo.
The Reuters Inside Track newsletter is your essential guide during the World Cup. Sign up here.
On Wednesday Huang attended an event held by gaming firm Sega Sammy (6460.T), opens new tab in the Akihabara electronics district and ate dinner at a Japanese "izakaya" pub.
Huang has achieved rock star status in Taiwan and his appearances have also generated interest from onlookers in Japan, which boasts leading companies in the chipmaking supply chain.
"I think he's the most influential man on Earth," said Chang Hui-Yu, a 57-year-old Taiwanese tourist, speaking outside the Sega event.
"It was my first time seeing Jensen Huang in person and I was so excited," said Brian Yang, 37, who is Taiwanese and lives in Tokyo.
Huang was pictured last night with executives of leading Japanese supply chain firms including the CEOs of chipmaker Kioxia (285A.T), opens new tab and equipment maker Tokyo Electron (8035.T), opens new tab.
Investors are weighing the strength of the AI investment cycle, with chipmaking equipment maker ASML (ASML.AS), opens new tab on Wednesday raising its sales forecast and pledging capacity expansion.
TSMC (2330.TW), opens new tab, the world's leading contract chipmaker, is expected to post a fifth consecutive quarter of record earnings on Thursday due to the AI boom.
Reporting by Sam Nussey, Irene Wang and Anton Bridge; Editing by Sonali Paul
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Gabriel Holding A/S prodává evropský FurnMaster společnosti Leggett & Platt za počáteční kupní cenu 67,3 mil. DKK s možností dodatečné platby až 7,5 mil. DKK. Transakce podléhá obvyklým podmínkám uzavření.
In August 2024, Gabriel Holding A/S announced that, as a result of an adjusted growth strategy with an increased focus on the development of the Group’s global textile business, it would initiate a full or partial divestment of the Group’s furniture manufacturing operations, the “FurnMaster business”.
FurnMaster has a leading position in the market and in Europe consists of two companies located in Poland and Lithuania respectively as well as a dedicated department in Gabriel A/S in Aalborg, Denmark.
The transaction agreement entails that a wholly owned subsidiary of Leggett & Platt, Incorporated acquires the shares in the two subsidiaries, UAB FurnMaster (Lithuania) and FurnMaster Sp. z o.o. (Poland), and will assume responsibility for the employees, assets and liabilities of the dedicated FurnMaster division within Gabriel A/S.
The Group’s Mexican FurnMaster business is not included in the transaction and will continue to be offered for sale.
The initial purchase price (Enterprise Value) has been agreed at DKK 67.3 million (approximately EUR 9 million). In addition, there is the possibility of a conditional deferred cash payment of up to DKK 7.5 million (approximately EUR 1 million).
The transaction remains subject to customary closing conditions.
Management has prioritised finding a qualified buyer who recognises FurnMaster’s strong market position and possesses the necessary capabilities and platform to further develop the business, while at the same time achieving a transaction value that positively impacts the Group’s financial position.
Management believes that the agreement fully satisfies these objectives, as the transaction both enables the continuing business to maintain its desired strategic focus on the development of the Group’s global textile operations and significantly strengthens the Group’s balance sheet through the cash proceeds from the sale.
With locations in North America, Europe and Asia, Legett and Platt’s Work Furniture business is a leading supplier of components and finished furniture to leading furniture brands. Through its strong global platform, including ownership of Trio Line in Poland, which it has successfully operated for a number of years, Leggett & Platt possesses the organisational structure and competencies required to support FurnMaster’s continued development. Consequently, management is highly satisfied that Leggett & Platt has become the new owner of the business.
For further information regarding the transaction, please contact CEO Anders Hedegaard Petersen, [email protected]
or telephone: +45 96 30 31 17.
Further Information:
Gabriel Holding A/S has been advised throughout the transaction by Deloitte Corporate Finance and DLA Piper.
About Leggett & Platt:
Leggett & Platt (NYSE: LEG) is a diversified manufacturer that designs and produces a broad variety of engineered components and products that can be found in many homes and automobiles. The 143-year-old company is a leading supplier of bedding components and solutions; automotive seat comfort and convenience systems; home and work furniture components; geo components; flooring underlayment; and hydraulic cylinders for material handling and heavy construction applications.
For further information, please visit www.legget.com
This is a translation of the original Danish text. In the event of discrepancies between the Danish and English texts, the Danish version shall prevail.
Gabriel Holding AS - Announcement no 18_Gabriel agrees to sell its European FurnMaster business to Leggett & Platt
Hyperion DeFi alokuje 500 000 staked HYPE do Skew Technologies, aby podpořila spuštění perpetual futures na Hyperliquid. Za to získá podíl ve Skew a část výnosů ze služeb spojených s listingem.
Hyperion DeFi, the NASDAQ-listed company trading under HYPD, is putting 500,000 staked HYPE tokens to work. The tokens are being deployed to Skew Technologies through a HYPE Asset Use Service (HAUS) agreement, giving Skew the economic backing it needs to launch perpetual futures markets on Hyperliquid’s HIP-3 permissionless infrastructure.
In return, Hyperion gets equity ownership in Skew plus a cut of the revenues generated from listing services. The revenue share has both fixed and scaling components, meaning Hyperion earns a baseline regardless of how much volume Skew’s new markets attract, while also participating in the upside if trading activity takes off.
How the deal actually works HIP-3, which went live on October 13, 2025, requires anyone deploying a new market to maintain 500,000 staked HYPE as what’s called “alignment capital.” That’s a meaningful barrier to entry, designed to ensure deployers have real skin in the game and face slashing risks if they misbehave.
Advertisement
Through the HAUS agreement, effective July 15, 2026, Hyperion essentially lends its staked position to Skew, which can then spin up new HIP-3 perpetual futures markets without needing to source and lock up half a million HYPE tokens on its own.
Skew’s initial focus will be on perpetual futures through HIP-3, with plans to eventually expand into outcome-based markets under HIP-4 once the core perps business reaches operational stability.
Why Hyperion is betting big on infrastructure Hyperion DeFi holds the distinction of being the first US publicly listed company built around the Hyperliquid ecosystem. Hyperion CEO Hyunsu Jung has pointed to growing global demand for HIP-3 launches as a key driver behind the company’s HAUS strategy.
This isn’t Hyperion’s first HAUS agreement. The company previously partnered with Felix Foundation in late 2025 under a similar arrangement. Recent reports also indicate Hyperion has been unwinding some of its other HYPE deployment deals.
What Skew brings to the table Skew Technologies is founded by a team with experience in financial markets and institutional trading. David Gil, Skew’s founder, has framed this partnership as a foundation for innovative institutional trading products, suggesting the company sees HIP-3 as a launchpad rather than an endpoint.
What this means for investors For Hyperion shareholders, each HAUS agreement transforms staked tokens into equity positions and revenue streams. The fixed component of the revenue share provides downside protection, while the scaling component offers leverage to trading volume growth.
The risk side of the equation centers on slashing. HIP-3’s alignment capital is actively at risk. If a market operator behaves badly or a technical failure triggers slashing conditions, Hyperion could lose a substantial portion of its deployed capital.
Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.
TSMC ve druhém čtvrtletí zvýšila čistý zisk o 77,4 % na rekordních NT$706,56 miliardy a výnosy vzrostly o 36 % na NT$1,27 bilionu. Výsledky překonaly odhady díky silné poptávce po AI čipech.
Taiwan Semiconductor Manufacturing Co on Thursday reported a 77.4% jump in second-quarter profit year on year, shattering estimates as the world's largest contract-chipmaker continues to set consecutive record-breaking milestones.
Here are TSMC's second-quarter results against LSEG SmartEstimates, which are weighted toward forecasts from analysts who are more consistently accurate:
Revenue: 1.27 trillion new Taiwan dollars ($39.45 billion ) vs. NT$1.264 trillion expectedNet income: NT$706.56 billion vs. NT$632.64 billion expected The Taiwanese tech giant's net income for the three months ended in June was a record high for a fifth consecutive quarter, and surged 23.4% from the prior quarter.
Revenue surged to NT$1.27 trillion, a 36% jump from NT$933.79 billion in the same period year ago. Advanced technologies — 7-nanometer and under — accounted for 77% of total wafer revenue, the company said.
The company capped off a quarter of massive growth that included stellar sales in June released earlier this week.
TSMC shares, which have gained over 58% so far this year, rose 1.23% Thursday.
Asia's most valuable company has been riding robust demand for AI chips it manufactures for global tech giants, including Nvidia, Apple and Broadcom.
Lockheed Martin Ventures otevře kancelář v Londýně a plánuje investovat nejméně 100 milionů USD do obranných technologií ve Spojeném království a Evropě.
, /PRNewswire/ -- Lockheed Martin (NYSE: LMT) is expanding the reach of its venture capital fund to support development of promising defense technologies in British and European markets. Lockheed Martin Ventures, the company's $1 billion startup investment arm, is opening a London office with the goal of investing at least $100 million of its funding in the United Kingdom and Europe.
"We are reaching even deeper into the investing ecosystem, meeting our potential partners where they are," said Chris Moran, vice president and general manager, Lockheed Martin Ventures. "Our presence will help us seize opportunities for investing earlier in the startup lifecycle, ensure technical interoperability with existing platforms, and better support our allied customers."
The decision follows the largest boost in available capital in the fund's history, when the company announced in April that it would boost investment capacity from $400 million to $1 billion. Using a portion of that enhanced funding capacity, Lockheed Martin Ventures Europe will accelerate the insertion of new technologies into defense technology — part of the company's commitment to strengthen the transatlantic defense industrial base.
"We are looking to invest in technologies that complement the company's national security capabilities and help advance solutions to meet current and future customer mission needs, while further strengthening the transatlantic defense industrial base," said Dan Tenney, senior vice president of Global Business Development and Strategy. "We expect our investment strategy to evolve as technologies emerge and the startup environment matures in markets where we do business around the world."
Why it Matters
The decision by Lockheed Martin Ventures leverages rapid increases in venture capital investment, particularly in the United Kingdom and Europe. European customers increasingly seek sovereign capabilities, and as the world's largest aerospace and defense company, Lockheed Martin is uniquely positioned to accelerate their development. The investments will help strengthen the defense industrial base and increase the resilience of our supply chain, generating economic benefits for the United States and our allies. Lockheed Martin Ventures has already invested in a number of promising companies in Europe, with more deals expected to close soon. Facts and Figures
Lockheed Martin Ventures is one of the most active and longest continuously operated Aerospace and Defense corporate venture capital firms in the United States. Since its founding it has matured 60 companies to become suppliers. Lockheed Martin Ventures was founded in 2007 with initial funding of $100 million. To date, it has invested more than $500 million in more than 120 companies, including several in European markets. Over the past two years alone, 25 companies have been added to the portfolio. Companies seeking more information about Lockheed Martin Ventures opportunities can contact the team here.
About Lockheed Martin Ventures
Lockheed Martin Ventures makes strategic investments in companies that are developing cutting edge technologies in core businesses and new segments of the national security market important to Lockheed Martin.
More than a source of capital, Lockheed Martin Ventures provides portfolio companies with access resources such as our world-class engineering talent, state-of-the-art technologies and research, and the full suite of Lockheed Martin's business and technical expertise
For additional information about Lockheed Martin Ventures, visit
www.lockheedmartinventures.com.
About Lockheed Martin
Lockheed Martin is a global defense technology company driving innovation and advancing scientific discovery. Our all-domain mission solutions and 21st Century Security® vision accelerate the delivery of transformative technologies to ensure those we serve always stay ahead of ready. More information at www.lockheedmartin.com.
Standard Chartered uzavřela s Broadcomem dlouhodobý strategický závazek na modernizaci globální infrastruktury pomocí VMware Cloud Foundation. Nová privátní cloudová platforma má podpořit klíčové bankovní služby ve 54 globálních trzích.
VMware Cloud Foundation to deliver a secure, unified private cloud platform driving global operational resilience and banking innovation July 16, 2026 02:00 ET | Source: Broadcom Inc.
PALO ALTO, Calif. and LONDON and SINGAPORE, July 16, 2026 (GLOBE NEWSWIRE) -- Broadcom Inc. (NASDAQ: AVGO) and Standard Chartered today announced a long-term strategic commitment to accelerate the bank’s global infrastructure modernization by establishing a secure, resilient private cloud foundation to seamlessly support critical banking services across 54 global markets.
As a leading international bank, Standard Chartered requires infrastructure that delivers operational consistency at global scale while staying ahead of evolving regulatory and security requirements. Standard Chartered has realigned its infrastructure delivery to a fully integrated software-defined private cloud environment using VMware Cloud Foundation (VCF). VCF embeds intrinsic zero-trust security directly into the infrastructure layer, providing uninterrupted availability and compressing infrastructure deployment from weeks to a day.
With 70% of its global infrastructure footprint already running on the new architecture, Standard Chartered has demonstrated that a consistent private cloud is successful at a global scale—laying the foundation for the next frontier in secure, resilient and compliant banking innovation.
John Sharratt, Global Head of Technology and Infrastructure, Standard Chartered, said, “Standardizing a fully virtualized software-defined infrastructure across our global operations enables Standard Chartered to meet the evolving demands of our clients while strengthening our technological core with the responsiveness, resilience and regulatory compliance that global banking demands. Our client-centric, long-term investments with global service providers, such as Broadcom, strengthen our ability to deliver always-on banking services in an ever changing and dynamic landscape, while accelerating innovation with a secure private cloud foundation.”
“Global financial institutions require infrastructure that combines resilience, security and operational simplicity at scale,” said Krish Prasad, senior vice president and general manager, VMware Cloud Foundation Division, Broadcom. “Standard Chartered is at the forefront of digital banking innovation, and we are proud to support their journey toward a highly automated, AI-driven, modern private cloud with VMware Cloud Foundation,” he added.
By modernizing the infrastructure that underpins its core banking, payments and digital services, Standard Chartered has enhanced its future-ready technology platform for sustainable growth and client-centric innovation—one that is anchored on a secure and resilient private cloud foundation.
About Standard Chartered
We are a leading international banking group, with a presence in 54 of the world’s most dynamic markets. Our purpose is to drive commerce and prosperity through our unique diversity, and our heritage and values are expressed in our brand promise, here for good.
Standard Chartered PLC is listed on the London and Hong Kong stock exchanges.
For more stories and expert opinions please visit Insights at sc.com. Follow Standard Chartered on X, LinkedIn, Instagram and Facebook.
About Broadcom
Broadcom Inc. (NASDAQ: AVGO) is a technology leader that designs, develops, and supplies semiconductors and infrastructure software for global organizations’ complex, mission-critical needs. Broadcom combines long-term R&D investment with superb execution to deliver the best technology, at scale. Broadcom is a Delaware corporation headquartered in Palo Alto, CA. For more information, visit www.broadcom.com.
Media Contacts:
Broadcom
Eloy Ontiveros
Broadcom Global Communications
+1-408-646-3944 [email protected]
Standard Chartered
Aida Mekonnen
Technology & Operations Communications [email protected]
Ethereum se blíží k rezistence 2 000 USD, zatímco americké spotové ETF přilákaly denní čisté přílivy ve výši 58,34 milionu USD a jejich čistá aktiva přesáhla 10 miliard USD.
Ethereum is approaching a key technical threshold, with its price edging near the $2,000 level amid renewed institutional interest and increased network activity.
Spot ETFs and Institutional DemandAt the latest reading, Ethereum changed hands at $1,920.11, registering a 1.49% gain over the past 24 hours. The modest uptick is attributed to fresh investments flowing into spot Ethereum exchange-traded funds (ETFs) and consistently stable trading activity.
SoSoValue reported that U.S. spot Ethereum ETFs attracted $58.34 million in daily net inflows, growing total net assets above $10 billion. Persistent inflows from large-scale investors typically reflect improving sentiment and greater market liquidity.
Analysts assess that a single day of strong inflows may not mark the beginning of a sustained trend, but ongoing institutional interest could provide stronger support for further price recovery.
MetricValueETH Price$1,920.1124h Change+1.49%ETF Daily Net Inflows$58.34 millionTotal ETF Net AssetsAbove $10 billionTechnical Analysis and Key LevelsEthereum faces its next technical test just below the $1,930–$2,000 resistance zone, a region where previous attempts to rally have lost steam. Market observers suggest that a confirmed close above this band could reinforce a bullish outlook. In contrast, renewed selling may keep ETH in its longer-term trading range.
Technical signals have improved recently, with the Moving Average Convergence Divergence (MACD) staying in positive territory and its main line holding above the signal line, hinting at growing upward momentum.
Trading volumes have also increased as the price recovered, reflecting firmer buyer participation. Buyers have been actively defending the $1,874 support zone, which remains an important threshold if the trend weakens.
A breakout beyond $2,000, especially if fueled by sustained trading volume, could provide more definitive proof that buyers are commanding the market.
Mini dictionary: MACD (Moving Average Convergence Divergence), a momentum indicator used in technical analysis to identify trend changes and the strength of price movements.
On-chain Activity and Market SentimentAccording to DefiLlama, Ethereum’s Total Value Locked (TVL) remains near recent highs, and active addresses are at elevated levels. Steady on-chain participation suggests users are engaging with the network, even amid recent market fluctuations.
Sustained user activity is often seen as a positive long-term signal, reinforcing fundamentals beyond short-term speculation.
Market analyst Ted Pillows commented on Ethereum’s technical setup, emphasizing that the “real test of $ETH will now start.” Pillows explained that since August 2025, Ethereum has often formed local tops within a few days after its daily Relative Strength Index (RSI) moved above 65. If ETH consolidates instead of reversing sharply, it could point to a potential shift in market behavior, not seen since April 2025.
Since August 2025, Ethereum has consistently peaked shortly after the daily RSI crossed above 65. If ETH price manages to consolidate as the RSI resets, it would mark the first major reversal signal since April 2025.
Outlook and Key TriggersMarket participants are closely checking whether Ethereum will break above the psychologically significant $2,000 threshold or face sellers at resistance once again. A successful push higher may encourage renewed bullish momentum and attract further investment. Conversely, a dip below the $1,874 support could put pressure back on buyers and increase the chance of another pullback.
Ethereum’s price action in the coming days may determine the near-term direction for both technical traders and longer-term investors.
Disclaimer: The information contained in this article does not constitute investment advice. Investors should be aware that cryptocurrencies carry high volatility and therefore risk, and should conduct their own research.
